

Compassionate Use of Remdesivir for Patients with Sev

New England Journal of Medicine

382, 2327-2336

DOI: [10.1056/nejmoa2007016](https://doi.org/10.1056/nejmoa2007016)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa345.	0.4	28
2	Calling for a united action to defeat COVID-19. <i>Precision Clinical Medicine</i> , 2020, 3, 235-239.	1.3	3
3	Treatment of coronavirus disease 2019. <i>Current Opinion in HIV and AIDS</i> , 2020, 15, 336-340.	1.5	8
4	Overview of coronavirus disease 2019: Treatment updates and advances. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 805-808.	0.6	10
5	Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. <i>Antioxidants</i> , 2020, 9, 936.	2.2	104
6	Integrated network pharmacology and molecular docking strategy to explore the mechanism of medicinal and edible <i>Astragali Radix</i> and <i>Attractylodis Macrocephalae Rhizoma</i> acting on pneumonia via immunomodulation. <i>Journal of Food Biochemistry</i> , 2020, 44, e13510.	1.2	5
7	Drug Weaponry to Fight Against SARS-CoV-2. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 204.	1.6	2
9	Analgesia and Sedation Strategies in Mechanically Ventilated Adults with COVID-19. <i>Pharmacotherapy</i> , 2020, 40, 1180-1191.	1.2	18
11	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2020, 49, 763-773.	0.8	19
12	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	1.5	33
13	Comparative epidemiology between the 2009 H1N1 influenza and COVID-19 pandemics. <i>Journal of Infection and Public Health</i> , 2020, 13, 1797-1804.	1.9	45
14	Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 759-763.	1.2	8
15	Is right to try being tried? Using crowdfunding data to better understand usage of nontrial pre-approval access pathways. <i>Regenerative Medicine</i> , 2020, 15, 1979-1985.	0.8	9
16	Reflections on the Collaborative Fight Against COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 565.	1.2	1
17	Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 560209.	1.6	20
18	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. <i>Virologica Sinica</i> , 2020, 35, 857-860.	1.2	39
19	Treatment for COVID-19: An overview. <i>European Journal of Pharmacology</i> , 2020, 889, 173644.	1.7	226
20	Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. <i>Biochemical Pharmacology</i> , 2020, 182, 114225.	2.0	83

#	ARTICLE	IF	CITATIONS
21	Repurposing anticancer drugs for the management of COVID-19. <i>European Journal of Cancer</i> , 2020, 141, 40-61.	1.3	59
22	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. <i>European Journal of Pharmacology</i> , 2020, 887, 173561.	1.7	14
23	Nanoceria as a possible agent for the management of COVID-19. <i>Nano Today</i> , 2020, 35, 100982.	6.2	71
24	COVID-19 in the Pediatric Population—Review and Current Evidence. <i>Current Infectious Disease Reports</i> , 2020, 22, 29.	1.3	32
25	SARS-CoV-2 another kind of liver aggressor, how does it do that?. <i>Annals of Hepatology</i> , 2020, 19, 592-596.	0.6	30
26	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 27, 100547.	3.2	29
27	Favipiravir: A new and emerging antiviral option in COVID-19. <i>Medical Journal Armed Forces India</i> , 2020, 76, 370-376.	0.3	267
28	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. <i>Frontiers in Pharmacology</i> , 2020, 11, 1224.	1.6	30
29	The spectrum of biochemical alterations associated with organ dysfunction and inflammatory status and their association with disease outcomes in severe COVID-19: A longitudinal cohort and time-series design study. <i>EClinicalMedicine</i> , 2020, 27, 100554.	3.2	19
30	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. <i>Genes and Diseases</i> , 2021, 8, 385-400.	1.5	60
31	Opinions on the current pandemic of COVID-19: Use functional food to boost our immune functions. <i>Journal of Infection and Public Health</i> , 2020, 13, 1811-1817.	1.9	27
32	Mechanisms and treatments of myocardial injury in patients with corona virus disease 2019. <i>Life Sciences</i> , 2020, 262, 118496.	2.0	8
33	Nanomedicine strategies to target coronavirus. <i>Nano Today</i> , 2020, 35, 100961.	6.2	48
34	Leukotrienes, a potential target for Covid-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2020, 161, 102174.	1.0	12
35	Clinical management of lung cancer patients during the outbreak of COVID-19 epidemic. <i>Infectious Agents and Cancer</i> , 2020, 15, 56.	1.2	5
36	The use of remdesivir outside of clinical trials during the COVID-19 pandemic. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 61.	1.1	3
37	The Potential of Antiviral Peptides as COVID-19 Therapeutics. <i>Frontiers in Pharmacology</i> , 2020, 11, 575444.	1.6	57
38	Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study. <i>Infectious Diseases and Therapy</i> , 2020, 9, 943-952.	1.8	19

#	ARTICLE	IF	CITATIONS
39	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. European Journal of Pharmacology, 2020, 887, 173568.	1.7	3
40	A review on coronavirus survivability on material's surfaces: present research scenarios, technologies and future directions. Surface Engineering, 2020, 36, 1226-1239.	1.1	14
41	Potential Therapeutic Options for COVID-19. Infectious Microbes & Diseases, 2020, 2, 89-95.	0.5	0
42	Pandemic treatments on trial: the bigger picture. N of many thinking in an N of one scenario. European Respiratory Journal, 2020, 56, 2002281.	3.1	2
43	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Digestive Diseases, 2021, 39, 119-139.	0.8	88
44	2020 update on human coronaviruses: One health, one world. Medicine in Novel Technology and Devices, 2020, 8, 100043.	0.9	21
45	Critical reappraisal of remdesivir investigational trials in COVID-19. New Microbes and New Infections, 2020, 38, 100745.	0.8	1
46	Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. Antiviral Research, 2020, 182, 104927.	1.9	9
47	Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. Virology, 2020, 550, 61-69.	1.1	33
48	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 " A PHARMACOLOGICAL REVIEW. Asian Journal of Pharmaceutical and Clinical Research, 2020, , 42-50.	0.3	2
49	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. Bioorganic Chemistry, 2020, 104, 104326.	2.0	18
50	Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International Immunopharmacology, 2020, 88, 106869.	1.7	40
51	COVID-19 disparities: An urgent call for race reporting and representation in clinical research. Contemporary Clinical Trials Communications, 2020, 19, 100630.	0.5	40
52	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. Transplantation Reviews, 2020, 34, 100567.	1.2	9
53	Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clinical Infectious Diseases, 2021, 73, e3996-e4004.	2.9	90
54	Neuroprotective immunity by essential nutrient "Choline" for the prevention of SARS CoV2 infections: An in silico study by molecular dynamics approach. Chemical Physics Letters, 2020, 761, 138057.	1.2	21
55	A linear prognostic score based on the ratio of interleukin-6 to interleukin-10 predicts outcomes in COVID-19. EBioMedicine, 2020, 61, 103026.	2.7	77
56	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. Expert Review of Anti-Infective Therapy, 2022, 20, 1275-1298.	2.0	21

#	ARTICLE	IF	CITATIONS
57	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. <i>Frontiers in Pharmacology</i> , 2020, 11, 585888.	1.6	11
58	Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1195-1200.	2.8	40
59	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26915-26925.	3.3	104
60	Remdesivir against COVID-19 and Other Viral Diseases. <i>Clinical Microbiology Reviews</i> , 2020, 34, .	5.7	181
61	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. <i>Immunobiology</i> , 2020, 225, 152008.	0.8	65
62	Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. <i>Trends in Immunology</i> , 2020, 41, 1083-1099.	2.9	154
63	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. <i>Advances in Biomarker Sciences and Technology</i> , 2020, 2, 1-23.	0.8	79
64	Virus-, host-, immune-based targets for COVID-19 therapy. <i>Drug Discovery Today</i> , 2020, 25, 2071-2073.	3.2	2
65	A materials-science perspective on tackling COVID-19. <i>Nature Reviews Materials</i> , 2020, 5, 847-860.	23.3	228
66	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1467-1476.	1.0	42
67	Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface. <i>Computational Biology and Chemistry</i> , 2020, 89, 107372.	1.1	30
68	Cardiac arrest and drug-related cardiac toxicity in the Covid-19 era. Epidemiology, pathophysiology and management. <i>Food and Chemical Toxicology</i> , 2020, 145, 111742.	1.8	5
69	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. <i>Journal of King Saud University - Science</i> , 2020, 32, 3159-3166.	1.6	10
70	The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 219.	7.1	37
71	Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. <i>Nature Communications</i> , 2020, 11, 4968.	5.8	183
72	Reacciones adversas a fármacos utilizados en el tratamiento específico de la infección por SARS-CoV-2. <i>Medicina Clínica</i> , 2020, 155, 448-453.	0.3	10
73	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <i>Nature Reviews Cardiology</i> , 2020, 17, 543-558.	6.1	999
74	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. <i>Cytotherapy</i> , 2020, 22, 474-481.	0.3	29

#	ARTICLE	IF	CITATIONS
75	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. <i>ACS Infectious Diseases</i> , 2020, 6, 2304-2318.	1.8	42
76	Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status. <i>SLAS Discovery</i> , 2020, 25, 1097-1107.	1.4	5
77	Repurposing Existing Drugs for the Treatment of COVID-19. <i>Annals of the American Thoracic Society</i> , 2020, 17, 1186-1194.	1.5	19
78	A bibliometric analysis using VOSviewer of publications on COVID-19. <i>Annals of Translational Medicine</i> , 2020, 8, 816-816.	0.7	247
79	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. <i>Frontiers in Public Health</i> , 2020, 8, 384.	1.3	13
80	Kurarinone Inhibits HCoV-OC43 Infection by Impairing the Virus-Induced Autophagic Flux in MRC-5 Human Lung Cells. <i>Journal of Clinical Medicine</i> , 2020, 9, 2230.	1.0	21
81	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. <i>Journal of NeuroImmune Pharmacology</i> , 2020, 15, 359-386.	2.1	391
82	Micro and nanoscale technologies in oral drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 157, 37-62.	6.6	123
83	Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19. <i>Cellular Signalling</i> , 2020, 74, 109721.	1.7	105
84	Remdesivir during induction chemotherapy for newly diagnosed paediatric acute lymphoblastic leukaemia with concomitant SARS-CoV-2 infection. <i>British Journal of Haematology</i> , 2020, 190, e274-e276.	1.2	20
85	A Randomized, Open-Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID-19, a Pilot Study. <i>Advanced Science</i> , 2020, 7, 2001435.	5.6	89
86	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 367-375.	1.8	24
87	Coagulopathy in COVID-19: Focus on vascular thrombotic events. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 146, 32-40.	0.9	49
88	Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 2020, 11, 1013.	1.6	59
89	Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment. <i>Biosafety and Health</i> , 2020, 2, 210-216.	1.2	23
90	Immune response in COVID-19: A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1619-1629.	1.9	281
91	The Economic and Public Health Imperatives Around Making Potential Coronavirus Disease 2019 Treatments Available and Affordable. <i>Value in Health</i> , 2020, 23, 1427-1431.	0.1	8
92	Emerging trends in inhaled drug delivery. <i>Advanced Drug Delivery Reviews</i> , 2020, 157, 63-70.	6.6	52

#	ARTICLE	IF	CITATIONS
93	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resistance Updates, 2020, 53, 100719.	6.5	110
94	Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. EClinicalMedicine, 2020, 25, 100449.	3.2	155
95	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. European Journal of Medicinal Chemistry, 2020, 203, 112647.	2.6	26
96	Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs. Journal of Chemical Information and Modeling, 2020, 60, 5730-5734.	2.5	3
97	Diselenide-Mediated Catalytic Functionalization of Hydrophosphoryl Compounds. Organic Letters, 2020, 22, 5811-5816.	2.4	28
98	Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. International Journal of Environmental Research and Public Health, 2020, 17, 5026.	1.2	55
99	Incidental diagnosis of lung adenocarcinoma following coronavirus OC 43 severe pneumonia. Monaldi Archives for Chest Disease, 2020, 90, .	0.3	6
100	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. SN Comprehensive Clinical Medicine, 2020, 2, 1120-1131.	0.3	19
101	COVID-19: Leave politics out of practicing medicine. Cardiovascular Revascularization Medicine, 2020, 21, 937-938.	0.3	4
102	Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. Nephrology Dialysis Transplantation, 2020, 35, 1250-1261.	0.4	73
103	The epidemiology and therapeutic options for the COVID-19. Precision Clinical Medicine, 2020, 3, 71-84.	1.3	17
104	Saxifraga spinulosa-Derived Components Rapidly Inactivate Multiple Viruses Including SARS-CoV-2. Viruses, 2020, 12, 699.	1.5	15
105	RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. SLAS Discovery, 2020, 25, 1141-1151.	1.4	131
106	Known drugs and small molecules in the battle for COVID-19 treatment. Genes and Diseases, 2020, 7, 528-534.	1.5	14
107	Emergency Nursing Care of Patients With Novel Coronavirus Disease 2019. Journal of Emergency Nursing, 2020, 46, 748-759.	0.5	18
108	The dynamic treatment of SARS-CoV-2 disease. Baylor University Medical Center Proceedings, 2020, 33, 572-579.	0.2	2
109	Use of tocilizumab in kidney transplant recipients with COVID-19. American Journal of Transplantation, 2020, 20, 3182-3190.	2.6	72
110	Communicating Science in the Time of a Pandemic. JAMA - Journal of the American Medical Association, 2020, 324, 443.	3.8	54

#	ARTICLE	IF	CITATIONS
111	Rapid production of clinical-grade SARS-CoV-2 specific T cells. <i>Advances in Cell and Gene Therapy</i> , 2020, 3, e101.	0.6	24
112	Opportunities for biomaterials to address the challenges of COVID-19. <i>Journal of Biomedical Materials Research - Part A</i> , 2020, 108, 1974-1990.	2.1	43
113	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. <i>Intensive Care Medicine</i> , 2020, 46, 2265-2283.	3.9	52
114	That Escalated Quickly: Remdesivir's Place in Therapy for COVID-19. <i>Infectious Diseases and Therapy</i> , 2020, 9, 525-536.	1.8	16
115	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020, 7, 572485.	1.2	15
116	Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19. <i>Frontiers in Medicine</i> , 2020, 7, 588711.	1.2	37
117	Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies. <i>Frontiers in Veterinary Science</i> , 2020, 7, 620.	0.9	25
118	Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8141.	1.8	4
119	Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. <i>Medical Anthropology Quarterly</i> , 2020, 34, 525-541.	0.7	41
120	Structure-guided discovery approach identifies potential lead compounds targeting Mpro of SARS-CoV-2. <i>VirusDisease</i> , 2020, 31, 549-553.	1.0	2
121	The unusual experience of managing a severe COVID-19 case at home: what can we do and where do we go?. <i>BMC Infectious Diseases</i> , 2020, 20, 862.	1.3	5
122	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. <i>Journal of Thoracic Disease</i> , 2020, 12, 6054-6069.	0.6	14
123	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 434-441.	0.6	5
124	The Emergency Response Capacity of Plant-Based Biopharmaceutical Manufacturing-What It Is and What It Could Be. <i>Frontiers in Plant Science</i> , 2020, 11, 594019.	1.7	48
125	Structure-based identification of potential SARS-CoV-2 main protease inhibitors. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 3595-3608.	2.0	50
126	Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. <i>Critical Care Medicine</i> , 2020, 48, 1841-1844.	0.4	70
127	Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort. <i>Revue De Medecine Interne</i> , 2020, 41, 732-740.	0.6	11
128	Novel aryltriazole acyclic C-azanucleosides as anticancer candidates. <i>Organic and Biomolecular Chemistry</i> , 2020, 18, 9689-9699.	1.5	5

#	ARTICLE	IF	CITATIONS
129	Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2663-2684.	1.1	13
130	<p>Repurposing Anti-Cancer Drugs for COVID-19 Treatment</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 5045-5058.	2.0	28
131	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	79
132	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096784.	0.6	17
133	Perinatal Maternal-Fetal/Neonatal Transmission of COVID-19: A Guide to Safe Maternal and Neonatal Care in the Era of COVID-19 and Physical Distancing. <i>NeoReviews</i> , 2020, 21, e783-e794.	0.4	9
134	Status of Novel Coronavirus Disease 2019 (COVID-19) and Animal Production. <i>Frontiers in Veterinary Science</i> , 2020, 7, 586919.	0.9	12
135	<p>N-Acetylcysteine to Combat COVID-19: An Evidence Review</p>. <i>Therapeutics and Clinical Risk Management</i> , 2020, Volume 16, 1047-1055.	0.9	87
136	Newly Reported Studies on the Increase in Gastrointestinal Symptom Prevalence with COVID-19 Infection: A Comprehensive Systematic Review and Meta-Analysis. <i>Diseases (Basel, Switzerland)</i> , 2020, 8, 41.	1.0	11
138	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. <i>Food and Chemical Toxicology</i> , 2020, 146, 111805.	1.8	31
139	Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2020, 14, 117954842096414.	0.5	4
140	Implications of COVID-19 pandemic on lung cancer management: A multidisciplinary perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103120.	2.0	17
141	Translating scientific discoveries during pandemics: ensuring equity for people affected by COVID-19 and tuberculosis. <i>ERJ Open Research</i> , 2020, 6, 00562-2020.	1.1	0
142	FDA efficiency for approval process of COVID-19 therapeutics. <i>Infectious Agents and Cancer</i> , 2020, 15, 73.	1.2	8
143	From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic. <i>Medicina Intensiva (English Edition)</i> , 2020, 44, 509-512.	0.1	0
144	Colorimetric Detection of SARS-CoV-2 and Drug-Resistant pH1N1 Using CRISPR/dCas9. <i>ACS Sensors</i> , 2020, 5, 4017-4026.	4.0	75
145	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa481.	0.4	22
146	Clinical Characteristics, Diagnosis, and Treatment of Major Coronavirus Outbreaks. <i>Frontiers in Medicine</i> , 2020, 7, 581521.	1.2	42
147	Coronavirus and Homo Sapiens in Coronavirus Disease 2019 (COVID-19). <i>Journal of Cardiac Critical Care TSS</i> , 2020, 4, 121-131.	0.0	0

#	ARTICLE	IF	CITATIONS
148	Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 491-500.	0.4	10
149	Pre-existing Liver Diseases and On-Admission Liver-Related Laboratory Tests in COVID-19: A Prognostic Accuracy Meta-Analysis With Systematic Review. <i>Frontiers in Medicine</i> , 2020, 7, 572115.	1.2	18
150	Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge. <i>Molecules</i> , 2020, 25, 5695.	1.7	64
151	Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study. <i>EClinicalMedicine</i> , 2020, 28, 100590.	3.2	129
152	Pulmonary vascular improvement in severe COVID-19 patients treated with tocilizumab. <i>Immunology Letters</i> , 2020, 228, 122-128.	1.1	14
153	Clinical Outcomes Following Tocilizumab Administration in Mechanically Ventilated Coronavirus Disease 2019 Patients. , 2020, 2, e0232.		7
154	<p>Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients</p>. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3907-3918.	1.1	2
155	Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases. <i>Microorganisms</i> , 2020, 8, 1733.	1.6	16
156	Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection. <i>Annals of Internal Medicine</i> , 2020, 173, 782-790.	2.0	175
157	Pandémie À SARS-CoV-2: Éthique et intégrité oubliées devant la précipitation pour publier. <i>La Presse Médicale Formation</i> , 2020, 1, 572-581.	0.1	5
158	Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 448-453.	0.1	4
159	Efficacy of early prone or lateral positioning in patients with severe COVID-19: a single-center prospective cohort. <i>Precision Clinical Medicine</i> , 2020, 3, 260-271.	1.3	10
160	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. <i>Methods in Pharmacology and Toxicology</i> , 2020, , 329-431.	0.1	4
161	Peptide and peptide-based inhibitors of SARS-CoV-2 entry. <i>Advanced Drug Delivery Reviews</i> , 2020, 167, 47-65.	6.6	132
162	The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. <i>International Journal of Infectious Diseases</i> , 2020, 100, 67-74.	1.5	12
163	Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 768-770.	0.7	27
164	The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro. <i>Antiviral Research</i> , 2020, 182, 104902.	1.9	25
165	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. <i>Transplantation Proceedings</i> , 2020, 52, 2659-2662.	0.3	21

#	ARTICLE	IF	CITATIONS
166	The COVID-19 pandemic: A community approach. <i>Clinical Transplantation</i> , 2020, 34, e14059.	0.8	10
167	<p>A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19</p>; Drug Design, Development and Therapy, 2020, Volume 14, 3215-3222.	2.0	44
168	COVID-19: The Immune Responses and Clinical Therapy Candidates. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5559.	1.8	25
169	Addendum to Systematic Review of Remdesivir for the Treatment of COVID-19. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 742-743.	0.6	3
170	Remdesivir: A beacon of hope from Ebola virus disease to <sc>COVID</sc>-19. <i>Reviews in Medical Virology</i> , 2020, 30, 1-13.	3.9	25
171	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. <i>European Journal of Pharmacology</i> , 2020, 887, 173467.	1.7	16
172	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. <i>International Immunopharmacology</i> , 2020, 88, 106885.	1.7	30
173	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1738-1748.	0.6	36
174	COVID-19: Pharmacology and kinetics of viral clearance. <i>Pharmacological Research</i> , 2020, 161, 105114.	3.1	17
175	In silico investigation of phytoconstituents from Indian medicinal herb <i>Tinospora cordifolia</i> (giloy) against SARS-CoV-2 (COVID-19) by molecular dynamics approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6792-6809.	2.0	109
176	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1821-1849.	0.9	6
177	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 957-975.	1.3	6
178	Tracking clinical resources for coronavirus disease 2019. <i>Current Opinion in Rheumatology</i> , 2020, 32, 441-448.	2.0	3
179	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
180	Emerging Therapeutic Modalities against COVID-19. <i>Pharmaceuticals</i> , 2020, 13, 188.	1.7	24
181	Drugs against SARS-CoV-2: What do we know about their mode of action?. <i>Reviews in Medical Virology</i> , 2020, 30, 1-10.	3.9	30
182	Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. <i>Annals of Emergency Medicine</i> , 2020, 76, 442-453.	0.3	219
183	Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review. <i>Journal of Infection and Public Health</i> , 2020, 13, 1187-1195.	1.9	67

#	ARTICLE	IF	CITATIONS
184	COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. <i>New Microbes and New Infections</i> , 2020, 37, 100738.	0.8	88
185	Racial Disproportionality in Covid Clinical Trials. <i>New England Journal of Medicine</i> , 2020, 383, e59.	13.9	126
186	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. <i>Virologica Sinica</i> , 2020, 35, 725-733.	1.2	40
187	Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105182.	0.7	24
188	Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. <i>Cell Discovery</i> , 2020, 6, 50.	3.1	246
189	Covering coronavirusâ€™ emerging tools for the fight against the common enemy. <i>Oxford Medical Case Reports</i> , 2020, 2020, omaa035.	0.2	0
190	Molecular Underpinnings of Severe Coronavirus Disease 2019. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 638.	3.8	11
191	The wave of â€™opinion articlesâ€™ in the coverage of COVID-19 in surgical literature. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 877-878.	0.8	2
193	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. <i>Food and Chemical Toxicology</i> , 2020, 144, 111639.	1.8	42
194	Rapid Adaptation of a Surgical Research Unit to Conduct Clinical Trials During the COVID-19 Pandemic. <i>Journal of Surgical Research</i> , 2020, 256, 76-82.	0.8	3
195	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. <i>Clinical Infectious Diseases</i> , 2021, 73, e4166-e4174.	2.9	135
196	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
197	Substance Use Disorder in the COVID-19 Pandemic: A Systematic Review of Vulnerabilities and Complications. <i>Pharmaceuticals</i> , 2020, 13, 155.	1.7	88
198	HRS/EHRA/APHRS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e009007.	2.1	15
199	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. <i>Biochemical Pharmacology</i> , 2020, 180, 114169.	2.0	26
200	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs. <i>RSC Advances</i> , 2020, 10, 26895-26916.	1.7	40
201	Treating COVID-19: Review of Drug Hypersensitivity Reactions. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 385-399.	0.6	7
202	Leveraging the United States Epicenter to Provide Insights on COVIDâ€™19 in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 1971-1980.	2.9	51

#	ARTICLE	IF	CITATIONS
203	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. <i>Current Pharmacology Reports</i> , 2020, 6, 228-240.	1.5	17
204	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100159.	1.3	34
205	Management of multiple myeloma during COVID-19 pandemic. <i>Leukemia Research Reports</i> , 2020, 14, 100212.	0.2	2
206	COVID-19: A Multidisciplinary Review. <i>Frontiers in Public Health</i> , 2020, 8, 383.	1.3	208
207	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 776-787.	3.7	82
208	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- γ plus TFF2 in patients with moderate COVID-19. <i>EClinicalMedicine</i> , 2020, 25, 100478.	3.2	20
209	Drug Discovery Strategies for SARS-CoV-2. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 127-138.	1.3	83
210	COVID-19 and the Kidneys: An Update. <i>Frontiers in Medicine</i> , 2020, 7, 423.	1.2	79
211	Liver injury in remdesivir-treated COVID-19 patients. <i>Hepatology International</i> , 2020, 14, 881-883.	1.9	96
212	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020, 7, e601-e612.	2.2	56
213	COVID-19 management in light of the circadian clock. <i>Nature Reviews Molecular Cell Biology</i> , 2020, 21, 494-495.	16.1	55
214	Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. <i>Nature Reviews Rheumatology</i> , 2020, 16, 581-589.	3.5	203
215	Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer. <i>Biopreservation and Biobanking</i> , 2020, 18, 492-502.	0.5	9
216	Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13362.	1.7	275
217	Clinical Factors Associated with Progression and Prolonged Viral Shedding in COVID-19 Patients: A Multicenter Study. , 2020, 11, 1069.		28
218	<p>Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 3001-3013.	2.0	21
219	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 745-764.	0.9	14
220	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 945-956.	1.3	3

#	ARTICLE	IF	CITATIONS
221	Review: An insight into coronaviruses: Challenges, security and scope. <i>Reviews in Medical Virology</i> , 2020, 30, 1-8.	3.9	6
222	Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: A pilot study. <i>Journal of Critical Care</i> , 2020, 60, 328-333.	1.0	37
223	The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. <i>Journal of Infection and Public Health</i> , 2020, 13, 1601-1610.	1.9	127
224	Remdesivir: Remedy the world is waiting for?. <i>Medical Journal Armed Forces India</i> , 2020, 76, 250-252.	0.3	0
225	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 6828-6841.	2.0	30
226	Tocilizumab in severe COVID-19. <i>Archives of Medical Science</i> , 2020, 16, 1457-1458.	0.4	4
227	Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection. <i>European Journal of Pharmacology</i> , 2020, 885, 173450.	1.7	15
228	Improvement of the <i>C</i> -glycosylation Step for the Synthesis of Remdesivir. <i>Organic Process Research and Development</i> , 2020, 24, 1772-1777.	1.3	26
229	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. <i>Hepatology</i> , 2020, 72, 1819-1837.	3.6	17
230	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. <i>Biochemical Pharmacology</i> , 2020, 180, 114184.	2.0	50
231	Severe COVID-19 disease in two pediatric oncology patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28432.	0.8	16
232	Safety profile of the antiviral drug remdesivir: An update. <i>Biomedicine and Pharmacotherapy</i> , 2020, 130, 110532.	2.5	82
233	Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2835-2836.	2.4	59
234	Actualizaci3n en COVID-19 y enfermedad hep3tica. <i>Gastroenterolog3a Y Hepatolog3a</i> , 2020, 43, 472-480.	0.2	25
235	Coronaviruses disease 2019 (COVID-19): Causative agent, mental health concerns, and potential management options. <i>Journal of Infection and Public Health</i> , 2020, 13, 1840-1844.	1.9	34
236	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. <i>Drug Discovery Today</i> , 2020, 25, 1822-1838.	3.2	13
237	COVID-19: Clinical aspects and therapeutics responses. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1004-1008.	1.2	39
238	Potential mechanisms of Chinese Herbal Medicine that implicated in the treatment of COVID-19 related renal injury. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1138-1148.	1.2	16

#	ARTICLE	IF	CITATIONS
239	Epidemiological and clinical differences of coronavirus disease 2019 patients with distinct viral exposure history. <i>Virulence</i> , 2020, 11, 1015-1023.	1.8	4
240	The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 712-718.	0.6	1
241	Joint analysis of duration of ventilation, length of intensive care, and mortality of COVID-19 patients: a multistate approach. <i>BMC Medical Research Methodology</i> , 2020, 20, 206.	1.4	83
242	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. <i>Life</i> , 2020, 10, 146.	1.1	6
243	Cardiovascular manifestation and treatment in COVID-19. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 704-709.	0.6	29
244	Remdesivir. <i>Reactions Weekly</i> , 2020, 1812, 250-250.	0.0	0
245	Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. <i>Kidney International</i> , 2020, 98, 1530-1539.	2.6	203
246	The 11th Trial of a Cardiovascular Clinical Trialist. <i>Cardiology in Review</i> , 2020, 28, 217-218.	0.6	1
247	Understanding COVID-19: From Origin to Potential Therapeutics. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5904.	1.2	13
248	Identification of a New Potential SARS-COV-2 RNA-Dependent RNA Polymerase Inhibitor via Combining Fragment-Based Drug Design, Docking, Molecular Dynamics, and MM-PBSA Calculations. <i>Frontiers in Chemistry</i> , 2020, 8, 584894.	1.8	35
249	Hordatinines as a Potential Inhibitor of COVID-19 Main Protease and RNA Polymerase: An In-Silico Approach. <i>Natural Products and Bioprospecting</i> , 2020, 10, 453-462.	2.0	11
250	Antivirals for COVID-19 in Solid Organ Transplant Recipients. <i>Current Transplantation Reports</i> , 2020, 7, 355-365.	0.9	12
251	Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area. <i>MBio</i> , 2020, 11, .	1.8	99
252	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 570927.	2.2	28
253	Exploring RdRpâ€™remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV. <i>SAR and QSAR in Environmental Research</i> , 2020, 31, 857-867.	1.0	8
254	Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19). <i>Obstetrics and Gynecology</i> , 2020, 136, 1025-1029.	1.2	37
255	PHARMACOLOGICAL TREATMENTS OF COVID-19 â€™ A REVIEW. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 16-22.	0.3	4
256	COVID-19 update: The race to therapeutic development. <i>Drug Resistance Updates</i> , 2020, 53, 100733.	6.5	49

#	ARTICLE	IF	CITATIONS
257	QTc Interval Prolongation and Life-Threatening Arrhythmias During Hospitalization in Patients With Coronavirus Disease 2019 (COVID-19): Results From a Multicenter Prospective Registry. <i>Clinical Infectious Diseases</i> , 2021, 73, e4031-e4038.	2.9	22
258	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. <i>BMJ</i> , The, 2020, 371, m3869.	3.0	16
259	Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. <i>Frontiers in Endocrinology</i> , 2020, 11, 583006.	1.5	8
260	Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing. <i>Pharmaceutics</i> , 2020, 12, 1002.	2.0	86
261	Assessing via Simulation the Operating Characteristics of the WHO Scale for COVID-19 Endpoints. <i>Statistics in Biopharmaceutical Research</i> , 2020, 12, 451-460.	0.6	3
262	Current Understanding of COVID-19 Clinical Course and Investigational Treatments. <i>Frontiers in Medicine</i> , 2020, 7, 555301.	1.2	23
263	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31
264	Hypoxia, HIF-1 \pm , and COVID-19: from pathogenic factors to potential therapeutic targets. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1539-1546.	2.8	154
265	COVID-19: An overview for dermatologists. <i>International Journal of Dermatology</i> , 2020, 59, 1437-1449.	0.5	16
266	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
267	Identification of SARS-CoV-2 entry inhibitors among already approved drugs. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 1347-1353.	2.8	66
268	Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. <i>Reviews in Medical Virology</i> , 2021, 31, e2187.	3.9	76
269	Intricate interplay between Covid-19 and cardiovascular diseases. <i>Reviews in Medical Virology</i> , 2020, 31, e2188.	3.9	9
270	Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 38, 101906.	1.5	33
271	IL-4/IL-13 remodeling pathway of COVID-19 lung injury. <i>Scientific Reports</i> , 2020, 10, 18689.	1.6	81
272	Answering 20 more questions on COVID-19 (March-April 2020). <i>Journal of Global Health</i> , 2020, 10, 020102.	1.2	9
273	A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases. <i>Cytokine</i> , 2020, 136, 155228.	1.4	9
274	The Case for Methodological Pluralism in Medical Science. <i>American Journal of Bioethics</i> , 2020, 20, 39-41.	0.5	2

#	ARTICLE	IF	CITATIONS
275	Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009. BMC Medicine, 2020, 18, 265.	2.3	15
276	Remdesivir: First Approval. Drugs, 2020, 80, 1355-1363.	4.9	176
277	Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience. Open Forum Infectious Diseases, 2020, 7, ofaa319.	0.4	16
278	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. SN Comprehensive Clinical Medicine, 2020, 2, 1777-1789.	0.3	51
279	Recommendations for prenatal, intrapartum, and postpartum care during COVID-19 pandemic in India. American Journal of Reproductive Immunology, 2020, 84, e13336.	1.2	7
280	COVID-19: In the Eye of the Cytokine Storm. Frontiers in Immunology, 2020, 11, 558898.	2.2	107
281	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. Molecules, 2020, 25, 3980.	1.7	80
282	Drug repurposing approach to fight COVID-19. Pharmacological Reports, 2020, 72, 1479-1508.	1.5	323
283	Immune Response Resetting as a Novel Strategy to Overcome SARS-CoV-2-Induced Cytokine Storm. Journal of Immunology, 2020, 205, 2566-2575.	0.4	16
284	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. Journal of Arrhythmia, 2020, 36, 813-826.	0.5	10
285	The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019. Journal of Translational Medicine, 2020, 18, 359.	1.8	20
286	Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thrombosis and Haemostasis, 2020, 120, 1680-1690.	1.8	38
287	Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians' Conundrum. Annals of the National Academy of Medical Sciences (India), 2020, 56, 119-125.	0.2	0
288	Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched cohort study. American Journal of Transplantation, 2020, 20, 3198-3205.	2.6	48
289	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. SLAS Discovery, 2020, 25, 1108-1122.	1.4	25
290	Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital. Medicina Clínica (English Edition), 2020, 155, 222-223.	0.1	0
291	Decreased HD-MIR2911 absorption in human subjects with the SIDT1 polymorphism fails to inhibit SARS-CoV-2 replication. Cell Discovery, 2020, 6, 63.	3.1	18
292	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). Clinical and Translational Science, 2020, 13, 1023-1033.	1.5	11

#	ARTICLE	IF	CITATIONS
293	Remdesivir: an antiviral for the treatment of COVID-19. <i>The Prescriber</i> , 2020, 31, 31-33.	0.1	1
294	Overview of the First 6 Months of Clinical Trials for COVID-19 Pharmacotherapy: The Most Studied Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 497.	1.3	14
295	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 599-609.	0.4	5
296	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a newly emerged pathogen: an overview. <i>Pathogens and Disease</i> , 2020, 78, .	0.8	17
297	Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 3359-3365.	1.3	41
298	Identification of Potential Inhibitors of Calcium/Calmodulin-Dependent Protein Kinase IV from Bioactive Phytoconstituents. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-14.	1.9	39
299	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. <i>Processes</i> , 2020, 8, 937.	1.3	23
300	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Journal of Medicinal Chemistry</i> , 2020, 63, 13205-13227.	2.9	40
301	Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C) <i>Tj ETQq0 00rgBT /Owlock 10</i>		
302	Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication. <i>Nature Communications</i> , 2020, 11, 4282.	5.8	334
303	Reverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-report. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 389.	0.7	28
304	Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). <i>Future Microbiology</i> , 2020, 15, 1287-1305.	1.0	86
305	Balancing Scientific Rigor With Urgency in the Coronavirus Disease 2019 Pandemic. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa304.	0.4	10
306	Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000650.	1.2	64
307	<p>A Review on Novel Drug Targets and Future Directions for COVID-19 Treatment</p>. <i>Biologics: Targets and Therapy</i> , 2020, Volume 14, 77-82.	3.0	17
308	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. <i>Frontiers in Immunology</i> , 2020, 11, 1969.	2.2	5
309	Is Nanotechnology Helping in the Fight Against COVID-19?. <i>Frontiers in Nanotechnology</i> , 2020, 2, .	2.4	27
310	COVID-19 pandemic and the tension between the need to act and the need to know. <i>Internal Medicine Journal</i> , 2020, 50, 904-909.	0.5	6

#	ARTICLE	IF	CITATIONS
311	Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for severe acute respiratory syndrome coronavirus 2 patients. <i>European Respiratory Journal</i> , 2020, 56, 2001531.	3.1	27
312	Bibliometric Analysis on COVID-19: A Comparison of Research Between English and Chinese Studies. <i>Frontiers in Public Health</i> , 2020, 8, 477.	1.3	83
313	What Should Be Known by a Urologist About the Medical Management of COVID-19's Patients?. <i>Current Urology Reports</i> , 2020, 21, 44.	1.0	0
314	Confronting hidden COVID-19 burden: a telemedical solution for elective urological outpatient clinics. <i>Infection</i> , 2020, 48, 935-939.	2.3	2
315	Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All. <i>Infectious Diseases and Therapy</i> , 2020, 9, 701-705.	1.8	23
316	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. <i>Frontiers in Pharmacology</i> , 2020, 11, 582025.	1.6	14
317	Analysis and prediction of the COVID-19 outbreak in Pakistan. <i>Journal of Biological Dynamics</i> , 2020, 14, 730-747.	0.8	7
318	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. <i>Shock</i> , 2020, 54, 416-437.	1.0	41
319	Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000646.	1.2	42
320	Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 550-563.	1.4	75
321	The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19). <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 129.	1.1	14
322	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. <i>EClinicalMedicine</i> , 2020, 26, 100525.	3.2	64
325	Severe acute respiratory syndrome coronavirus-2 and the deduction effect of angiotensin-converting enzyme 2 in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 812-816.	0.6	14
326	Improvement of Severe COVID-19 in an Elderly Man by Sequential Use of Antiviral Drugs. <i>Case Reports in Infectious Diseases</i> , 2020, 2020, 1-4.	0.2	1
327	Directly Acting Antivirals for COVID-19: Where Do We Stand?. <i>Frontiers in Microbiology</i> , 2020, 11, 1857.	1.5	18
328	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. <i>Advances in Therapy</i> , 2020, 37, 4107-4131.	1.3	3
329	Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies. <i>Pulmonary Medicine</i> , 2020, 2020, 1-10.	0.5	202
330	COVID-19 Therapeutic Options Under Investigation. <i>Frontiers in Pharmacology</i> , 2020, 11, 1196.	1.6	65

#	ARTICLE	IF	CITATIONS
331	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 1258.	1.6	91
332	Comorbidity Assessment Is Essential During COVID-19 Treatment. <i>Frontiers in Physiology</i> , 2020, 11, 984.	1.3	29
333	A family cluster of diagnosed coronavirus disease 2019 (COVID-19) kidney transplant recipient in Thailand. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 534-543.	1.3	8
334	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2591.	1.0	17
335	COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions. <i>Microorganisms</i> , 2020, 8, 1228.	1.6	29
336	Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases. <i>Current Medical Science</i> , 2020, 40, 597-601.	0.7	6
337	Is there any potential management against COVID-19? A systematic review and meta-analysis. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2020, 28, 765-777.	0.9	13
338	Analysis of COVID-19 Cases and Public Measures in China. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1306-1312.	0.3	8
339	Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. <i>Journal of Proteome Research</i> , 2020, 19, 4442-4454.	1.8	142
340	On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2. <i>Cell Death and Disease</i> , 2020, 11, 656.	2.7	40
341	Critical Care Management for Novel 2019 SARS-CoV-2 and HCoV-NL63 Coinfection in a Young Immunocompromised Patient: A Chicago Experience. <i>Case Reports in Critical Care</i> , 2020, 2020, 1-8.	0.2	7
342	Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. <i>Clinical Trials</i> , 2020, 17, 491-500.	0.7	56
343	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. <i>Microorganisms</i> , 2020, 8, 1259.	1.6	14
344	A Narrative Review of Emerging Therapeutics for COVID-19. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 745-758.	1.2	7
345	Taming the Autophagy as a Strategy for Treating COVID-19. <i>Cells</i> , 2020, 9, 2679.	1.8	52
346	Blockage of interleukin-1 β with canakinumab in patients with Covid-19. <i>Scientific Reports</i> , 2020, 10, 21775.	1.6	58
347	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697.	1.6	65
348	Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase. <i>IScience</i> , 2020, 23, 101849.	1.9	51

#	ARTICLE	IF	CITATIONS
349	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. <i>BMC Geriatrics</i> , 2020, 20, 538.	1.1	38
350	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. <i>Frontiers in Pharmacology</i> , 2020, 11, 584956.	1.6	51
351	The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective. <i>Frontiers in Medicine</i> , 2020, 7, 596587.	1.2	12
352	Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. <i>Nature Communications</i> , 2020, 11, 6385.	5.8	103
353	Phylogenetic supertree reveals detailed evolution of SARS-CoV-2. <i>Scientific Reports</i> , 2020, 10, 22366.	1.6	39
354	Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic. <i>Frontiers in Medicine</i> , 2020, 7, 598038.	1.2	24
355	A Glimpse of the First Eight Months of the COVID-19 Literature on Microsoft Academic Graph: Themes, Citation Contexts, and Uncertainties. <i>Frontiers in Research Metrics and Analytics</i> , 2020, 5, 607286.	0.9	96
356	Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2. <i>Frontiers in Chemistry</i> , 2020, 8, 590263.	1.8	24
357	COVID-19 and dermatology. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1751-1759.	0.4	26
358	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9360.	1.2	11
359	Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey. <i>EClinicalMedicine</i> , 2020, 27, 100539.	3.2	15
360	Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations. <i>Journal of Physical Chemistry B</i> , 2020, 124, 11337-11348.	1.2	71
361	COVID-19-Induced Cytokine Release Syndrome Associated with Pulmonary Vein Thromboses, Atrial Cardiomyopathy, and Arterial Intima Inflammation. <i>TH Open</i> , 2020, 04, e271-e279.	0.7	15
362	Tocilizumab Use in a Chronic Hemodialysis Patient for the Management of COVID-19-Associated Pneumonia and Acute Respiratory Distress Syndrome. <i>Case Reports in Nephrology</i> , 2020, 2020, 1-5.	0.2	4
363	COVID-19 in Renal Transplant Recipients: Case Series and a Brief Review of Current Evidence. <i>Nephron</i> , 2021, 145, 192-198.	0.9	29
364	Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey. <i>Cardio-Oncology</i> , 2020, 6, 28.	0.8	19
365	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. <i>Frontiers in Immunology</i> , 2020, 11, 586572.	2.2	69
366	Gender differences in treatment of Coronavirus Disease-2019. <i>Monaldi Archives for Chest Disease</i> , 2020, 90, .	0.3	10

#	ARTICLE	IF	CITATIONS
367	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100137.	3.3	56
368	Coronavirus pandemic: treatment and future prevention. <i>Future Microbiology</i> , 2020, 15, 1507-1521.	1.0	2
369	The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 590870.	2.2	37
370	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8155.	1.2	63
371	Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. <i>BMJ Case Reports</i> , 2020, 13, e239210.	0.2	8
372	Marked Sinus Bradycardia Associated With Remdesivir in COVID-19. <i>JACC: Case Reports</i> , 2020, 2, 2260-2264.	0.3	68
373	COVID-19 and liver disease: An update. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020, 43, 472-480.	0.0	15
374	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. <i>MedComm</i> , 2020, 1, 270-301.	3.1	22
375	Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center. <i>Transplantation</i> , 2020, 104, 2208-2214.	0.5	97
376	Tocilizumab and liver injury in patients with COVID-19. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482095918.	1.4	33
377	COVID-19: the epidemiology and treatment. <i>British Journal of Hospital Medicine (London, England:)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.2	9
378	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. <i>Journal of Clinical Medicine</i> , 2020, 9, 3488.	1.0	59
379	Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience. <i>Journal of Osteopathic Medicine</i> , 2020, 120, 926-933.	0.4	10
380	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. <i>Drugs</i> , 2020, 80, 1961-1972.	4.9	24
381	A current review of COVID-19 for the cardiovascular specialist. <i>American Heart Journal</i> , 2020, 226, 29-44.	1.2	97
382	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. <i>Autoimmunity Reviews</i> , 2020, 19, 102569.	2.5	173
383	Current targeted therapeutics against COVID-19: Based on first-line experience in China. <i>Pharmacological Research</i> , 2020, 157, 104854.	3.1	30
384	Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. <i>ACS Central Science</i> , 2020, 6, 672-683.	5.3	684

#	ARTICLE	IF	CITATIONS
385	Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs. <i>Pathogens</i> , 2020, 9, 320.	1.2	26
386	An environmental and health perspective for COVID-19 outbreak: Meteorology and air quality influence, sewage epidemiology indicator, hospitals disinfection, drug therapies and recommendations. <i>Journal of Environmental Chemical Engineering</i> , 2020, 8, 104006.	3.3	171
387	To counter the pandemic, clinicians bank on repurposed drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 10616-10620.	3.3	6
388	Angiotensinâ€converting enzyme 2 (<sc>ACE2</sc>), <sc>SARSâ€CoV</sc>â€2 and the pathophysiology of coronavirus disease 2019 (<sc>COVID</sc>â€19). <i>Journal of Pathology</i> , 2020, 251, 228-248.	2.1	791
389	Early experience with remdesivir in SARS-CoV-2 pneumonia. <i>Infection</i> , 2020, 48, 779-782.	2.3	23
390	COVID-19 â€“ What does a paediatrician need to know?. <i>Paediatric Respiratory Reviews</i> , 2020, 35, 3-8.	1.2	5
391	Three months of <sc>COVID</sc>â€19: A systematic review and metaâ€analysis. <i>Reviews in Medical Virology</i> , 2020, 30, e2113.	3.9	38
392	Repurposing current therapeutics for treating COVID â€19: A vital role of prescription records data mining. <i>Drug Development Research</i> , 2020, 81, 777-781.	1.4	17
393	The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. <i>Case Reports in Women's Health</i> , 2020, 27, e00221.	0.2	67
394	Old and re-purposed drugs for the treatment of COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 843-847.	2.0	49
395	Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	3
396	COVID-19 as an Acute Inflammatory Disease. <i>Journal of Immunology</i> , 2020, 205, 12-19.	0.4	133
397	The liver in times of COVID-19: What hepatologists should know. <i>Annals of Hepatology</i> , 2020, 19, 353-358.	0.6	72
398	Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report. <i>International Journal of Infectious Diseases</i> , 2020, 97, 215-218.	1.5	41
399	COVID-19, asthma, and biological therapies: What we need to know. <i>World Allergy Organization Journal</i> , 2020, 13, 100126.	1.6	90
400	COVID-19: An Update about the Discovery Clinical Trial. <i>Pharmaceuticals</i> , 2020, 13, 98.	1.7	10
401	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. <i>Vaccines</i> , 2020, 8, 224.	2.1	47
402	COVIDâ€19 Clinical trials: Quality matters more than quantity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2542-2547.	2.7	20

#	ARTICLE	IF	CITATIONS
403	Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E). <i>Molecules</i> , 2020, 25, 2343.	1.7	31
404	Prioritization of Anti-SARS-CoV-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 775-790.	2.3	118
405	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. <i>Military Medical Research</i> , 2020, 7, 22.	1.9	57
406	In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE2 receptor homologs and human TLRs. <i>Journal of Medical Virology</i> , 2020, 92, 2105-2113.	2.5	354
407	COVID-19 and Cancer: a Comprehensive Review. <i>Current Oncology Reports</i> , 2020, 22, 53.	1.8	220
408	Severe Acute Respiratory Syndrome Coronavirus 2: Genomic Observations and Emerging Therapies. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 49-52.	0.3	1
409	Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. <i>Stem Cells and Development</i> , 2020, 29, 747-754.	1.1	469
410	Coronavirus Pandemic—Therapy and Vaccines. <i>Biomedicines</i> , 2020, 8, 109.	1.4	42
411	Rapid review for the anti-coronavirus effect of remdesivir. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 73-76.	0.6	48
412	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	2.2	808
413	Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 100-102.	0.6	38
414	An Update on Current Therapeutic Drugs Treating COVID-19. <i>Current Pharmacology Reports</i> , 2020, 6, 56-70.	1.5	438
415	AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. <i>Gastroenterology</i> , 2020, 159, 320-334.e27.	0.6	330
416	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 382, 2147-2156.	13.9	67
417	COVID-19 and toxicity from potential treatments: Panacea or poison. <i>EMA - Emergency Medicine Australasia</i> , 2020, 32, 697-699.	0.5	8
418	Review article: COVID-19 and liver disease—what we know on 1st May 2020. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 267-275.	1.9	137
419	Drug repurposing against COVID-19: focus on anticancer agents. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 86.	3.5	57
420	Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. <i>Journal of Traditional and Complementary Medicine</i> , 2020, 10, 420-427.	1.5	190

#	ARTICLE	IF	CITATIONS
421	A Collaborative Multidisciplinary Approach to the Management of Coronavirus Disease 2019 in the Hospital Setting. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1467-1481.	1.4	21
422	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 315-325.	2.3	44
423	Information and Disinformation: Social Media in the COVID-19 Crisis. <i>Academic Emergency Medicine</i> , 2020, 27, 640-641.	0.8	125
424	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. <i>British Journal of Haematology</i> , 2020, 190, 346-357.	1.2	17
425	Clinical Characteristics of Elderly Patients with COVID-19 in Hunan Province, China: A Multicenter, Retrospective Study. <i>Gerontology</i> , 2020, 66, 467-475.	1.4	94
426	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?. <i>Frontiers in Pharmacology</i> , 2020, 11, 791.	1.6	16
427	Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients. <i>Journal of Medical Virology</i> , 2020, 92, 2648-2656.	2.5	34
428	Anticoagulation, immortality, and observations of COVID-19. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 674-676.	1.0	7
429	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. <i>Organic Process Research and Development</i> , 2020, 24, 940-976.	1.3	77
430	Review of the present features and the infection control challenges of COVID-19 pandemic in dialysis facilities. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 393-398.	0.8	5
432	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. <i>Viruses</i> , 2020, 12, 526.	1.5	197
433	Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 730-733.	2.3	22
434	Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. <i>Pharmacological Research</i> , 2020, 158, 104899.	3.1	175
435	What Do We Know About Remdesivir Drug Interactions?. <i>Clinical and Translational Science</i> , 2020, 13, 842-844.	1.5	71
436	Compassionate Use of Remdesivir in Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, e101.	13.9	126
437	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. <i>MSphere</i> , 2020, 5, .	1.3	66
438	Drug repurposing in the era of COVID-19: a call for leadership and government investment. <i>Medical Journal of Australia</i> , 2020, 212, 450.	0.8	14
439	Current evidence for directed and supportive investigational therapies against COVID-19. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2020, 26, 45.	0.3	1

#	ARTICLE	IF	CITATIONS
440	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. <i>Science China Life Sciences</i> , 2020, 63, 1515-1521.	2.3	121
441	Immunology of COVID-19: Current State of the Science. <i>Immunity</i> , 2020, 52, 910-941.	6.6	1,387
442	Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 58-60.	1.5	24
443	Remdesivir in Treatment of COVID-19: A Systematic Benefit-Risk Assessment. <i>Drug Safety</i> , 2020, 43, 645-656.	1.4	54
444	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 893-903.	5.1	421
445	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. <i>American Journal of Pathology</i> , 2020, 190, 1680-1690.	1.9	239
446	Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients. , 2020, 213, 107587.		216
447	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. <i>Current Research in Translational Medicine</i> , 2020, 68, 93-104.	1.2	18
449	Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit. <i>AAPS Journal</i> , 2020, 22, 77.	2.2	98
450	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). <i>Pharmacological Research</i> , 2020, 158, 104929.	3.1	95
451	Development of a Large-Scale Cyanation Process Using Continuous Flow Chemistry En Route to the Synthesis of Remdesivir. <i>Organic Process Research and Development</i> , 2020, 24, 2113-2121.	1.3	51
452	Potential specific therapies in COVID-19. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092685.	1.0	18
453	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	2.9	95
454	COVID-19: a brief history and treatments in development. <i>The Prescriber</i> , 2020, 31, 23-28.	0.1	35
455	The COVID-19 Pandemic in Japan. <i>Surgery Today</i> , 2020, 50, 787-793.	0.7	50
456	Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review. <i>Infectious Diseases and Therapy</i> , 2020, 9, 435-449.	1.8	46
457	Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. <i>Medical Hypotheses</i> , 2020, 143, 109851.	0.8	53
458	Early Outpatient Treatment of Symptomatic, High-Risk COVID-19 Patients That Should Be Ramped Up Immediately as Key to the Pandemic Crisis. <i>American Journal of Epidemiology</i> , 2020, 189, 1218-1226.	1.6	58

#	ARTICLE	IF	CITATIONS
459	Practice considerations on the use of investigational anti- COVID-19 medications: Dosage, administration and monitoring. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1199-1205.	0.7	10
460	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. <i>Journal of Inflammation</i> , 2020, 17, 21.	1.5	73
461	Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent. <i>Letters in Drug Design and Discovery</i> , 2020, 17, 940-942.	0.4	6
462	Current emerging SARS-CoV-2 pandemic: Potential direct/indirect negative impacts of virus persistence and related therapeutic drugs on the aquatic compartments. <i>Environmental Research</i> , 2020, 188, 109808.	3.7	40
463	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. <i>Hellenic Journal of Cardiology</i> , 2020, 61, 381-395.	0.4	43
464	HRS/EHRA/APHRS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1363-1374.	1.2	37
465	Covid-19: a comprehensive review of a formidable foe and the road ahead. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 869-879.	1.0	15
466	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. <i>Heart Rhythm</i> , 2020, 17, e255-e268.	0.3	20
467	A compendium answering 150 questions on COVID-19 and SARS-CoV-2 . <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	2.7	95
468	Metabolic syndrome and COVID-19 : An update on the associated comorbidities and proposed therapies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 809-814.	1.8	99
469	The Effects of ARBs, ACEIs, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 909-914.e2.	1.2	145
471	COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2354-2356.	1.3	27
472	Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. <i>Cell Research</i> , 2020, 30, 678-692.	5.7	662
473	The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 . <i>Cytokine and Growth Factor Reviews</i> , 2020, 54, 51-61.	3.2	84
474	Arthroplasty during the COVID-19 Pandemic. <i>Arthroplasty Today</i> , 2020, 6, 427-430.	0.8	12
475	A systematic review of pathological findings in COVID-19 : a pathophysiological timeline and possible mechanisms of disease progression. <i>Modern Pathology</i> , 2020, 33, 2128-2138.	2.9	378
476	SARS-CoV-2 infection in kidney transplant recipients: Experience of the Italian Marche region. <i>Transplant Infectious Disease</i> , 2020, 22, e13377.	0.7	22
477	Application of System Biology to Explore the Association of Neprilysin, Angiotensin-Converting Enzyme 2 (ACE2), and Carbonic Anhydrase (CA) in Pathogenesis of SARS-CoV-2. <i>Biological Procedures Online</i> , 2020, 22, 11.	1.4	32

#	ARTICLE	IF	CITATIONS
478	Novel therapeutic approaches for treatment of COVID-19. Journal of Molecular Medicine, 2020, 98, 789-803.	1.7	42
479	A lesson from a saboteur: High-MW kininogen impact in coronavirus-induced disease 2019. British Journal of Pharmacology, 2020, 177, 4866-4872.	2.7	32
480	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. Physiological Reviews, 2020, 100, 1455-1466.	13.1	116
481	Implications of COVID-19 in pediatric rheumatology. Rheumatology International, 2020, 40, 1193-1213.	1.5	35
482	Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatology, The, 2020, 2, e393-e400.	2.2	526
483	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung and Circulation, 2020, 29, 973-987.	0.2	136
484	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. European Journal of Medicinal Chemistry, 2020, 201, 112527.	2.6	85
485	Current regulatory approaches for accessing potential COVID-19 therapies. Journal of Pharmaceutical Policy and Practice, 2020, 13, 16.	1.1	7
486	Vaccines and Therapies in Development for SARS-CoV-2 Infections. Journal of Clinical Medicine, 2020, 9, 1885.	1.0	46
488	Neurological manifestations and implications of COVID-19 pandemic. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093203.	1.5	114
489	Erythropoietin as candidate for supportive treatment of severe COVID-19. Molecular Medicine, 2020, 26, 58.	1.9	43
490	Consensus statement of the Italian society of pediatric allergy and immunology for the pragmatic management of children and adolescents with allergic or immunological diseases during the COVID-19 pandemic. Italian Journal of Pediatrics, 2020, 46, 84.	1.0	69
491	Rapid advice guidelines for management of children with COVID-19. Annals of Translational Medicine, 2020, 8, 617-617.	0.7	26
492	Interrelationship Between Coronavirus Infection and Liver Disease. Clinical Liver Disease, 2020, 15, 175-180.	1.0	52
494	COVID-19 research: pandemic <i>versus</i> â€œpaperdemicâ€, integrity, values and risks of the â€œspeed scienceâ€. Forensic Sciences Research, 2020, 5, 174-187.	0.9	84
495	The Combination of Tocilizumab and Methylprednisolone Along With Initial Lung Recruitment Strategy in Coronavirus Disease 2019 Patients Requiring Mechanical Ventilation: A Series of 21 Consecutive Cases. , 2020, 2, e0145.		10
496	Perspectives on Cardiopulmonary Critical Care for Patients With COVID-19: From Members of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation. Journal of the American Heart Association, 2020, 9, e017111.	1.6	5
497	Infant With SARS-CoV-2 Infection Causing Severe Lung Disease Treated With Remdesivir. Pediatrics, 2020, 146, .	1.0	43

#	ARTICLE	IF	CITATIONS
498	Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 624-624.	0.7	10
499	Potential Treatments for SARS-CoV-2 Infection. <i>Clinical Liver Disease</i> , 2020, 15, 181-186.	1.0	6
500	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. <i>Aging Clinical and Experimental Research</i> , 2020, 32, 1599-1608.	1.4	277
501	Tracing open data in emergencies: The case of the COVID-19 pandemic. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13323.	1.7	15
502	Dissecting the interaction between COVID-19 and diabetes mellitus. <i>Journal of Diabetes Investigation</i> , 2020, 11, 1104-1114.	1.1	44
503	Novel insights on the pulmonary vascular consequences of COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L277-L288.	1.3	125
504	Developing an Ethics Framework for Allocating Remdesivir in the COVID-19 Pandemic. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1946-1954.	1.4	12
505	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. <i>Modern Pathology</i> , 2020, 33, 2104-2114.	2.9	257
506	The laboratory's role in combating COVID-19. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 400-414.	2.7	42
507	Oral Methioninase for Covid-19 Methionine-restriction Therapy. <i>In Vivo</i> , 2020, 34, 1593-1596.	0.6	12
508	Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. <i>In Vivo</i> , 2020, 34, 1597-1602.	0.6	53
509	Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019. <i>Clinical and Translational Medicine</i> , 2020, 10, e35.	1.7	37
510	COVID-19: from epidemiology to treatment. <i>European Heart Journal</i> , 2020, 41, 2092-2112.	1.0	67
511	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2775-2793.	2.7	23
512	Drugs being investigated for children with COVID-19. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 1905-1906.	0.7	0
513	Redundancy and methodological issues in articles on COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13301.	1.7	3
514	Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1384-1386.	3.0	142
515	COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. <i>In Vivo</i> , 2020, 34, 1567-1588.	0.6	87

#	ARTICLE	IF	CITATIONS
516	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-CoV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020, 135, 251-259.	1.3	102
517	COVID-19 infection: the China and Italy perspectives. <i>Cell Death and Disease</i> , 2020, 11, 438.	2.7	76
518	Additive treatment considerations in COVID-19: The clinician's perspective on extracorporeal adjunctive purification techniques. <i>Artificial Organs</i> , 2020, 44, 918-925.	1.0	20
519	How likely are COVID-19 interventions to benefit the sickest patients?. <i>Intensive Care Medicine</i> , 2020, 46, 1441-1444.	3.9	3
520	The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. <i>Leukemia</i> , 2020, 34, 1805-1815.	3.3	188
521	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. <i>New England Journal of Medicine</i> , 2020, 382, 2354-2364.	13.9	15
522	How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 899-904.	0.4	96
523	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 1770.	1.0	42
524	Acute kidney injury in critically ill patients with COVID-19. <i>Intensive Care Medicine</i> , 2020, 46, 1339-1348.	3.9	385
525	Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2020, 1866, 165878.	1.8	770
526	Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. <i>Cell</i> , 2020, 182, 734-743.e5.	13.5	398
527	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. <i>European Journal of Internal Medicine</i> , 2020, 77, 163-164.	1.0	2
528	Vitamin D receptor stimulation to reduce acute respiratory distress syndrome (ARDS) in patients with coronavirus SARS-CoV-2 infections. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2020, 202, 105719.	1.2	128
529	COVID-19 Diagnostics, Tools, and Prevention. <i>Diagnostics</i> , 2020, 10, 409.	1.3	62
530	Discovering small-molecule therapeutics against SARS-CoV-2. <i>Drug Discovery Today</i> , 2020, 25, 1535-1544.	3.2	85
531	Practical Considerations for Solid Organ Transplantation During the COVID-19 Global Outbreak: The Experience from Singapore. <i>Transplantation Direct</i> , 2020, 6, e554.	0.8	21
532	The Global Phosphorylation Landscape of SARS-CoV-2 Infection. <i>Cell</i> , 2020, 182, 685-712.e19.	13.5	825
533	Possible SARS-coronavirus 2 inhibitor revealed by simulated molecular docking to viral main protease and host toll-like receptor. <i>Future Virology</i> , 2020, 15, 359-368.	0.9	42

#	ARTICLE	IF	CITATIONS
534	Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines). <i>Cancer Treatment Reviews</i> , 2020, 88, 102063.	3.4	30
535	Semantic and Geographical Analysis of COVID-19 Trials Reveals a Fragmented Clinical Research Landscape Likely to Impair Informativeness. <i>Frontiers in Medicine</i> , 2020, 7, 367.	1.2	8
536	The rise and evolution of COVID-19. <i>International Journal of Women's Dermatology</i> , 2020, 6, 248-254.	1.1	6
537	Supportive treatment of COVID 19 patients with mild respiratory failure in a primary hospital. <i>Medicina Clínica</i> , 2020, 155, 222-223.	0.3	4
538	Treating a Global Health Crisis with a Dose of Synthetic Chemistry. <i>ACS Central Science</i> , 2020, 6, 1017-1030.	5.3	25
539	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. <i>Theranostics</i> , 2020, 10, 7448-7464.	4.6	180
540	Fundamental protective mechanisms of face masks against droplet infections. <i>Journal of Aerosol Science</i> , 2020, 148, 105617.	1.8	139
541	GS-5734: a potentially approved drug by FDA against SARS-Cov-2. <i>New Journal of Chemistry</i> , 2020, 44, 12417-12429.	1.4	24
542	Pathological Role of Angiotensin II in Severe COVID-19. <i>TH Open</i> , 2020, 04, e138-e144.	0.7	87
543	Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2977-2980.	1.3	90
544	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. <i>Medicina (Lithuania)</i> , 2020, 56, 315.	0.8	4
545	Remdesivir "Bringing Hope for COVID-19 Treatment. <i>Scientia Pharmaceutica</i> , 2020, 88, 29.	0.7	24
546	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. <i>International Journal of Infectious Diseases</i> , 2020, 97, 396-403.	1.5	445
547	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 285-299.	1.5	46
548	Low-dose radiation as a treatment for COVID-19 pneumonia: A threat or real opportunity?. <i>Medical Physics</i> , 2020, 47, 3773-3776.	1.6	17
550	Natural history of COVID-19 and current knowledge on treatment therapeutic options. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110493.	2.5	118
551	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. <i>European Urology Focus</i> , 2020, 6, 1028-1031.	1.6	5
552	Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update. <i>Journal of Digestive Endoscopy</i> , 2020, 11, 69-72.	0.1	3

#	ARTICLE	IF	CITATIONS
553	Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. <i>Critical Care</i> , 2020, 24, 389.	2.5	158
554	Large vessel stroke and COVID-19: Case report and literature review. <i>ENeurologicalSci</i> , 2020, 20, 100250.	0.5	21
555	COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106080.	1.1	149
556	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	1.4	36
557	SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approachesâ€”Insights into Chemical Structureâ€”Biological Activity and Toxicological Screening. <i>Journal of Clinical Medicine</i> , 2020, 9, 2084.	1.0	38
558	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. <i>Cell Reports</i> , 2020, 32, 107940.	2.9	412
559	Pandemic COVID-19: Current status and challenges of antiviral therapies. <i>Genes and Diseases</i> , 2020, 7, 502-519.	1.5	11
560	Covid-19 treatment-induced neuropsychiatric adverse effects. <i>General Hospital Psychiatry</i> , 2020, 67, 163-164.	1.2	27
561	Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 584-599.	1.9	194
562	COVID-19 Serological Tests: How Well Do They Actually Perform?. <i>Diagnostics</i> , 2020, 10, 453.	1.3	109
563	Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. <i>Future Medicinal Chemistry</i> , 2020, 12, 1565-1578.	1.1	22
564	Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. <i>Reviews in Medical Virology</i> , 2020, 30, e2136.	3.9	12
565	COVID-19 Pandemic in India: What Lies Ahead-Letter to the Editor. <i>Indian Journal of Clinical Biochemistry</i> , 2020, 35, 380-381.	0.9	19
566	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. <i>Communications Biology</i> , 2020, 3, 374.	2.0	112
567	Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19. <i>Journal of Drug Targeting</i> , 2020, 28, 742-754.	2.1	34
568	Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13342.	1.7	11
569	Expert consensus on prevention and control of COVID-19 in the neurological intensive care unit (first) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.5	1
570	Progress in the Research and Development of Anti-COVID-19 Drugs. <i>Frontiers in Public Health</i> , 2020, 8, 365.	1.3	21

#	ARTICLE	IF	CITATIONS
572	Successful management of the first reported case in Austria of COVID-19 with ARDS. <i>Infection</i> , 2020, 48, 647-651.	2.3	11
573	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 694-699.	0.3	30
574	Compassionate drug use: an imperative challenge for Bulgarian health system during COVID-19. <i>Health Policy and Technology</i> , 2020, 9, 274-275.	1.3	5
575	What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials. <i>Med</i> , 2020, 1, 9-10.	2.2	5
576	Severe SARS-CoV-2 infection in critical care. <i>Trends in Anaesthesia and Critical Care</i> , 2020, 34, 28-37.	0.4	3
577	COVID-19: From pathogenesis models to the first drug trials. <i>Microbial Biotechnology</i> , 2020, 13, 1289-1299.	2.0	2
578	Commercial influence and covid-19. <i>BMJ, The</i> , 2020, 369, m2456.	3.0	17
579	Pharmacotherapeutics Advice in Guidelines for COVID-19. <i>Frontiers in Pharmacology</i> , 2020, 11, 950.	1.6	6
580	COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. <i>Journal of Clinical Medicine</i> , 2020, 9, 1917.	1.0	137
581	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. <i>Frontiers in Immunology</i> , 2020, 11, 1294.	2.2	17
582	COVID-19 and Heart: From Clinical Features to Pharmacological Implications. <i>Journal of Clinical Medicine</i> , 2020, 9, 1944.	1.0	36
583	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. <i>Advanced Science</i> , 2020, 7, 2001474.	5.6	14
584	COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 653-661.	2.7	978
585	Environmental concern regarding the effect of humidity and temperature on 2019-nCoV survival: fact or fiction. <i>Environmental Science and Pollution Research</i> , 2020, 27, 36027-36036.	2.7	63
586	COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. <i>Heart Rhythm</i> , 2020, 17, 1984-1990.	0.3	217
587	A prospect on the use of antiviral drugs to control local outbreaks of COVID-19. <i>BMC Medicine</i> , 2020, 18, 191.	2.3	47
588	Current therapies under investigation for COVID-19: potential COVID-19 treatments. <i>Canadian Journal of Physiology and Pharmacology</i> , 2020, 98, 483-489.	0.7	6
589	Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy. <i>Frontiers in Pharmacology</i> , 2020, 11, 1095.	1.6	44

#	ARTICLE	IF	CITATIONS
590	Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein. <i>Protein Science</i> , 2020, 29, 1890-1901.	3.1	218
591	Case report study of the first five COVID-19 patients treated with remdesivir in France. <i>International Journal of Infectious Diseases</i> , 2020, 98, 290-293.	1.5	30
592	Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry. <i>Emerging Microbes and Infections</i> , 2020, 9, 1695-1701.	3.0	7
593	COVID-19: Progress in diagnostics, therapy and vaccination. <i>Theranostics</i> , 2020, 10, 7821-7835.	4.6	121
594	Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?. <i>Pharmacological Research</i> , 2020, 160, 105055.	3.1	5
595	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. <i>Therapeutic Advances in Psychopharmacology</i> , 2020, 10, 204512532093530.	1.2	39
596	Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100164.	1.3	24
597	Outbreak of COVID-19: An emerging global pandemic threat. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110499.	2.5	48
598	Complete Heart Block, Severe Ventricular Dysfunction, and Myocardial Inflammation in a Child With COVID-19 Infection. <i>JACC: Case Reports</i> , 2020, 2, 1351-1355.	0.3	33
599	Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France. <i>Clinical Infectious Diseases</i> , 2020, 71, 2447-2456.	2.9	50
600	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemic: the right choice at the right time. <i>Journal of Cardiovascular Medicine</i> , 2020, 21, 535-537.	0.6	8
601	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2020, 395, 1569-1578.	6.3	2,875
603	Remdesivir in covid-19. <i>BMJ, The</i> , 2020, 369, m1610.	3.0	91
604	Remdesivir for COVID-19: challenges of underpowered studies. <i>Lancet, The</i> , 2020, 395, 1525-1527.	6.3	74
605	The clinical manifestations and management of COVID-19-related liver injury. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1016-1018.	0.8	35
606	Treatment Considerations for COVID-19. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1454-1466.	1.4	79
607	COVID-19: treating and managing severe cases. <i>Cell Research</i> , 2020, 30, 370-371.	5.7	19
608	Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment. <i>Pathogens</i> , 2020, 9, 324.	1.2	184

#	ARTICLE	IF	CITATIONS
609	Candidate drugs against SARS-CoV-2 and COVID-19. <i>Pharmacological Research</i> , 2020, 157, 104859.	3.1	426
610	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. <i>Cell Reports Medicine</i> , 2020, 1, 100016.	3.3	102
611	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 144, 47-53.	0.9	111
612	Cutaneous side effects of the potential COVID-19 drugs. <i>Dermatologic Therapy</i> , 2020, 33, e13476.	0.8	55
613	Redundancy in reporting on COVID-19. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13257.	1.7	5
614	Antiviral treatment of COVID-19. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 611-619.	0.4	214
615	Novel coronavirus disease (COVID-19) in children. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 592-603.	0.4	144
616	Radiation therapy considerations during the COVID-19 Pandemic: Literature review and expert opinions. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 6-12.	0.8	14
617	COVID-19—What we know and what we need to know: There are more questions than answers. <i>Herz</i> , 2020, 45, 311-312.	0.4	7
618	Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e147-e160.	2.0	37
619	COVID-19: Immunology and treatment options. <i>Clinical Immunology</i> , 2020, 215, 108448.	1.4	485
620	COVID-19 pandemic—a focused review for clinicians. <i>Clinical Microbiology and Infection</i> , 2020, 26, 842-847.	2.8	289
621	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With Coronavirus Disease 2019 (COVID-19). <i>Clinical Infectious Diseases</i> , 2020, , .	2.9	708
623	Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6558-6570.	1.6	86
624	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. <i>Hepatology</i> , 2020, 72, 287-304.	3.6	408
625	Current status of potential therapeutic candidates for the COVID-19 crisis. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 59-73.	2.0	239
626	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 701-715.	0.6	130
627	Taking the Longer View of COVID-19. <i>Oncologist</i> , 2020, 25, 455-457.	1.9	7

#	ARTICLE	IF	CITATIONS
628	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 1954-1963.	1.5	148
629	Never Give Up: Lesson learned from a severe COVID-19 patient. <i>Pulmonology</i> , 2021, 27, 257-260.	1.0	0
630	Pharmacotherapy for hospitalized patients with COVID-19: Waiting or doing?. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 2049.	1.5	1
631	COVID-19 Patients with Recent Influenza A/B Infection: A Retrospective Study. <i>Journal of Infection</i> , 2021, 82, 159-198.	1.7	9
632	The impact of the SARS-CoV-2 infection, with special reference to the hematological setting. <i>Journal of Medical Virology</i> , 2021, 93, 223-233.	2.5	23
633	RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target. <i>Journal of Medical Virology</i> , 2021, 93, 300-310.	2.5	82
634	A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 205-214.	1.3	18
635	Heparin 2.0: A New Approach to the Infection Crisis. <i>Blood Purification</i> , 2021, 50, 28-34.	0.9	69
636	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. <i>Europace</i> , 2021, 23, 313-313.	0.7	32
637	Recent insights for the emerging COVID-19: Drug discovery, therapeutic options and vaccine development. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 4-23.	4.3	46
638	MuLBSTA score is a useful tool for predicting COVID-19 disease behavior. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 284-290.	0.8	11
639	Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. <i>Microbial Pathogenesis</i> , 2021, 152, 104554.	1.3	88
640	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. <i>Briefings in Bioinformatics</i> , 2021, 22, 1232-1238.	3.2	10
641	Insights from nanotechnology in COVID-19 treatment. <i>Nano Today</i> , 2021, 36, 101019.	6.2	146
642	SARS-CoV-2 and the pandemic of COVID-19. <i>Postgraduate Medical Journal</i> , 2021, 97, 110-116.	0.9	179
643	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 " can we end this viral series?. <i>Archives of Medical Science</i> , 2021, 17, 275-284.	0.4	6
644	A literature review of 2019 novel coronavirus (SARS-CoV2) infection in neonates and children. <i>Pediatric Research</i> , 2021, 89, 1101-1108.	1.1	48
645	Emerging Human Coronavirus Infections (SARS, MERS, and COVID-19): Where They Are Leading Us. <i>International Reviews of Immunology</i> , 2021, 40, 5-53.	1.5	20

#	ARTICLE	IF	CITATIONS
646	Comparison of COVID-19 Health Risks With Other Viral Occupational Hazards. <i>International Journal of Health Services</i> , 2021, 51, 37-49.	1.2	6
647	COVID-19 and AIDS: Outcomes from the coexistence of two global pandemics and the importance of chronic antiretroviral therapy. <i>Journal of Medical Virology</i> , 2021, 93, 641-643.	2.5	12
648	Virus-CKB: an integrated bioinformatics platform and analysis resource for COVID-19 research. <i>Briefings in Bioinformatics</i> , 2021, 22, 882-895.	3.2	28
649	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. <i>Vascular</i> , 2021, 29, 220-227.	0.4	1
650	Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. <i>Drug Development Research</i> , 2021, 82, 12-26.	1.4	15
651	Covid-19 and the cardiovascular system: a comprehensive review. <i>Journal of Human Hypertension</i> , 2021, 35, 4-11.	1.0	238
652	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2021, 93, 775-785.	2.5	19
653	Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis. <i>Hepatology</i> , 2021, 73, 1521-1530.	3.6	39
654	Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study. <i>Journal of Medical Virology</i> , 2021, 93, 831-842.	2.5	37
655	Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 249-259.	1.3	33
656	Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH). <i>Medicina Intensiva</i> , 2021, 45, 104-121.	0.4	18
657	Severe SARS-CoV-2 disease in the context of a NF- κ B2 loss-of-function pathogenic variant. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 532-544.e1.	1.5	25
658	Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. <i>Genomics</i> , 2021, 113, 1221-1232.	1.3	126
659	Characteristics of SARS-CoV-2 and COVID-19. <i>Nature Reviews Microbiology</i> , 2021, 19, 141-154.	13.6	3,334
660	COVID-19: Between Past and Present. <i>Viral Immunology</i> , 2021, 34, 145-157.	0.6	3
661	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. <i>Inflammation</i> , 2021, 44, 13-34.	1.7	162
662	COVID-19: Discovery, diagnostics and drug development. <i>Journal of Hepatology</i> , 2021, 74, 168-184.	1.8	302
663	Targeting Polyamines Inhibits Coronavirus Infection by Reducing Cellular Attachment and Entry. <i>ACS Infectious Diseases</i> , 2021, 7, 1423-1432.	1.8	26

#	ARTICLE	IF	CITATIONS
664	Are open-source approaches the most efficient way forward for COVID-19 drug discovery?. Expert Opinion on Drug Discovery, 2021, 16, 115-117.	2.5	1
665	Remdesivir and its antiviral activity against COVID-19: A systematic review. Clinical Epidemiology and Global Health, 2021, 9, 123-127.	0.9	143
666	Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 165978.	1.8	22
667	Antiviral therapies: advances and perspectives. Fundamental and Clinical Pharmacology, 2021, 35, 305-320.	1.0	30
668	SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?. Annals of the New York Academy of Sciences, 2021, 1486, 15-38.	1.8	100
669	Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options. ChemBioChem, 2021, 22, 939-948.	1.3	50
670	Perspectives on mechanistic implications of ROS inducers for targeting viral infections. European Journal of Pharmacology, 2021, 890, 173621.	1.7	9
671	Does IHU-Mediterranean Infection influence Gilead Sciences' stock price?. New Microbes and New Infections, 2021, 39, 100711.	0.8	2
672	Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU. British Journal of Anaesthesia, 2021, 126, e33-e35.	1.5	21
673	MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs. Briefings in Bioinformatics, 2021, 22, 946-962.	3.2	21
674	SARS-CoV-2 (COVID-19) in patients with some degree of immunosuppression. Reumatologia Clínica (English Edition), 2021, 17, 408-419.	0.2	17
675	Pathogenesis-directed therapy of 2019 novel coronavirus disease. Journal of Medical Virology, 2021, 93, 1320-1342.	2.5	40
676	Severe acute respiratory syndrome-coronavirus spike (S) protein based vaccine candidates: State of the art and future prospects. Reviews in Medical Virology, 2021, 31, e2183.	3.9	43
677	Cardiac Involvement of COVID-19: A Comprehensive Review. American Journal of the Medical Sciences, 2021, 361, 14-22.	0.4	104
678	COVID 19 and liver: An "Z" literature review. Digestive and Liver Disease, 2021, 53, 146-152.	0.4	65
679	Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus. Advanced Therapeutics, 2021, 4, 2000203.	1.6	16
680	C4 article: Implications of COVID-19 in transplantation. American Journal of Transplantation, 2021, 21, 1801-1815.	2.6	15
681	Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. Clinical Immunology, 2021, 223, 108631.	1.4	15

#	ARTICLE	IF	CITATIONS
682	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. <i>Biochemical Pharmacology</i> , 2021, 183, 114296.	2.0	79
683	Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: A case-series. <i>Artificial Organs</i> , 2021, 45, E101-E112.	1.0	54
684	Toward a Molecular Basis of Cellular Nucleoside Transport in Humans. <i>Chemical Reviews</i> , 2021, 121, 5336-5358.	23.0	19
685	Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. <i>International Journal of Clinical Practice</i> , 2021, 75, e13868.	0.8	54
686	Nanotechnology for virus treatment. <i>Nano Today</i> , 2021, 36, 101031.	6.2	58
687	Use of dexamethasone, remdesivir, convalescent plasma and prone positioning in the treatment of severe COVID-19 infection in pregnancy: A case report. <i>Case Reports in Women's Health</i> , 2021, 29, e00273.	0.2	21
688	The Effects of Traditional Chinese Medicine as an Auxiliary Treatment for COVID-19: A Systematic Review and Meta-Analysis. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 225-237.	2.1	28
689	Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models. <i>Cell Research</i> , 2021, 31, 17-24.	5.7	86
690	Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 95-103.	1.3	46
691	Immunity and inflammatory biomarkers in COVID-19: A systematic review. <i>Reviews in Medical Virology</i> , 2021, 31, e2199.	3.9	48
692	Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia. <i>Leukemia</i> , 2021, 35, 635-638.	3.3	30
693	COVID-19; current situation and recommended interventions. <i>International Journal of Clinical Practice</i> , 2021, 75, e13886.	0.8	18
694	Public perceptions about pharmacists' role in prescribing, providing education and delivering medications during COVID-19 pandemic era. <i>International Journal of Clinical Practice</i> , 2021, 75, e13890.	0.8	16
695	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. <i>Medicinal Research Reviews</i> , 2021, 41, 1375-1426.	5.0	28
696	Immunopathogenesis and treatment of cytokine storm in COVID-19. <i>Theranostics</i> , 2021, 11, 316-329.	4.6	314
697	Targeting arachidonic acid-related metabolites in COVID-19 patients: potential use of drug-loaded nanoparticles. <i>Emergent Materials</i> , 2021, 4, 265-277.	3.2	20
698	Beneficial aspects of high dose intravenous vitamin C on patients with COVID-19 pneumonia in severe condition: a retrospective case series study. <i>Annals of Palliative Medicine</i> , 2021, 10, 1599-1609.	0.5	39
699	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. <i>International Reviews of Immunology</i> , 2021, 40, 108-125.	1.5	53

#	ARTICLE	IF	CITATIONS
700	Decoding the silent walk of COVID-19: Halting its spread using old bullets. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 110891.	2.5	1
701	A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111037.	2.5	58
702	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. <i>Theranostics</i> , 2021, 11, 731-753.	4.6	60
703	Imaging algorithm for COVID-19: A practical approach. <i>Clinical Imaging</i> , 2021, 72, 22-30.	0.8	14
704	<sc>IDentif</sc>.<sc>AI</sc>: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) with digital drug development. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10196.	3.9	27
705	Computational study of pomegranate peel extract polyphenols as potential inhibitors of SARS-CoV-2 virus internalization. <i>Molecular and Cellular Biochemistry</i> , 2021, 476, 1179-1193.	1.4	41
706	Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. <i>Chemistry and Physics of Lipids</i> , 2021, 234, 105009.	1.5	57
707	Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis. <i>Age and Ageing</i> , 2021, 50, 284-293.	0.7	27
708	Caution warranted for low-dose radiation therapy for Covid-19. <i>British Journal of Radiology</i> , 2021, 94, 20200466.	1.0	4
709	Management of Pregnancy during the COVID-19 Pandemic. <i>Global Challenges</i> , 2021, 5, 2000052.	1.8	11
710	Drug repurposing: new strategies for addressing COVID-19 outbreak. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 689-706.	2.0	17
711	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. <i>Chest</i> , 2021, 159, 1884-1893.	0.4	20
712	Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 168, 272-278.	3.6	27
713	Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. <i>Science Bulletin</i> , 2021, 66, 925-936.	4.3	29
714	Dynamics and Correlation Among Viral Positivity, Seroconversion, and Disease Severity in COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 453-461.	2.0	46
715	Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic. <i>Trends in Food Science and Technology</i> , 2021, 108, 187-196.	7.8	74
716	COVID-19: The experience from Iran. <i>Clinics in Dermatology</i> , 2021, 39, 23-32.	0.8	11
717	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 74-102.	0.5	13

#	ARTICLE	IF	CITATIONS
718	Building a hemodiafiltration system from readily available components for continuous renal replacement therapy under disasters and pandemics: preparing for an acute kidney injury surge during COVID-19. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 93-96.	1.0	2
719	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. <i>Frontiers in Molecular Biosciences</i> , 2021, 7, 585899.	1.6	12
720	Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic.. <i>Drug Discovery Today</i> , 2021, 26, 593-603.	3.2	52
721	Use of Remdesivir in Patients With COVID-19 on Hemodialysis: A Study of Safety and Tolerance. <i>Kidney International Reports</i> , 2021, 6, 586-593.	0.4	61
722	Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections. <i>Phytomedicine</i> , 2021, 86, 153440.	2.3	64
723	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalinizing Small Molecules. <i>ACS Infectious Diseases</i> , 2021, 7, 1389-1408.	1.8	74
724	Remdesivir and Coronavirus Disease 2019 (COVID-19): Essential Questions and Answers for Pharmacists and Pharmacy Technicians. <i>Journal of Pharmacy Technology</i> , 2021, 37, 62-74.	0.5	5
725	Remdesivir: From Ebola to COVID-19. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 145-150.	1.0	39
726	A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. <i>Biomedical Journal</i> , 2021, 44, 63-73.	1.4	14
727	Lymphocyte-depleting chemotherapy for aggressive hematologic malignancies in two patients with positive SARS-CoV-2 PCR. <i>Leukemia Research</i> , 2021, 100, 106473.	0.4	3
728	Virological cure, clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies. <i>Pharmacie Hospitalier Et Clinicien</i> , 2021, 56, 90-93.	0.3	0
729	In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease. <i>Frontiers in Chemistry</i> , 2020, 8, 595097.	1.8	28
730	A mechanism-based pharmacokinetic model of remdesivir leveraging interspecies scaling to simulate COVID-19 treatment in humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 89-99.	1.3	21
731	COVID-19 pandemic in Japan. <i>Rheumatology International</i> , 2021, 41, 1-5.	1.5	51
732	Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 1-15.	1.9	18
733	Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. <i>ACS Infectious Diseases</i> , 2021, 7, 1303-1316.	1.8	1
734	COVID-19. <i>Critical Care Nursing Quarterly</i> , 2021, 44, 128-137.	0.4	17
735	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <i>American Journal of Medicine</i> , 2021, 134, 166-175.	0.6	11

#	ARTICLE	IF	CITATIONS
736	Remdesivir: Critical Clinical Appraisal for COVID 19 Treatment. <i>Drug Research</i> , 2021, 71, 138-148.	0.7	10
737	Challenges of drug development during the COVID-19 pandemic: Key considerations for clinical trial designs. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2170-2185.	1.1	15
738	Emerging treatment strategies for COVID-19 infection. <i>Clinical and Experimental Medicine</i> , 2021, 21, 167-179.	1.9	232
739	Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically ill patients with COVID-19. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 454-459.	0.7	22
740	Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2. <i>Transfusion</i> , 2021, 61, 78-93.	0.8	17
741	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, 54, 27-36.	1.5	28
742	Multispecialty Nursing During COVID-19:. <i>Nurse Leader</i> , 2021, 19, 170-178.	0.4	11
743	Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing. <i>Stem Cells Translational Medicine</i> , 2021, 10, 239-250.	1.6	18
744	Recent progress of antiviral therapy for coronavirus disease 2019. <i>European Journal of Pharmacology</i> , 2021, 890, 173646.	1.7	32
745	Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis. <i>Life Sciences</i> , 2021, 264, 118663.	2.0	36
746	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 183-202.	1.4	62
747	Blood ozonization in patients with mild to moderate COVID-19 pneumonia: a single centre experience. <i>Internal and Emergency Medicine</i> , 2021, 16, 669-675.	1.0	19
748	Remdesivir in COVID-19 management: availability and relevance to low- and middle-income countries. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 26-28.	0.3	2
749	Filling the gaps in the characterization of the clinical management of COVID-19: 30-day hospital admission and fatality rates in a cohort of 118%150 cases diagnosed in outpatient settings in Spain. <i>International Journal of Epidemiology</i> , 2021, 49, 1930-1939.	0.9	32
750	Union is strength: antiviral and anti-inflammatory drugs for COVID-19. <i>Drug Discovery Today</i> , 2021, 26, 229-239.	3.2	23
751	Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 141-144.	0.8	5
752	Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. <i>Journal of Neurology</i> , 2021, 268, 1580-1591.	1.8	34
753	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. <i>Leukemia</i> , 2021, 35, 1121-1133.	3.3	61

#	ARTICLE	IF	CITATIONS
754	COVID-19 and hepatic involvement: The liver as a main actor of the pandemic novel. <i>Scandinavian Journal of Immunology</i> , 2021, 93, e12977.	1.3	17
755	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. <i>Clinical Infectious Diseases</i> , 2021, 72, e558-e565.	2.9	114
756	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
757	Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting. <i>Transplant Infectious Disease</i> , 2021, 23, e13470.	0.7	8
758	A Rationale for Use of High Flow Nasal Cannula for Select Patients With Suspected or Confirmed Severe Acute Respiratory Syndrome Coronavirus-2 Infection. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 9-17.	1.3	17
759	The effect of antivirals on COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 473-486.	2.0	10
760	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 34-48.	0.6	85
761	SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects. <i>Reviews in Medical Virology</i> , 2021, 31, e2168.	3.9	28
762	Management of SARS-CoV-2 pneumonia. <i>Journal of Medical Virology</i> , 2021, 93, 1276-1287.	2.5	22
763	Coronavirus Disease-2019 Treatment Strategies Targeting Interleukin-6 Signaling and Herbal Medicine. <i>OMICS A Journal of Integrative Biology</i> , 2021, 25, 13-22.	1.0	16
764	COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays. <i>Medicinal Research Reviews</i> , 2021, 41, 5-28.	5.0	72
765	Diagnosis and treatment of 471 patients with 2019 novel coronavirus disease (COVID-19). <i>Annals of Translational Medicine</i> , 2021, 9, 163-163.	0.7	0
766	A review: Mechanism of action of antiviral drugs. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110026.	1.0	141
767	COVID-19: What Should the General Practitioner Know?. <i>Clinical Interventions in Aging</i> , 2021, Volume 16, 43-56.	1.3	7
768	COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 46-60.	0.8	7
769	Application of Nanotechnology in the COVID-19 Pandemic. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 623-649.	3.3	60
770	Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant. <i>Current Opinion in Nephrology and Hypertension</i> , 2021, 30, 47-53.	1.0	3
771	Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19. <i>Topics in Current Chemistry</i> , 2021, 379, 4.	3.0	15

#	ARTICLE	IF	CITATIONS
772	Pathogenic Human Coronaviruses. , 2021, , .		5
773	Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents. Communications Biology, 2021, 4, 93.	2.0	158
774	Exploring the Association Between Sialic Acid and SARS-CoV-2 Spike Protein Through a Molecular Dynamics-Based Approach. Frontiers in Medical Technology, 2020, 2, 614652.	1.3	25
775	Inflammatory pathways and potential therapies for COVID-19: A mini review. European Journal of Inflammation, 2021, 19, 205873922110029.	0.2	6
776	Therapeutic targets and potential agents for the treatment of COVID-19. Medicinal Research Reviews, 2021, 41, 1775-1797.	5.0	21
777	Therapeutic options for COVID-19: a quick review. Journal of Chemotherapy, 2021, 33, 67-84.	0.7	10
778	DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses. Briefings in Bioinformatics, 2021, 22, 1076-1084.	3.2	17
779	Proteomic Approaches to Study SARS-CoV-2 Biology and COVID-19 Pathology. Journal of Proteome Research, 2021, 20, 1133-1152.	1.8	27
780	COVID-19-related medical research: a meta-research and critical appraisal. BMC Medical Research Methodology, 2021, 21, 1.	1.4	158
781	Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tocilizumab: A case series. Respiratory Medicine Case Reports, 2021, 32, 101319.	0.2	2
782	Robotics and 'Wissenschaft'. Journal of the Robotics Society of Japan, 2021, 39, 56-62.	0.0	0
783	Viral Infections in the ICU. , 2021, , 217-231.		0
784	SARS-CoV-2 (COVID-19): Beginning to Understand a New Virus. Advances in Experimental Medicine and Biology, 2021, 1321, 3-19.	0.8	10
785	Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients. Scientific Reports, 2021, 11, 1015.	1.6	20
786	Emerging therapeutics in the management of COVID-19. World Journal of Virology, 2021, 10, 1-29.	1.3	7
787	Coronavirus Pneumonia and Pulmonary Thromboembolism. BIO Integration, 2021, 1, .	0.9	1
788	A review on potential of natural products in the management of COVID-19. RSC Advances, 2021, 11, 16711-16735.	1.7	59
789	Applying the lessons learned from coronavirus disease 2019 to improve pneumonia management. Current Opinion in Infectious Diseases, 2021, 34, 175-179.	1.3	1

#	ARTICLE	IF	CITATIONS
790	Two polymorphs of remdesivir: crystal structure, solubility, and pharmacokinetic study. <i>CrystEngComm</i> , 2021, 23, 2923-2927.	1.3	5
791	Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-14.	2.0	5
792	Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis. <i>Genes and Genomics</i> , 2021, 43, 55-67.	0.5	3
793	MDA5 Governs the Innate Immune Response to SARS-CoV-2 in Lung Epithelial Cells. <i>Cell Reports</i> , 2021, 34, 108628.	2.9	287
794	20-Week Study of Clinical Outcomes of Over-the-Counter COVID-19 Prophylaxis and Treatment. <i>Journal of Evidence-based Integrative Medicine</i> , 2021, 26, 2515690X2110261.	1.4	16
795	Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2021, 36, 147-153.	2.5	29
796	Early mortality benefit with COVID-19 convalescent plasma: a matched control study. <i>British Journal of Haematology</i> , 2021, 192, 706-713.	1.2	45
797	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. <i>Journal of Biomedical Science</i> , 2021, 28, 9.	2.6	167
798	COVID-19: treatments and the potential for cardiotoxicity. <i>British Journal of Cardiology</i> , 2021, , .	0.7	3
799	Public Health Emergencies. <i>The International Library of Bioethics</i> , 2021, , 271-304.	0.1	0
800	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. <i>Alexander Saltanov Intensive Care Herald</i> , 2021, , 9-143.	0.2	6
801	Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. , 2021, , 27-89.		0
803	Transmission, diagnosis, and treatment of coronavirus disease 2020: a review. <i>Journal of Biochemical and Clinical Genetics</i> , 0, , 381-386.	0.1	0
804	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. <i>Frontiers in Physiology</i> , 2021, 12, 593223.	1.3	113
805	Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?. <i>Current Research in Pharmacology and Drug Discovery</i> , 2021, 2, 100048.	1.7	6
806	Low-dose radiotherapy for COVID 19: A radioimmunological perspective. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 295.	0.3	5
807	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. <i>International Journal of Risk and Safety in Medicine</i> , 2021, 32, 3-17.	0.3	4
808	Clinical Features for Severely and Critically Ill Patients with COVID-19 in Shandong: A Retrospective Cohort Study. <i>Therapeutics and Clinical Risk Management</i> , 2021, Volume 17, 9-21.	0.9	5

#	ARTICLE	IF	CITATIONS
809	Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis. Turkish Journal of Emergency Medicine, 2021, 21, 43.	0.3	11
810	“Update vision on COVID-19: Structure, immune pathogenesis, treatment and safety assessment” Sensors International, 2021, 2, 100073.	4.9	23
811	Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. Nature Computational Science, 2021, 1, 33-41.	3.8	88
812	A Hybrid Deep Learning Model for COVID-19 Prediction and Current Status of Clinical Trials Worldwide. Computers, Materials and Continua, 2021, 66, 1896-1919.	1.5	14
813	Pharmacists’™ role in infectious pandemics: illustration with COVID-19. , 2021, , 849-876.		3
814	Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus. Briefings in Bioinformatics, 2021, 22, 1378-1386.	3.2	39
815	Advanced Nanobiomedical Approaches to Combat Coronavirus Disease of 2019. Advanced NanoBiomed Research, 2021, 1, 2000063.	1.7	5
816	A Meta-Analysis of Association between Remdesivir and Mortality among Critically-Ill COVID-19 Patients. Infection and Chemotherapy, 2021, 53, 512.	1.0	3
817	Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients. Open Forum Infectious Diseases, 2021, 8, ofab001.	0.4	11
818	Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 2020, 7, 606429.	1.2	45
819	A review of Pharmacological Agents Used to Treat COVID-19 During the Pandemic.. Ahi Evran Medical Journal, 0, , .	0.1	0
821	Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants. Emerging Microbes and Infections, 2021, 10, 1227-1240.	3.0	17
822	The Immune Response and Effectiveness of COVID-19 Therapies. Advances in Experimental Medicine and Biology, 2021, 1321, 115-126.	0.8	6
823	Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19. Frontiers in Immunology, 2020, 11, 598402.	2.2	25
824	Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2. MAbs, 2021, 13, 1893426.	2.6	22
825	Common anti-COVID-19 drugs and their anticipated interaction with anesthetic agents. Journal of Anaesthesiology Clinical Pharmacology, 2021, 37, 160.	0.2	6
826	Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2). PLoS ONE, 2021, 16, e0245258.	1.1	19
827	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. Comparative Medicine, 2021, 71, 342-358.	0.4	3

#	ARTICLE	IF	CITATIONS
828	Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100083.	2.0	38
829	Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. <i>Clinics</i> , 2021, 76, e2342.	0.6	8
830	Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?. <i>Reviews in Medical Virology</i> , 2021, 31, 1-22.	3.9	18
831	COVID-19 infection in renal transplant patients: Early report from india. <i>Indian Journal of Nephrology</i> , 2021, 31, 271.	0.2	5
832	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. <i>Infection</i> , 2021, 49, 401-410.	2.3	66
833	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. <i>Frontiers in Physiology</i> , 2020, 11, 605908.	1.3	89
834	Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. <i>AAPS Journal</i> , 2021, 23, 14.	2.2	291
835	Autoimmune Processes Involved in Organ System Failure Following Infection with SARS-CoV-2. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 355-368.	0.8	0
836	Therapeutic Development in COVID-19. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1318, 435-448.	0.8	2
837	Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. <i>Lung India</i> , 2021, 38, 382-386.	0.3	5
838	Computational Technique for Effectiveness of Treatments Used in Curing SARS-CoV-2. <i>Intelligent Automation and Soft Computing</i> , 2021, 28, 617-628.	1.6	14
839	COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm. <i>Frontiers in Oncology</i> , 2020, 10, 599502.	1.3	9
840	Prediction of adverse drug reactions using drug convolutional neural networks. <i>Journal of Bioinformatics and Computational Biology</i> , 2021, 19, 2050046.	0.3	4
841	A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2. <i>Journal of Contemporary Studies in Epidemiology and Public Health</i> , 2021, 2, ep21001.	0.1	0
842	Therapeutic Strategies in the Management of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 636738.	1.6	10
843	Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. <i>Biological Procedures Online</i> , 2021, 23, 5.	1.4	20
844	Microvascular Angiopathic Consequences of COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 636843.	1.1	25
845	Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 6755-6770.	2.0	10

#	ARTICLE	IF	CITATIONS
846	The Era of the Coronavirus Disease 2019 Pandemic: A Review on Dynamics, Clinical Symptoms and Complications, Diagnosis, and Treatment. <i>Genetic Testing and Molecular Biomarkers</i> , 2021, 25, 85-101.	0.3	6
847	Atteintes pulmonaires liées à la COVID-19. <i>La Presse Médicale Formation</i> , 2021, 2, 14-24.	0.1	1
848	A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CL ^{pro} Inhibitor PF-00835231 as a Potential New Treatment for COVID-19. <i>Journal of Virology</i> , 2021, 95, .	1.5	94
849	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 583914.	1.6	8
850	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e22483.	1.2	2
851	Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements. <i>3 Biotech</i> , 2021, 11, 110.	1.1	2
852	Recent advances in materials science: a reinforced approach toward challenges against COVID-19. <i>Emergent Materials</i> , 2021, 4, 57-73.	3.2	6
853	Evolution of COVID-19 management in critical care: review and perspective from a hospital in the United Kingdom. <i>Acute and Critical Care</i> , 2021, 36, 1-14.	0.6	6
854	Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. <i>Annals of Medicine and Surgery</i> , 2021, 62, 43-48.	0.5	24
855	Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 628144.	1.6	74
856	Therapeutic Features and Updated Clinical Trials of Mesenchymal Stem Cell (MSC)-Derived Exosomes. <i>Journal of Clinical Medicine</i> , 2021, 10, 711.	1.0	84
857	Intensive care management of patients with COVID-19: a practical approach. <i>Annals of Intensive Care</i> , 2021, 11, 36.	2.2	73
858	Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 18.	0.8	29
859	Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review. <i>Current Respiratory Medicine Reviews</i> , 2021, 16, 165-183.	0.1	0
860	An early experience of Itolizumab with best supportive care in the treatment of moderate to severe COVID-19 patients: A retrospective study. <i>IP Indian Journal of Immunology and Respiratory Medicine</i> , 2021, 6, 24-28.	0.1	2
861	Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019. <i>Frontiers in Pharmacology</i> , 2020, 11, 634266.	1.6	8
862	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. <i>Frontiers in Medicine</i> , 2021, 8, 604087.	1.2	1
863	Mortality of critical care interventions in the COVID-19: A systematic review. <i>World Journal of Meta-analysis</i> , 2021, 9, 64-73.	0.1	0

#	ARTICLE	IF	CITATIONS
864	Efficacy and safety outcomes with remdesivir in COVID-19 patients: A meta-analysis. <i>World Journal of Meta-analysis</i> , 2021, 9, 74-87.	0.1	1
865	COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review. <i>Archives of Microbiology</i> , 2021, 203, 2043-2057.	1.0	9
867	Effectiveness of early therapeutic intervention in phases one and two after COVID-19 infection: systematic review. <i>Revista Da Associação Médica Brasileira</i> , 2021, 67, 302-312.	0.3	1
868	A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an <i>in silico</i> investigation. <i>Briefings in Bioinformatics</i> , 2021, 22, 1476-1498.	3.2	58
870	SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19. <i>PLoS Computational Biology</i> , 2021, 17, e1008686.	1.5	72
871	The FDA and the COVID-19: A political economy perspective. <i>Southern Economic Journal</i> , 2021, 87, 1210-1228.	1.3	11
872	Mesenchymal stem cell-derived exosomes for organ development and cell-free therapy. <i>Nano Select</i> , 2021, 2, 1291-1325.	1.9	4
873	Comparison of COVID-19 and influenza characteristics. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 87-98.	1.3	27
874	Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus. <i>Biomolecules</i> , 2021, 11, 330.	1.8	6
875	Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19. <i>BMC Nephrology</i> , 2021, 22, 52.	0.8	34
876	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <i>Cancer Reports</i> , 2021, 4, e1355.	0.6	2
877	Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 275-296.	2.6	152
878	Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment. <i>Archivos De Cardiologia De Mexico</i> , 2021, 1, .	0.1	0
879	Antiviral optical techniques as a possible novel approach to COVID-19 treatment. <i>Journal of Innovative Optical Health Sciences</i> , 2021, 14, 2130002.	0.5	6
880	Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology. <i>Current Drug Targets</i> , 2021, 22, 254-281.	1.0	27
881	Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19. <i>Journal of Dietary Supplements</i> , 2022, 19, 336-365.	1.4	13
882	Balancing clinical evidence in the context of a pandemic. <i>Nature Biotechnology</i> , 2021, 39, 270-274.	9.4	6
883	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. <i>Oncology Reviews</i> , 2021, 15, 510.	0.8	2

#	ARTICLE	IF	CITATIONS
884	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. <i>Frontiers in Pharmacology</i> , 2020, 11, 590154.	1.6	8
886	The relationship between positivity for COVID-19 RT-PCR and symptoms, clinical findings, and mortality in Turkey. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 245-250.	1.5	9
887	The prognostic value of comorbidity for the severity of COVID-19: A systematic review and meta-analysis study. <i>PLoS ONE</i> , 2021, 16, e0246190.	1.1	64
888	Prevalence of Foreign Body Aspiration in Children in a Tertiary Care Hospital. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 111-115.	0.1	3
890	Combination anti-coronavirus therapies based on nonlinear mathematical models. <i>Chaos</i> , 2021, 31, 023136.	1.0	0
891	Remdesivir for the Treatment of COVID-19: A Need for Combined <i>In Vivo</i> and <i>In Vitro</i> Studies to Evaluate the Efficacy. <i>Journal of Pharmacy Practice</i> , 2021, 34, 343-346.	0.5	3
892	A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19). <i>Bulletin of the National Research Centre</i> , 2021, 45, 36.	0.7	25
893	Efficacy and tolerability of bevacizumab in patients with severe Covid-19. <i>Nature Communications</i> , 2021, 12, 814.	5.8	101
894	IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study. <i>Journal of Immunology</i> , 2021, 206, 1569-1575.	0.4	51
895	The Situation of Small Molecules Targeting Key Proteins in combatting SARS-CoV-2: Synthesis, Metabolic Pathway, Mechanism of Action, and Potential Therapeutic Applications. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 273-311.	1.1	3
896	Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies. <i>Analytical Biochemistry</i> , 2021, 617, 114118.	1.1	27
897	Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. <i>International Journal of Biological Macromolecules</i> , 2021, 172, 524-541.	3.6	123
898	Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1297-1307.	0.8	4
899	Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach. <i>Infectious Diseases and Therapy</i> , 2021, 10, 815-825.	1.8	4
900	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. <i>Health Care Management Science</i> , 2021, 24, 339-355.	1.5	8
901	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 607408.	1.6	15
902	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 429-460.	1.0	22
903	A review of potential suggested drugs for coronavirus disease (COVID-19) treatment. <i>European Journal of Pharmacology</i> , 2021, 895, 173890.	1.7	86

#	ARTICLE	IF	CITATIONS
904	Coronavirus Disease 2019 Treatmentâ€”T-Cells Hold the Key in Severe Cases. Indian Journal of Medical and Paediatric Oncology, 2021, 42, 003-005.	0.1	0
905	Longitudinal multi-omics transition associated with fatality in critically ill COVID-19 patients. Intensive Care Medicine Experimental, 2021, 9, 13.	0.9	9
908	Discrete Time Multistate Model With Regime Switching for Modeling COVID-19 Disease Progression and Clinical Outcomes. Statistics in Biopharmaceutical Research, 2022, 14, 52-66.	0.6	5
909	Improving the Understanding of the Immunopathogenesis of Lymphopenia as a Correlate of SARS-CoV-2 Infection Risk and Disease Progression in African Patients: Protocol for a Cross-sectional Study. JMIR Research Protocols, 2021, 10, e21242.	0.5	4
910	Scores based on neutrophil percentage and lactate dehydrogenase with or without oxygen saturation predict hospital mortality risk in severe COVID-19 patients. Virology Journal, 2021, 18, 67.	1.4	5
911	The utility of a local multidisciplinary working group to oversee the establishment of rapidly evolving standards of care and to support trial recruitment during the COVID-19 pandemic. Clinical Medicine, 2021, 21, e287-e289.	0.8	1
912	Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India. BMC Infectious Diseases, 2021, 21, 241.	1.3	22
913	Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. Journal of Antimicrobial Chemotherapy, 2021, 76, 1962-1968.	1.3	62
914	Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen. Frontiers in Pharmacology, 2021, 12, 646676.	1.6	40
915	SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opinion on Therapeutic Patents, 2021, 31, 325-337.	2.4	84
916	Pharmacological treatment in pregnant women with moderate symptoms of coronavirus disease 2019 (COVID-19) pneumonia. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 5970-5977.	0.7	11
917	Environmental aspect and applications of nanotechnology to eliminate COVID-19 epidemiology risk. Nanotechnology for Environmental Engineering, 2021, 6, 1.	2.0	2
918	Exploring relationship between COVID-19 cases and eating habits using data of London boroughs. , 2021, , .		1
919	Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egyptian Liver Journal, 2021, 11, 21.	0.3	5
920	COVID-19: Overview. Health Evaluation and Promotion, 2021, 48, 220-228.	0.0	0
921	A Review of the Progress of COVID-19 Vaccine Development. Duzce Universitesi Tip FakÃ¼ltesi Dergisi, 2021, 23, 1-23.	0.3	7
922	Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 11. two-dimensional isotope dilution LCâ€”MS/MS method in human serum. Journal of Pharmaceutical and Biomedical Analysis, 2021, 196, 113935.	1.4	50
923	Risk factors for mortality in COVIDâ€”19 patients in a community teaching hospital. Journal of Medical Virology, 2021, 93, 3184-3193.	2.5	13

#	ARTICLE	IF	CITATIONS
924	Therapeutic approaches to pediatric COVID-19: an online survey of pediatric rheumatologists. <i>Rheumatology International</i> , 2021, 41, 911-920.	1.5	3
925	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. <i>PLoS Biology</i> , 2021, 19, e3001128.	2.6	99
926	Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. <i>Baylor University Medical Center Proceedings</i> , 2021, 34, 473-477.	0.2	19
927	Abnormal Liver Function Test in Patients Infected with Coronavirus (SARS-CoV-2): A Retrospective Single-Center Study from Spain. <i>Journal of Clinical Medicine</i> , 2021, 10, 1039.	1.0	10
928	Translational Virology in the Age of Pandemics. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	2
929	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). <i>Medicina Intensiva (English Edition)</i> , 2021, 45, 104-121.	0.1	11
930	An Overview of Current Knowledge of Deadly CoVs and Their Interface with Innate Immunity. <i>Viruses</i> , 2021, 13, 560.	1.5	15
931	Editor's introduction to this issue (G&I 19:1, 2021). <i>Genomics and Informatics</i> , 2021, 19, e1.	0.4	2
932	MRC5 cells engineered to express ACE2 serve as a model system for the discovery of antivirals targeting SARS-CoV-2. <i>Scientific Reports</i> , 2021, 11, 5376.	1.6	18
933	Gastrointestinal manifestations in COVID-19. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, 115, 1362-1388.	0.7	76
934	Detecting SARS-CoV-2 in the Breath of COVID-19 Patients. <i>Frontiers in Medicine</i> , 2021, 8, 604392.	1.2	22
935	Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1213-1223.	2.0	5
936	Comparative sequence analysis of SARS-CoV-2 suggests its high transmissibility and pathogenicity. <i>Future Virology</i> , 2021, 16, 245-254.	0.9	9
937	Development of a Low-Resource Operating Room and a Wide-Awake Orthopedic Surgery Program During the COVID-19 Pandemic. <i>Surgical Innovation</i> , 2021, 28, 183-188.	0.4	7
938	In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase. <i>Molecular Diversity</i> , 2022, 26, 279-292.	2.1	23
939	Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100150.	1.3	9
940	Longitudinal antibody repertoire in mild versus severe COVID-19 patients reveals immune markers associated with disease severity and resolution. <i>Science Advances</i> , 2021, 7, .	4.7	63
941	COVID-19 pandemic management and the rheumatology patient. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101663.	1.4	3

#	ARTICLE	IF	CITATIONS
942	Risk management strategies and therapeutic modalities to tackle COVID-19/SARS-CoV-2. Journal of Infection and Public Health, 2021, 14, 331-346.	1.9	12
943	Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19. , 0, , .		0
944	A Review on Repurposed Drugs and Vaccine Trials for Combating SARS CoV-2. Current Drug Research Reviews, 2021, 13, 203-221.	0.7	2
945	Experimental therapies under investigation for COVID-19. Journal of Community Hospital Internal Medicine Perspectives, 2021, 11, 187-193.	0.4	3
947	Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	64
948	Clinical Reviews of COVID-19 for Otorhinolaryngologists. Journal of Rhinology, 2021, 28, 1-13.	0.1	1
949	Drug discovery and development targeting the life cycle of SARS-CoV-2. Fundamental Research, 2021, 1, 151-165.	1.6	9
950	Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients. Process Biochemistry, 2021, 102, 150-156.	1.8	35
951	Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants. Scientific Reports, 2021, 11, 5543.	1.6	63
952	TREATMENT MODALITIES OF THE COVID-19 PANDEMIC THROUGH REPURPOSED DRUGS AND STATUS OF VACCINES. International Journal of Applied Pharmaceutics, 0, , 48-58.	0.3	4
953	Precision therapeutic targets for COVID-19. Virology Journal, 2021, 18, 66.	1.4	40
954	Cyclodextrins in Antiviral Therapeutics and Vaccines. Pharmaceutics, 2021, 13, 409.	2.0	24
955	<scp>COVID</scp>â€19: immunopathology, pathophysiological mechanisms, and treatment options. Journal of Pathology, 2021, 254, 307-331.	2.1	86
956	Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	27
957	COVID-19 preparedness: capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa. Globalization and Health, 2021, 17, 24.	2.4	40
958	COVID-19 epidemic in a Respiratory Diseases Unit: predictor ranking and mining. Journal of Thoracic Disease, 2021, 13, 2569-2574.	0.6	1
959	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. Infectious Disease Reports, 2021, 13, 259-284.	1.5	27
960	Is COVID-19-induced liver injury different from other RNA viruses?â€. World Journal of Meta-analysis, 2021, 9, 108-127.	0.1	0

#	ARTICLE	IF	CITATIONS
961	Can Yogic Breathing Techniques Like Simha Kriya and Isha Kriya Regulate COVID-19-Related Stress?. <i>Frontiers in Psychology</i> , 2021, 12, 635816.	1.1	8
962	The therapeutic effect and safety of the drugs for COVID-19. <i>Medicine (United States)</i> , 2021, 100, e25532.	0.4	3
963	Combination Drug Therapy in COVID-19: Are We Using Sound Science in the Management of These Patients?. <i>International Journal of Infection</i> , 2021, 8, .	0.4	0
964	Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 2423-2431.	1.8	47
965	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) in Kidney transplant patients: A case series and literature review. <i>Medical Journal of the Islamic Republic of Iran</i> , 2021, 35, 17.	0.9	1
966	Current diagnostic and therapeutic strategies for COVID-19. <i>Journal of Pharmaceutical Analysis</i> , 2021, 11, 129-137.	2.4	11
967	No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. <i>European Journal of Pharmacology</i> , 2021, 897, 173947.	1.7	66
968	Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. <i>Viruses</i> , 2021, 13, 667.	1.5	79
969	Coronavirus-related Disease Pandemic: A Review on Machine Learning Approaches and Treatment Trials on Diagnosed Population for Future Clinical Decision Support. <i>Current Medical Imaging</i> , 2022, 18, 104-112.	0.4	8
970	Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies. <i>Coronaviruses</i> , 2021, 2, 353-358.	0.2	2
971	Epidemiological and clinical characteristics of 65 hospitalized patients with COVID-19 in Liaoning, China. <i>World Journal of Clinical Cases</i> , 2021, 9, 2205-2217.	0.3	3
973	Nanocarrier vaccines for SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 171, 215-239.	6.6	66
974	Compassionate Use of Remdesivir in Children With Severe COVID-19. <i>Pediatrics</i> , 2021, 147, .	1.0	81
975	Mortality in mechanically ventilated patients with COVID-19: a systematic review. <i>Expert Review of Medical Devices</i> , 2021, 18, 1-15.	1.4	8
976	Upregulation of CCR4 in activated CD8 ⁺ T cells indicates enhanced lung homing in patients with severe acute SARS-CoV-2 infection. <i>European Journal of Immunology</i> , 2021, 51, 1436-1448.	1.6	22
977	Present and future treatment strategies for coronavirus disease 2019. <i>Future Journal of Pharmaceutical Sciences</i> , 2021, 7, 84.	1.1	12
978	Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients. <i>Phytomedicine</i> , 2021, 84, 153494.	2.3	63
979	Machine learning based on clinical characteristics and chest CT quantitative measurements for prediction of adverse clinical outcomes in hospitalized patients with COVID-19. <i>European Radiology</i> , 2021, 31, 7925-7935.	2.3	13

#	ARTICLE	IF	CITATIONS
980	Computational exploration of natural peptides targeting ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 8018-8029.	2.0	4
981	Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study. <i>Phytochemistry Reviews</i> , 2021, 20, 1013-1032.	3.1	17
983	Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 238-244.	0.5	10
984	An Overview of the Treatment Contributions Measured Globally for the COVID-19 Outbreak. <i>Coronaviruses</i> , 2021, 2, 198-203.	0.2	1
985	The treatment of SARS-CoV2 with antivirals and mitigation of the cytokine storm syndrome: the role of gene expression. <i>Genome</i> , 2021, 64, 400-415.	0.9	0
986	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. <i>European Journal of Pharmacology</i> , 2021, 897, 173926.	1.7	82
987	Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses. <i>Scientific Reports</i> , 2021, 11, 8692.	1.6	26
988	Discovering symptom patterns of COVID-19 patients using association rule mining. <i>Computers in Biology and Medicine</i> , 2021, 131, 104249.	3.9	66
989	Characteristics of patients with novel coronavirus disease (COVID-19) during the first surge versus the second surge of infections in Osaka Prefecture, Japan. <i>Global Health & Medicine</i> , 2021, 3, 82-89.	0.6	7
990	Çocuklarda COVID-19 ve Karaciğer. <i>Pediatric Practice and Research</i> , 2021, 9, 45-49.	0.0	0
991	Critically Ill COVID-19 Patient with Chronic Liver Disease - Insights into a Comprehensive Liver Intensive Care. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	0
992	The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010â€“20. <i>International Journal of Infectious Diseases</i> , 2021, 105, 91-104.	1.5	28
993	COVID-19: The Unprecedented Malady- A Holistic Review. <i>Coronaviruses</i> , 2021, 2, 172-181.	0.2	0
994	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	0
995	Current COVID-19 treatments: Rapid review of the literature. <i>Journal of Global Health</i> , 2021, 11, 10003.	1.2	26
996	CRISPR/Cas System: A Potential Technology for the Prevention and Control of COVID-19 and Emerging Infectious Diseases. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 639108.	1.8	13
997	Quality and consistency of clinical practice guidelines for treating children with COVID-19. <i>Annals of Translational Medicine</i> , 2021, 9, 633-633.	0.7	9
998	Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan. <i>Global Health & Medicine</i> , 2021, 3, 62-66.	0.6	6

#	ARTICLE	IF	CITATIONS
999	SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. <i>Biomolecules</i> , 2021, 11, 607.	1.8	97
1001	A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. <i>Annals of Palliative Medicine</i> , 2021, 10, 4777-4798.	0.5	9
1002	Development and validation of a simple-to-use nomogram to predict the deterioration and survival of patients with COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 356.	1.3	7
1004	Prognostic value of serum lactate dehydrogenase in hospitalized patients with Covid-19. <i>Romanian Journal of Laboratory Medicine</i> , 2021, 29, 131-141.	0.1	1
1005	The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019. <i>Infectious Diseases & Immunity</i> , 2021, 1, 52-58.	0.2	0
1006	Juggling sand: Ethics, identity, and archaeological geophysics in the Mississippian world. <i>Journal of Archaeological Science: Reports</i> , 2021, 36, 102882.	0.2	2
1007	Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 633769.	2.2	20
1008	Pathophysiology and pharmacological management of pulmonary and cardiovascular features of COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 153, 72-85.	0.9	12
1009	Anticoagulation in COVID-19: current concepts and controversies. <i>Postgraduate Medical Journal</i> , 2022, 98, 395-402.	0.9	53
1010	Drugs intervention study in COVID-19 management. <i>Drug Metabolism and Personalized Therapy</i> , 2021, .	0.3	7
1011	Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review. <i>Current Microbiology</i> , 2021, 78, 1718-1729.	1.0	11
1012	Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure. <i>Frontiers in Immunology</i> , 2021, 12, 645989.	2.2	10
1013	The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application. <i>Frontiers in Pharmacology</i> , 2021, 12, 633292.	1.6	10
1014	Dynamic Antibody Responses in Patients with Different Severity of COVID-19: A Retrospective Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1379-1390.	1.8	5
1015	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab278.	0.4	31
1016	Repurposing of antibiotics for clinical management of COVID-19: a narrative review. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2021, 20, 37.	1.7	33
1018	Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2. <i>Pathogens</i> , 2021, 10, 636.	1.2	2
1019	Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. <i>BMC Geriatrics</i> , 2021, 21, 321.	1.1	82

#	ARTICLE	IF	CITATIONS
1020	Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study. <i>Applied Soft Computing Journal</i> , 2021, 103, 107135.	4.1	38
1021	Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. <i>Cell Discovery</i> , 2021, 7, 37.	3.1	11
1022	The Course of SARS-CoV-2 in a Patient After a Recent Kidney Transplant: A Literature Review on COVID-19 Therapy. <i>Transplantation Proceedings</i> , 2021, 53, 1194-1201.	0.3	10
1023	Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4861-4867.	1.1	7
1024	Clinical Characteristics, Management, and Outcome of the First 19 Patients With Pneumonia Due to the 2019 Novel Coronavirus Disease Treated in an Intensive Care Unit in the Republic of Cyprus. <i>Cureus</i> , 2021, 13, e15114.	0.2	0
1025	The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111267.	2.5	70
1026	COVID-19 and the liver: an adverse outcome pathway perspective. <i>Toxicology</i> , 2021, 455, 152765.	2.0	8
1027	One-Stop Serum Assay Identifies COVID-19 Disease Severity and Vaccination Responses. <i>ImmunoHorizons</i> , 2021, 5, 322-335.	0.8	19
1028	Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells. <i>Scientific Reports</i> , 2021, 11, 9561.	1.6	1
1029	Pitfalls and perils of survival analysis under incorrect assumptions: the case of COVID-19 data. <i>Biomedica</i> , 2021, 41, 21-28.	0.3	4
1030	A review of Covid-19 and acute kidney injury: from pathophysiology to clinical results. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 551-571.	0.4	20
1031	Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials. <i>Mini-Reviews in Medicinal Chemistry</i> , 2021, 21, 1123-1143.	1.1	8
1032	Early vs. Late Onset Cardiac Injury and Mortality in Hospitalized COVID-19 Patients in Wuhan. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 645587.	1.1	4
1033	Efficacy of traditional herbal medicine for psychological sequelae in COVID-19 survivors. <i>Medicine (United States)</i> , 2021, 100, e25609.	0.4	3
1034	New Approaches and Repurposed Antiviral Drugs for the Treatment of the SARS-CoV-2 Infection. <i>Pharmaceuticals</i> , 2021, 14, 503.	1.7	6
1035	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. <i>Transplantation Proceedings</i> , 2021, 53, 1187-1193.	0.3	8
1036	How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. <i>Annals of Internal Medicine</i> , 2021, 174, 731.	2.0	0
1037	Third force in the treatment of COVID-19: A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2021, 65, 102218.	0.5	1

#	ARTICLE	IF	CITATIONS
1038	Better outcome of COVID-19 positive kidney transplant recipients during the unremitting stage with optimized anticoagulation and immunosuppression. <i>Clinical Transplantation</i> , 2021, 35, e14297.	0.8	9
1039	Recent Antiviral Treatment and Vaccination Strategies Against SARS-CoV-2. <i>Klinische Monatsblätter Für Augenheilkunde</i> , 2021, 238, 569-578.	0.3	6
1041	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 601-621.	1.3	144
1042	Current Strategies of Antiviral Drug Discovery for COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 671263.	1.6	75
1043	Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives. <i>World Journal of Clinical Cases</i> , 2021, 9, 2951-2968.	0.3	8
1044	Evidence and the Main Adverse Effects Regarding Drug Therapies in the War Against COVID-19. <i>Current Medicinal Chemistry</i> , 2021, 28, 3147-3157.	1.2	0
1045	Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions. <i>Current Medicinal Chemistry</i> , 2021, 28, 3173-3192.	1.2	5
1046	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. <i>VirusDisease</i> , 2021, 32, 211-219.	1.0	6
1047	Mesenchymal stromal cell secretome in liver failure: Perspectives on COVID-19 infection treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 1905-1919.	1.4	7
1048	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 104, 107851.	1.3	29
1049	High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions. <i>Drug Discovery Today</i> , 2021, 26, 2439-2444.	3.2	21
1050	Therapeutic Agents Against COVID-19 with Clinical Evidence. <i>Current Pharmaceutical Design</i> , 2021, 27, 1608-1617.	0.9	4
1051	Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections. <i>Journal of Infection and Public Health</i> , 2021, 14, 655-660.	1.9	12
1053	Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. <i>Infectious Diseases</i> , 2021, 53, 691-699.	1.4	24
1054	Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation. <i>Transplant Infectious Disease</i> , 2021, 23, e13629.	0.7	24
1055	Hydrophobic deep eutectic solvents: Current progress and future directions. <i>Journal of Industrial and Engineering Chemistry</i> , 2021, 97, 142-162.	2.9	61
1056	Platforms for Personalized Polytherapeutics Discovery in COVID-19. <i>Journal of Molecular Biology</i> , 2021, 433, 166945.	2.0	4
1057	Effect of comorbid pulmonary disease on the severity of COVID-19: A systematic review and meta-analysis. <i>Respirology</i> , 2021, 26, 552-565.	1.3	32

#	ARTICLE	IF	CITATIONS
1058	Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2021, 24, 227-236.	0.9	2
1059	Secondary sclerosing cholangitis as a complication of severe COVID-19: A case report and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04068.	0.2	28
1060	Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study. <i>Virology Journal</i> , 2021, 18, 102.	1.4	7
1061	Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target. <i>Genes</i> , 2021, 12, 796.	1.0	30
1062	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 520.	1.7	24
1063	An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 661424.	1.6	16
1064	Phytochemical analysis and potential natural compounds against SARS-CoV-2/COVID-19 in essential oils derived from medicinal plants originating from Lebanon. An information note. <i>Plant Biosystems</i> , 2022, 156, 855-864.	0.8	5
1065	Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening. <i>Cell Reports</i> , 2021, 35, 109218.	2.9	38
1067	A Step Toward Optimizing Regenerative Medicine Principle to Combat COVID-19. <i>Annals of the National Academy of Medical Sciences (India)</i> , 2021, 57, 202-213.	0.2	0
1068	Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?. <i>Cancers</i> , 2021, 13, 2896.	1.7	5
1069	The experiences of critical care nurses caring for patients with COVID-19 during the 2020 pandemic: A qualitative study. <i>Applied Nursing Research</i> , 2021, 59, 151418.	1.0	98
1070	Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 857-863.	0.8	2
1071	Unraveling the thread of uncontrolled immune response in COVID-19 and STEMI: an emerging need for knowledge sharing. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H2240-H2254.	1.5	5
1072	Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir. <i>Frontiers in Immunology</i> , 2021, 12, 680188.	2.2	8
1073	COVID-19 and Indirect Liver Injury: A Narrative Synthesis of the Evidence. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	0.7	12
1074	Clinical and molecular characteristics of COVID-19 patients with persistent SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3501.	5.8	40
1075	Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. <i>Current Drug Research Reviews</i> , 2021, 13, 184-202.	0.7	3
1076	A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase. <i>Antiviral Research</i> , 2021, 190, 105078.	1.9	69

#	ARTICLE	IF	CITATIONS
1077	Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. <i>British Journal of Cancer</i> , 2021, 125, 658-671.	2.9	20
1078	Antimalarial and Antiviral Drugs: A Review of Trials and Effectiveness in Treating COVID-19. <i>Bioscience Biotechnology Research Communications</i> , 2021, 14, 231-236.	0.1	0
1079	A randomized and comparative study to assess safety and efficacy of supplemental treatment of a herbal formulation - Aayudh Advance comprising essential oils in patients with corona virus 2019 (COVID-19). <i>Contemporary Clinical Trials Communications</i> , 2021, 22, 100755.	0.5	14
1080	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9
1081	Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis. <i>Journal of the Formosan Medical Association</i> , 2021, 120, S77-S85.	0.8	5
1082	The significance of bioengineered nanoplatfoms against SARS-CoV-2: From detection to genome editing. <i>Life Sciences</i> , 2021, 274, 119289.	2.0	9
1083	Successful Treatment of a Critically Ill COVID-19 Patient Using Continuous Renal Replacement Therapy With Enhanced Cytokine Removal and Tocilizumab: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 649583.	1.2	5
1084	Cardiac Arrhythmia Related to Remdesivir in COVID-19. <i>ISMMS Journal of Science and Medicine</i> , 2021, 1, 15.	0.1	0
1085	Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1555-1567.	5.7	42
1086	Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 42, 128067.	1.0	5
1087	The Effect of COVID-19 on NF- κ B and Neurological Manifestations of Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4178-4187.	1.9	31
1088	Novel adenosine derivatives against SARS-CoV-2 RNA-dependent RNA polymerase: an in silico perspective. <i>Pharmacological Reports</i> , 2021, 73, 1754-1764.	1.5	10
1089	The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, 514-526.	0.4	14
1090	Medication Use Among Patients With COVID-19 in a Large, National Dataset: Cerner Real-World Data. <i>Clinical Therapeutics</i> , 2021, 43, e173-e196.	1.1	3
1091	COVID-19 Pandemic and Virtual Clinics for Diabetes Care. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, S-3-S-15.	2.4	6
1092	An Overview of the Epidemiologic, Diagnostic and Treatment Approaches of COVID-19: What do We Know?. <i>Public Health Reviews</i> , 2021, 42, 1604061.	1.3	6
1093	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2415-2418.	1.3	7
1094	Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111518.	2.5	50

#	ARTICLE	IF	CITATIONS
1095	The Outbreak of COVID-19 and its Manifold Socio-psychological Implications: A Case Study of District Khyber, Khyber Pakhtunkhwa, Pakistan. <i>Review of Applied Management and Social Sciences</i> , 2021, 4, 521-530.	0.1	0
1096	COVID-19 impact on the liver. <i>World Journal of Clinical Cases</i> , 2021, 9, 3814-3825.	0.3	15
1097	Immunosuppressant Drugs And Covid-19: Associated Risks, Drug-Drug Interactions & Contraindications. <i>Coronaviruses</i> , 2021, 02, .	0.2	0
1098	Coronavirus disease and the cardiovascular system: a narrative review of the mechanisms of injury and management implications. <i>Cardiovascular Diagnosis and Therapy</i> , 2021, 11, 939-953.	0.7	0
1099	Alcohol-Related Liver Disease in the Covid-19 Era: Position Paper of the Italian Society on Alcohol (SIA). <i>Digestive Diseases and Sciences</i> , 2022, 67, 1975-1986.	1.1	7
1100	Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. <i>Medicina Clínica</i> , 2022, 158, 509-518.	0.3	4
1101	Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111457.	2.5	23
1102	Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 233.	7.1	203
1103	SARS-CoV-2 exacerbates proinflammatory responses in myeloid cells through C-type lectin receptors and Tweety family member 2. <i>Immunity</i> , 2021, 54, 1304-1319.e9.	6.6	115
1104	Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, 213-231.	1.1	2
1105	Reinforcing our defense or weakening the enemy? A comparative overview of defensive and offensive strategies developed to confront COVID-19. <i>Drug Metabolism Reviews</i> , 2021, 53, 508-541.	1.5	0
1106	Nanotraps for the containment and clearance of SARS-CoV-2. <i>Matter</i> , 2021, 4, 2059-2082.	5.0	38
1107	Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e048416.	0.8	46
1108	Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System. <i>Pharmaceuticals</i> , 2021, 14, 611.	1.7	28
1109	Identification and evaluation of the inhibitory effect of <i>Prunella vulgaris</i> extract on SARS-coronavirus 2 virus entry. <i>PLoS ONE</i> , 2021, 16, e0251649.	1.1	23
1110	Flavonoids as Promising Antiviral Agents against SARS-CoV-2 Infection: A Mechanistic Review. <i>Molecules</i> , 2021, 26, 3900.	1.7	43
1111	A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19. <i>Applied Nanoscience (Switzerland)</i> , 2023, 13, 111-118.	1.6	6
1112	Digestive involvement in COVID-19: what we have learned in the past 12 months. <i>Medicine and Pharmacy Reports</i> , 0, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1113	A protein interactions map of multiple organ systems associated with COVID-19 disease. <i>Genomics and Informatics</i> , 2021, 19, e14.	0.4	2
1114	Three coronavirus disease 2019 cases with acute progression of respiratory failure were improved after methylprednisolone therapy. <i>Journal of Xiangya Medicine</i> , 0, 6, 20-20.	0.2	0
1115	Pneumatosis Intestinalis in the Setting of COVID-19: A Single Center Case Series From New York. <i>Frontiers in Medicine</i> , 2021, 8, 638075.	1.2	5
1116	Use of remdesivir in the treatment of coronavirus disease 2019 (COVID-19) infection among Sudanese patients: a case series. <i>F1000Research</i> , 2021, 10, 512.	0.8	1
1117	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 211-229.	2.0	10
1118	Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2. <i>ACS Infectious Diseases</i> , 2021, 7, 2337-2351.	1.8	23
1119	COVID-19 and gastroenteric manifestations. <i>World Journal of Clinical Cases</i> , 2021, 9, 4990-4997.	0.3	8
1120	Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals. <i>Bioorganic Chemistry</i> , 2021, 112, 104889.	2.0	46
1121	Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients. <i>Frontiers in Oncology</i> , 2021, 11, 664794.	1.3	14
1122	Potential activity of Linezolid against SARS-CoV-2 using electronic and molecular docking study. <i>Journal of Molecular Modeling</i> , 2021, 27, 222.	0.8	6
1123	Trends in COVID-19 cases and clinical management in Veterans Health Administration medical facilities: A national cohort study. <i>PLoS ONE</i> , 2021, 16, e0246217.	1.1	4
1124	Clinical course and serial chest ultra-low-dose CT findings in a patient with COVID-19 treated with remdesivir. <i>Minerva Medica</i> , 2021, 112, 516-518.	0.3	2
1125	Remdesivir might induce changes in electrocardiogram beyond bradycardia in patients with coronavirus disease 2019â€”The pilot study. <i>Journal of Medical Virology</i> , 2021, 93, 5724-5725.	2.5	20
1126	Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience. <i>Annals of Hematology</i> , 2021, 100, 2541-2546.	0.8	9
1127	Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 4959-4984.	3.3	26
1128	Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge. <i>Journal of Medical Virology</i> , 2021, 93, 5756-5767.	2.5	26
1129	DNA Polymerase δ : A Cancer Drug Target with Reverse Transcriptase Activity. <i>Genes</i> , 2021, 12, 1146.	1.0	10
1130	COVID-19 Severity: Lung-Heart Interplay. <i>Current Cardiology Reviews</i> , 2021, 17, e230421189016.	0.6	11

#	ARTICLE	IF	CITATIONS
1131	Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments. <i>Frontiers in Immunology</i> , 2021, 12, 716407.	2.2	40
1132	Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 5811-5820.	1.9	18
1133	Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review. <i>Journal of Infection and Public Health</i> , 2021, 14, 910-921.	1.9	14
1134	Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	121
1135	High mortality with High false negative rate: COVID-19 infection in patients with hematologic malignancies. <i>Leukemia Research</i> , 2021, 106, 106582.	0.4	6
1136	The Emergency Use Authorization of Pharmaceuticals: History and Utility During the COVID-19 Pandemic. <i>Pharmaceutical Medicine</i> , 2021, 35, 203-213.	1.0	11
1137	Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). <i>Carbohydrate Research</i> , 2021, 505, 108326.	1.1	48
1138	Recent developments and opportunities in fighting COVID-19. <i>Coronaviruses</i> , 2021, 2, .	0.2	0
1139	Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1219-1244.	2.0	6
1140	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. <i>Life</i> , 2021, 11, 753.	1.1	14
1141	ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential. <i>Pharmaceuticals</i> , 2021, 14, 655.	1.7	50
1142	Efficacy and Safety of Leflunomide for Refractory COVID-19: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 581833.	1.6	5
1143	Pharmacological Treatment for the Management of COVID 19: A Narrative Review. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 614-621.	0.1	3
1144	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 50.	1.0	22
1145	Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis. <i>Infection</i> , 2022, 50, 27-41.	2.3	46
1146	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 736.	1.7	15
1147	Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations. <i>Carbohydrate Polymers</i> , 2021, 264, 118011.	5.1	35
1148	The COVID-19 Medicine Remdesivir Is Therapeutically Activated by Carboxylesterase-1, and Excessive Hydrolysis Increases Cytotoxicity. <i>Hepatology Communications</i> , 2021, 5, 1622-1623.	2.0	12

#	ARTICLE	IF	CITATIONS
1149	Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 599-602.	1.3	1
1150	Association of hypothermia with increased mortality rate in SARS-CoV-2 infection. <i>International Journal of Infectious Diseases</i> , 2021, 108, 167-170.	1.5	7
1151	Remdesivir shifts circadian rhythmicity to eveningness; similar to the most prevalent chronotype in ADHD. <i>Journal of Neural Transmission</i> , 2021, 128, 1159-1168.	1.4	5
1152	Considerações sobre interações entre medicamentos usados no tratamento de linfomas e na terapia experimental da COVID-19. <i>Research, Society and Development</i> , 2021, 10, e18910917962.	0.0	0
1153	Assessment of COVID-19 treatment advised in different ethnic populations. <i>Current Drug Safety</i> , 2021, 16, .	0.3	1
1154	A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 17-25.	0.7	10
1155	The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 341-351.	1.3	3
1156	Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients. <i>Russian Journal of Bioorganic Chemistry</i> , 2021, 47, 789-804.	0.3	1
1157	Changing Trend in COVID 19 Pandemic, Orthopaedic Care, and Arthroplasty - A Prospective Study Conducted in Indira Gandhi Institute of Medical Sciences, an Apex Tertiary Centre of Bihar. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2021, 8, 2544-2550.	0.0	1
1158	Subclinical myopathic changes in COVID-19. <i>Neurological Sciences</i> , 2021, 42, 3973-3979.	0.9	13
1159	Machine Learning Can Unlock Insights Into Mortality. <i>American Journal of Public Health</i> , 2021, 111, S65-S68.	1.5	0
1160	Liver injury in COVID-19: Known and unknown. <i>World Journal of Clinical Cases</i> , 2021, 9, 4980-4989.	0.3	11
1161	Drug Policies Skyline during COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , 2021, 10, 3117.	1.0	1
1162	Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 3771-3788.	2.5	17
1163	Determination of Ligand Binding Modes in Hydrated Viral Ion Channels to Foster Drug Design and Repositioning. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4011-4022.	2.5	10
1164	Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment. <i>Journal of Infection and Chemotherapy</i> , 2021, 27, 1072-1075.	0.8	3
1165	Natural product remedies for COVID-19: A focus on safety. <i>South African Journal of Botany</i> , 2021, 139, 386-398.	1.2	32
1166	Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data. <i>European Radiology</i> , 2022, 32, 205-212.	2.3	42

#	ARTICLE	IF	CITATIONS
1167	Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase. <i>Biochemical Journal</i> , 2021, 478, 2405-2423.	1.7	46
1168	An outline of SARS-CoV-2 pathogenesis and the complement cascade of immune system. <i>Bulletin of the National Research Centre</i> , 2021, 45, 123.	0.7	5
1169	High-throughput human primary cell-based airway model for evaluating influenza, coronavirus, or other respiratory viruses in vitro. <i>Scientific Reports</i> , 2021, 11, 14961.	1.6	37
1170	Impact of Tocilizumab on Clinical Outcomes in COVID-19-Associated Cytokine Release Syndrome: A Single-Center Experience. <i>Journal of Pharmacy Practice</i> , 2021, , 089719002110282.	0.5	1
1171	Making trials part of good clinical care: lessons from the RECOVERY trial. <i>Future Healthcare Journal</i> , 2021, 8, e243-e250.	0.6	32
1172	Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e853-e864.	0.2	16
1173	Predictive Value of CAR for In-Hospital Mortality in Patients with COVID-19 Pneumonia: A Retrospective Cohort Study. <i>Archives of Medical Research</i> , 2021, 52, 554-560.	1.5	20
1174	SARS-CoV-2 infection during pregnancy and pregnancy-related conditions: Concerns, challenges, management and mitigation strategies—a narrative review. <i>Journal of Infection and Public Health</i> , 2021, 14, 863-875.	1.9	43
1175	An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). <i>Expert Opinion on Drug Discovery</i> , 2021, , 1-10.	2.5	16
1176	COVID-19 and Liver dysfunction: Epidemiology, Association and Potential Mechanisms. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101793.	0.7	14
1177	Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expedient Antiviral Approaches Against Newer Strains of COVID-19. <i>AAPS PharmSciTech</i> , 2021, 22, 214.	1.5	5
1178	Individual health behaviours to combat the COVID-19 pandemic: lessons from HIV socio-behavioural science. <i>Journal of the International AIDS Society</i> , 2021, 24, e25771.	1.2	9
1179	Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications. <i>Epilepsy Research</i> , 2021, 174, 106675.	0.8	18
1180	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-12.	2.0	9
1181	COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon. <i>Cytokine and Growth Factor Reviews</i> , 2021, 60, 28-45.	3.2	21
1183	Remdesivir and Mortality in Patients With Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 1812-1820.	2.9	25
1184	The impact of tocilizumab on respiratory support states transition and clinical outcomes in COVID-19 patients. A Markov model multi-state study. <i>PLoS ONE</i> , 2021, 16, e0251378.	1.1	3
1185	Theory and reality of antivirals against SARS-CoV-2. <i>World Journal of Clinical Cases</i> , 2021, 9, 6663-6673.	0.3	1

#	ARTICLE	IF	CITATIONS
1187	Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1559-1564.	1.0	20
1188	Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8663.	1.8	18
1189	Abbreviated Profile of Drugs (APOD): modeling drug safety profiles to prioritize investigational COVID-19 treatments. <i>Heliyon</i> , 2021, 7, e07666.	1.4	3
1190	Development of a Scalable Lanthanide Halide/Quaternary Ammonium Salt System for the Nucleophilic Addition of Grignard Reagents to Carbonyl Groups and Application to the Synthesis of a Remdesivir Intermediate. <i>Organic Process Research and Development</i> , 2022, 26, 754-763.	1.3	5
1191	What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis. <i>Transfusion Clinique Et Biologique</i> , 2021, 28, 321-329.	0.2	1
1192	Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 2021, 12, 706901.	1.6	16
1193	Pre-Hospital Administration of Remdesivir During a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak in a Skilled Nursing Facility. <i>Clinical Infectious Diseases</i> , 2022, 74, 1476-1479.	2.9	2
1194	ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 315.	7.1	53
1195	Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 740-746.	3.6	450
1197	Evaluation of the Treatment Efficacy and Safety of Remdesivir for COVID-19: a Meta-analysis. <i>SN Comprehensive Clinical Medicine</i> , 2021, , 1-12.	0.3	6
1198	Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 88-90.	0.2	4
1199	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications. <i>Journal of Heterocyclic Chemistry</i> , 2021, 58, 2226-2260.	1.4	15
1200	Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease. <i>HeartRhythm Case Reports</i> , 2021, 7, 514-517.	0.2	14
1201	Covid-19 pandemic: Perspectives on management. <i>Journal of Reproductive Immunology</i> , 2021, 146, 103344.	0.8	4
1202	COVID-19 Tanımlı Testleri, Tedavisindeki Aşamalar ve Akut Durum. <i>Uludağ Üniversitesi Tıp Fakültesi Dergisi</i> , 2021, 47, 295-308.	0.2	1
1203	Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. <i>Healthcare (Switzerland)</i> , 2021, 9, 1108.	1.0	7
1204	Sustained expression of inflammatory monocytes and activated T cells in COVID-19 patients and recovered convalescent plasma donors. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1279-1290.	1.3	14
1205	COVID-19 and the Liver: Lessons Learnt from the EAST and the WEST, A Year Later. <i>Journal of Viral Hepatitis</i> , 2022, 29, 4-20.	1.0	36

#	ARTICLE	IF	CITATIONS
1206	Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID-19 patients: A prospective observational study conducted on Pakistani population. <i>Journal of Medical Virology</i> , 2021, 93, 6732-6736.	2.5	10
1207	Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far. <i>Current Drug Research Reviews</i> , 2022, 14, 11-19.	0.7	2
1208	Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1299-1307.	1.0	11
1209	SARS-CoV-2 Treatment: Current Therapeutic Options and the Pursuit of Tailored Therapy. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 7457.	1.3	11
1210	Mesenchymal stem cell transfusion: Possible beneficial effects in COVID-19 patients. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103237.	0.5	1
1211	A comparative study on virology, epidemiology, and clinical features of SARS and COVID-19. <i>Disaster Medicine and Public Health Preparedness</i> , 2021, , 1-23.	0.7	1
1212	Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19. <i>Pathogens</i> , 2021, 10, 1218.	1.2	4
1213	Cardiovascular system and coronavirus disease-2019 (COVID-19): mutual injuries and unexpected outcomes. <i>Egyptian Heart Journal</i> , 2021, 73, 77.	0.4	4
1214	Serum Krebs von den Lungen-6 levels are associated with mortality and severity in patients with coronavirus disease 2019. <i>Respiratory Investigation</i> , 2021, 59, 596-601.	0.9	15
1215	Clinical Symptoms and Types of Samples Are Critical Factors for the Molecular Diagnosis of Symptomatic COVID-19 Patients: A Systematic Literature Review. <i>International Journal of Microbiology</i> , 2021, 2021, 1-20.	0.9	12
1217	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 2305-2315.	0.4	26
1218	Potenciales efectos pro-arrátmicos de la farmacoterapia contra SARS-CoV-2. <i>Archivos De Cardiologia De Mexico</i> , 2021, 90, 36-40.	0.1	1
1219	Revealed pathophysiological mechanisms of crosslinking interaction of affected vital organs in COVID-19. <i>Comparative Clinical Pathology</i> , 2021, 30, 1-17.	0.3	1
1220	Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. <i>Drug Safety</i> , 2021, 44, 1125-1149.	1.4	35
1221	In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. <i>PLoS Pathogens</i> , 2021, 17, e1009929.	2.1	108
1222	From Molecular Pathology of COVID 19 to Nigella Sativum as a Treatment Option: Scientific Based Evidence of Its Myth or Reality. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 88-95.	0.7	0
1223	In Silico Identification of New Anti-SARS-CoV-2 Agents from Bioactive Phytochemicals Targeting the Viral Spike Glycoprotein and Human TLR4. <i>Letters in Drug Design and Discovery</i> , 2022, 19, 175-191.	0.4	18
1225	Inhibitors of L-Type Calcium Channels Show Therapeutic Potential for Treating SARS-CoV-2 Infections by Preventing Virus Entry and Spread. <i>ACS Infectious Diseases</i> , 2021, 7, 2807-2815.	1.8	32

#	ARTICLE	IF	CITATIONS
1226	Numerical simulation of the unsteady flow field in the human pulmonary acinus. <i>Sadhana - Academy Proceedings in Engineering Sciences</i> , 2021, 46, 1.	0.8	5
1227	Potential Effects of Coronaviruses on the Liver: An Update. <i>Frontiers in Medicine</i> , 2021, 8, 651658.	1.2	38
1228	Neuropsychiatric Manifestations of COVID-19. <i>Advances in Psychiatry and Behavioral Health</i> , 2021, 1, 161-172.	0.4	1
1229	Coronavirus disease 2019 and renal transplantation. <i>World Journal of Clinical Cases</i> , 2021, 9, 7986-7997.	0.3	3
1230	Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study. <i>BMC Infectious Diseases</i> , 2021, 21, 952.	1.3	1
1231	Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. <i>Contemporary Clinical Trials Communications</i> , 2021, 23, 100804.	0.5	9
1232	Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial. <i>Journal of Medical Virology</i> , 2022, 94, 263-271.	2.5	45
1233	Potent antiviral activity of <i>Agrimonia pilosa</i> , <i>Galla rhois</i> , and their components against SARS-CoV-2. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 45, 116329.	1.4	19
1234	The Role of Nanotechnology in Antiviral Regime: An Overview. <i>Nano LIFE</i> , 0, , 2130011.	0.6	1
1235	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, , .	1.0	3
1237	Liver Injury in COVID-19: A Direct Hit or Collateral Damage?. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	2
1238	Possibility of new shielding device for upper gastrointestinal endoscopy. <i>Endoscopy International Open</i> , 2021, 09, E1536-E1541.	0.9	7
1239	Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review. <i>Frontiers in Medicine</i> , 2021, 8, 731436.	1.2	40
1240	The nucleoside antiviral prodrug remdesivir in treating COVID-19 and beyond with interspecies significance. <i>Animal Diseases</i> , 2021, 1, 15.	0.6	4
1241	Therapeutic and Protective Potential of Mesenchymal Stem Cells, Pharmaceutical Agents and Current Vaccines Against COVID-19. <i>Current Stem Cell Research and Therapy</i> , 2022, 17, 166-185.	0.6	5
1242	Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatric patients. <i>Journal of Medical Virology</i> , 2022, 94, 161-172.	2.5	13
1243	The Extrapulmonary Manifestations of SARS-CoV-2. <i>The Open Covid Journal</i> , 2021, 1, 80-92.	0.4	0
1244	Theaflavin-3-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir. <i>Drug Research</i> , 2021, 71, 462-472.	0.7	8

#	ARTICLE	IF	CITATIONS
1245	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. <i>Science Translational Medicine</i> , 2021, 13, eabd5524.	5.8	62
1246	Characterisation of Drug-Induced Liver Injury in Patients with COVID-19 Detected by a Proactive Pharmacovigilance Program from Laboratory Signals. <i>Journal of Clinical Medicine</i> , 2021, 10, 4432.	1.0	20
1247	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. <i>Biologics</i> , 2021, 1, 252-284.	2.3	11
1248	Remdesivir-associated bradycardia. <i>BMJ Case Reports</i> , 2021, 14, e245289.	0.2	11
1249	Recent advances in combating Nipah virus. <i>Faculty Reviews</i> , 2021, 10, 74.	1.7	15
1250	Antiviral and antibacterial activity of hand sanitizer and surface disinfectant formulations. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121139.	2.6	9
1251	Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19. <i>Molecules</i> , 2021, 26, 5795.	1.7	125
1252	Potential Therapeutic Effect of Micrnas in Extracellular Vesicles from Mesenchymal Stem Cells against SARS-CoV-2. <i>Cells</i> , 2021, 10, 2393.	1.8	29
1253	Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital. <i>Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	0.4	5
1254	Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1092-1101.	0.7	11
1255	Prospective Study of Policies and Use of Therapies for COVID-19 Amongst Australian Health Services during 2020. <i>Internal Medicine Journal</i> , 2021, , .	0.5	1
1256	Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. <i>Molecules and Cells</i> , 2021, 44, 688-695.	1.0	11
1257	Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2182-2191.e7.	2.4	28
1258	Scoping insight on antiviral drugs against COVID-19. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103385.	2.3	5
1259	5-Hydroxymethyltubercidin exhibits potent antiviral activity against flaviviruses and coronaviruses, including SARS-CoV-2. <i>IScience</i> , 2021, 24, 103120.	1.9	6
1260	Efficacy of Ninjin'yoeito in treating severe coronavirus disease 2019 in patients in an intensive care unit. <i>Neuropeptides</i> , 2021, 90, 102201.	0.9	5
1261	Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. <i>Biomedicine and Pharmacotherapy</i> , 2021, 142, 111966.	2.5	22
1262	Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. <i>Respiratory Medicine</i> , 2021, 188, 106602.	1.3	38

#	ARTICLE	IF	CITATIONS
1263	COVID-19, cytokines, inflammation, and spices: How are they related?. Life Sciences, 2021, 284, 119201.	2.0	68
1264	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
1265	Therapeutic Strategies for Treatment of COVID-19. Health Information Systems and the Advancement of Medical Practice in Developing Countries, 2022, , 55-72.	0.1	0
1266	A randomized pilot study using calcitriol in hospitalized COVID-19 patients. Bone, 2022, 154, 116175.	1.4	41
1267	Drugs for the Treatment of COVID-19. , 2021, , 193-204.		0
1268	Etiopathogenesis, Diagnosis and Clinical Management of SARS-COV-2. , 2021, 01, .		0
1269	Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review. Annals of Medicine, 2021, 53, 318-334.	1.5	27
1270	Remdesivir â€œ Current evidence & perspective in management of COVID-19 infection. Journal of Family Medicine and Primary Care, 2021, 10, 1808.	0.3	5
1271	Emerging Potential of Metallo drugs to Target Coronavirus: Efficacy, Toxicity and their Mechanism of Action. Asian Journal of Chemistry, 2021, 33, 1191-1207.	0.1	1
1272	SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus. Membranes, 2021, 11, 64.	1.4	0
1273	A review on clinical, pathological characteristics and drug designing for COVID-19. Arab Journal of Basic and Applied Sciences, 2021, 28, 172-186.	1.0	1
1274	Experimental Pharmacotherapy for COVID-19: The Latest Advances. Journal of Experimental Pharmacology, 2021, Volume 13, 1-13.	1.5	22
1275	Antiviral treatment in COVID-19: which is the most promising?â€”a narrative review. Annals of Palliative Medicine, 2021, 10, 707-720.	0.5	4
1276	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. International Journal of Environmental Research and Public Health, 2021, 18, 955.	1.2	6
1277	Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights. Redox Biology, 2021, 38, 101810.	3.9	13
1278	Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection. European Journal of Pediatrics, 2021, 180, 1627-1627.	1.3	24
1279	A Comprehensive Summary of the Knowledge on COVID-19 Treatment. , 2021, 12, 155.		25
1280	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. Infectious Diseases and Therapy, 2021, 10, 93-113.	1.8	13

#	ARTICLE	IF	CITATIONS
1281	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Internal and Emergency Medicine, 2021, 16, 281-308.	1.0	46
1282	Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19). Microbiology Australia, 2021, 42, 47.	0.1	2
1283	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Research, 2021, 31, 272-290.	5.7	229
1284	No significant benefit of moderate-dose vitamin C on severe COVID-19 cases. Open Medicine (Poland), 2021, 16, 1403-1414.	0.6	11
1285	COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Molecular Pharmaceutics, 2021, 18, 754-771.	2.3	193
1286	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. JCI Insight, 2021, 6, .	2.3	34
1287	Pharmacotherapeutics of SARS-CoV-2 Infections. Journal of NeuroImmune Pharmacology, 2021, 16, 12-37.	2.1	4
1288	Research Progress on the Mechanism of COVID-19 Complicated with Renal Injury. Advances in Clinical Medicine, 2021, 11, 1585-1591.	0.0	0
1289	Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19. Indian Journal of Critical Care Medicine, 2021, 25, 240-241.	0.3	6
1290	Impact of repurposed drugs on the symptomatic COVID-19 patients. Journal of Infection and Public Health, 2021, 14, 24-38.	1.9	8
1291	COVID-19 Antiviral and Treatment Candidates: Current Status. Immune Network, 2021, 21, e7.	1.6	8
1292	Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses. Virulence, 2021, 12, 444-469.	1.8	26
1293	The safety, tolerability and mortality reduction efficacy of remdesivir; based on randomized clinical trials, observational and case studies reported safety outcomes: an updated systematic review and meta-analysis. Therapeutic Advances in Drug Safety, 2021, 12, 204209862110425.	1.0	17
1294	Penanganan Pasien Covid-19 Pada Rumah Sakit di Indonesia. Jurnal Kesehatan, 2020, 8, 162-170.	0.0	1
1295	Research Progress on the Cardiac Injury from ACE2 Targeting in SARS-CoV-2 Infection. Biomolecules, 2021, 11, 196.	1.8	4
1296	A Bioelectromagnetic Proposal Approaching the Complex Challenges of COVID-19. Open Journal of Biophysics, 2021, 11, 1-67.	0.7	1
1297	Are Patients with Asthma and Chronic Obstructive Pulmonary Disease Preferred Targets of COVID-19?. Tuberculosis and Respiratory Diseases, 2021, 84, 22-34.	0.7	14
1298	SARS-CoV-2 therapeutics: how far do we stand from a remedy?. Pharmacological Reports, 2021, 73, 750-768.	1.5	17

#	ARTICLE	IF	CITATIONS
1299	Cardiovascular risk factors and mortality in hospitalized patients with COVID-19: systematic review and meta-analysis of 45 studies and 18,300 patients. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 23.	0.7	88
1300	Recent advances made in the synthesis of small drug molecules for clinical applications: An insight. <i>Current Research in Green and Sustainable Chemistry</i> , 2021, 4, 100097.	2.9	14
1301	Genetic Aspects and Immune Responses in Covid-19: Important Organ Involvement. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1327, 3-22.	0.8	5
1302	Review of investigational drugs for coronavirus disease 2019. <i>Journal of Education and Health Promotion</i> , 2021, 10, 31.	0.3	6
1303	Remdesivir potently inhibits carboxylesteraseâ€² through covalent modifications: signifying strong drugâ€²drug interactions. <i>Fundamental and Clinical Pharmacology</i> , 2021, 35, 432-434.	1.0	15
1304	Remdesivir therapy causing bradycardia in COVID-19 patients: Two case reports. <i>IDCases</i> , 2021, 26, e01254.	0.4	9
1305	Remdesivir: A Closer Look at Its Effect in COVID-19 Pandemic. <i>Pharmacology</i> , 2021, 106, 462-468.	0.9	16
1306	1â€²-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 5852-5863.	1.3	33
1307	Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. <i>Nature Communications</i> , 2021, 12, 279.	5.8	412
1308	COVIDâ€²19 and multisystem inflammatory syndrome in children: A systematic review and metaâ€²analysis. <i>Pediatric Pulmonology</i> , 2021, 56, 837-848.	1.0	127
1309	Drugâ€²drug interactions with candidate medications used for COVIDâ€²19 treatment: An overview. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00705.	1.1	30
1310	Management of Coronavirus Disease 2019 (COVIDâ€²19) Pandemic: From Diagnosis to Treatment Strategies. <i>Advanced Therapeutics</i> , 2021, 4, 2000173.	1.6	3
1311	Care for patients with ventricular assist devices and suspected <sc>COVID</sc>â€²19 infection. <i>European Journal of Heart Failure</i> , 2020, 22, 937-940.	2.9	7
1312	TMPRSS2: Potential Biomarker for COVIDâ€²19 Outcomes. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 801-807.	1.0	63
1313	Remdesivir: Review of Pharmacology, Preâ€²clinical Data, and Emerging Clinical Experience for COVIDâ€²19. <i>Pharmacotherapy</i> , 2020, 40, 659-671.	1.2	197
1314	Therapeutic approaches against coronaviruses acute respiratory syndrome. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00691.	1.1	7
1315	Clinical practice guidance for hepatology and liver transplant providers during the COVID-19 pandemic: APASL expert panel consensus recommendations. <i>Hepatology International</i> , 2020, 14, 415-428.	1.9	65
1316	Repurposing old drugs as antiviral agents for coronaviruses. <i>Biomedical Journal</i> , 2020, 43, 368-374.	1.4	54

#	ARTICLE	IF	CITATIONS
1317	COVID-19 therapy: What weapons do we bring into battle?. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115757.	1.4	22
1318	Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. <i>Drug Resistance Updates</i> , 2020, 53, 100721.	6.5	80
1319	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020, 14, 641-648.	1.8	142
1320	Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. <i>European Journal of Internal Medicine</i> , 2020, 76, 36-42.	1.0	158
1321	Biomedical application, drug delivery and metabolic pathway of antiviral nanotherapeutics for combating viral pandemic: A review. <i>Environmental Research</i> , 2020, 191, 110119.	3.7	28
1322	Extra-respiratory manifestations of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106024.	1.1	231
1323	Drug repurposing and cytokine management in response to COVID-19: A review. <i>International Immunopharmacology</i> , 2020, 88, 106947.	1.7	46
1324	Mitigating the transmission of infection and death due to SARS-CoV-2 through non-pharmaceutical interventions and repurposing drugs. <i>ISA Transactions</i> , 2022, 124, 236-246.	3.1	7
1325	Nanotheranostics against COVID-19: From multivalent to immune-targeted materials. <i>Journal of Controlled Release</i> , 2020, 328, 112-126.	4.8	35
1326	COVID-19 in clinical practice: A narrative synthesis. <i>MÃ©decine Et Maladies Infectieuses</i> , 2020, 50, 639-647.	5.1	2
1327	A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application. <i>Medical Hypotheses</i> , 2020, 144, 109876.	0.8	15
1328	Diagnostic approaches and potential therapeutic options for coronavirus disease 2019. <i>New Microbes and New Infections</i> , 2020, 38, 100770.	0.8	12
1329	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. <i>ReumatologÃ­a ClÃ­nica</i> , 2022, 18, 150-156.	0.2	44
1330	Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. <i>Lancet, The</i> , 2020, 395, 1845-1854.	6.3	1,127
1331	Horizontal transmission of severe acute respiratory syndrome coronavirus 2 to a premature infant: multiple organ injury and association with markers of inflammation. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 548-551.	2.7	26
1332	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16
1333	Hopes rise for coronavirus drug remdesivir. <i>Nature</i> , 2020, , .	13.7	41
1334	Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy. <i>Bioscience Reports</i> , 2020, 40, .	1.1	129

#	ARTICLE	IF	CITATIONS
1335	Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission. <i>Clinical Science</i> , 2020, 134, 2137-2160.	1.8	68
1336	COVID-19 in Kidney Transplantation: Outcomes, Immunosuppression Management, and Operational Challenges. <i>Advances in Chronic Kidney Disease</i> , 2020, 27, 383-389.	0.6	19
1338	SARS-CoV-2 and Pregnancy: A Review of the Facts. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2020, 42, 562-568.	0.3	11
1339	Current Insights into the Novel Coronavirus Disease 2019 (COVID-19) and Its Homoeopathic Management. <i>Homopathic Links</i> , 2020, 33, 171-179.	0.1	3
1340	Design and in silico study of the novel coumarin derivatives against SARS-CoV-2 main enzymes. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, , 1-16.	2.0	13
1341	Police brutality against Blacks in the United States and ensuing protests: Implications for social distancing and Black health during COVID-19. <i>Journal of Human Behavior in the Social Environment</i> , 2021, 31, 262-270.	1.1	28
1342	Treatments in the COVID-19 pandemic: an update on clinical trials. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 81-88.	1.0	11
1343	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1009-1027.	2.0	23
1344	Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. <i>Journal of Immunoassay and Immunochemistry</i> , 2020, 41, 960-975.	0.5	6
1345	Natural history of COVID-19 and therapeutic options. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1159-1184.	1.3	101
1346	Coronavirus disease 2019 in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 297-306.	1.4	59
1347	COVID-19: patients with stroke or risk of stroke. <i>European Heart Journal Supplements</i> , 2020, 22, P25-P28.	0.0	15
1348	SARS-CoV-2 infection and the antiviral innate immune response. <i>Journal of Molecular Cell Biology</i> , 2021, 12, 963-967.	1.5	18
1349	Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa103.	1.4	15
1350	Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information. <i>Critical Care Medicine</i> , 2021, 49, e11-e19.	0.4	18
1351	Human Coronavirus Infections and Pregnancy. <i>Maternal-Fetal Medicine</i> , 2021, 3, 53-65.	0.4	12
1352	Evaluating sources of bias in observational studies of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use during COVID-19: beyond confounding. <i>Journal of Hypertension</i> , 2021, 39, 795-805.	0.3	41
1353	COVID-19 in Chronic Liver Disease and Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2021, 55, 187-194.	1.1	39

#	ARTICLE	IF	CITATIONS
1354	Current drugs with potential for coronavirus disease 2019 therapy: a literature review. <i>Reviews in Medical Microbiology</i> , 2022, 33, e148-e160.	0.4	3
1355	COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice. <i>Transplantation Direct</i> , 2020, 6, e582.	0.8	21
1401	<scp>COVIDâ€™SAFER</scp>: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 1636-1646.	1.3	29
1402	Perspective: SARS-CoV-2, COVID-19 and Haematologists. <i>Acta Haematologica</i> , 2021, 144, 117-121.	0.7	12
1404	Clinical and pathological investigation of patients with severe COVID-19. <i>JCI Insight</i> , 2020, 5, .	2.3	232
1405	Hydroxychloroquine and chloroquine for COVID-19: psychiatric aspects of patient safety considerations. <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862095714.	1.0	3
1406	Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China. <i>Annals of Intensive Care</i> , 2020, 10, 73.	2.2	151
1407	Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study. <i>Annals of Intensive Care</i> , 2020, 10, 131.	2.2	39
1408	Lithiumâ€™s antiviral effects: a potential drug for CoVID-19 disease?. <i>International Journal of Bipolar Disorders</i> , 2020, 8, 21.	0.8	52
1409	Battling COVID-19: using old weapons for a new enemy. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2020, 6, 6.	0.9	20
1410	Management of Atrial Fibrillation in COVID-19 Pandemic. <i>Circulation Journal</i> , 2020, 84, 1679-1685.	0.7	18
1411	First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection. <i>American Journal of Case Reports</i> , 2020, 21, e925020.	0.3	25
1412	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 2020, 9, 1109.	0.8	8
1413	Novel respiratory infectious diseases in Korea. <i>Yeungnam University Journal of Medicine</i> , 2020, 37, 286-295.	0.7	4
1414	Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2020, 8, 6181-6189.	0.3	2
1415	Antiviral treatment of COVID-19: a clinical pharmacology narrative review. <i>Medical Journal of Indonesia</i> , 2020, 29, 332-45.	0.2	8
1416	A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro. <i>PLoS Computational Biology</i> , 2020, 16, e1008489.	1.5	42
1417	Scientific quality of COVID-19 and SARS CoV-2 publications in the highest impact medical journals during the early phase of the pandemic: A case control study. <i>PLoS ONE</i> , 2020, 15, e0241826.	1.1	59

#	ARTICLE	IF	CITATIONS
1418	Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0243705.	1.1	62
1419	Validation and repurposing of the MSL-COVID-19 score for prediction of severe COVID-19 using simple clinical predictors in a triage setting: The Nutri-CoV score. PLoS ONE, 2020, 15, e0244051.	1.1	22
1420	COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	0.7	14
1421	Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia. Annals of Hepato-biliary-pancreatic Surgery, 2020, 24, 526-532.	0.1	10
1422	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. Journal of Clinical Medicine Research, 2020, 12, 463-471.	0.6	5
1423	COVID-19 and Possible Pharmacological Preventive Options. Journal of Clinical Medicine Research, 2020, 12, 758-772.	0.6	3
1424	Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient. Clinical Chemistry and Laboratory Medicine, 2020, 58, 1461-1468.	1.4	36
1425	Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratology Information Service experience during COVID-19 outbreak in Italy. Journal of Perinatal Medicine, 2020, 48, 1001-1007.	0.6	5
1426	Chronic neurological diseases and COVID-19: Associations and considerations. Translational Neuroscience, 2020, 11, 294-301.	0.7	13
1427	Fast news or fake news?. EMBO Reports, 2020, 21, e50817.	2.0	32
1428	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. EMBO Molecular Medicine, 2021, 13, e13105.	3.3	62
1429	Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Molecular Medicine, 2021, 13, e13426.	3.3	87
1430	Insights into Potential Mechanisms of Injury and Treatment Targets in COVID-19, SARS-Cov-2 Infection. International Journal of Clinical Research & Trials, 2020, 5, .	1.6	5
1431	SCIENTIST'S PURSUIT FOR CORONAVIRUS SARS-COV-2, WHICH CAUSES COVID-19: SCIENTIFIC STRATEGIES AGAINST PANDEMIC. Visnik Nacional Noi Akademii Nauk Ukraini, 2020, , 29-71.	0.0	6
1434	Coronaviral Infection (COVID-19) in Children (Situation on April 2020). PediatriĀeskaĀĉ FarmakologiĀĉ, 2020, 17, 85-94.	0.1	14
1435	New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2020, 19, 123-131.	0.1	30
1436	COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Memorias Do Instituto Oswaldo Cruz, 2020, 115, e200254.	0.8	26
1437	Off label, compassionate and irrational use of medicines in Covid-19 pandemic, health consequences and ethical issues. Ciencia E Saude Coletiva, 2020, 25, 3413-3419.	0.1	25

#	ARTICLE	IF	CITATIONS
1438	Treatment and research lines for the patient with COVID-19. What do we have and where are we going?. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 125-132.	0.7	5
1439	Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. <i>Tohoku Journal of Experimental Medicine</i> , 2020, 251, 27-30.	0.5	16
1441	COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic. <i>Revista Espanola De Enfermedades Digestivas</i> , 2020, 112, 389-396.	0.1	20
1443	COVID-19 and children. <i>Pulmonologiya</i> , 2020, 30, 609-628.	0.2	15
1444	The efficacy of remdesivir in coronavirus disease 2019 (COVID-19): a systematic review. <i>Iranian Journal of Microbiology</i> , 2020, 12, 376-387.	0.8	12
1445	Prospects for a COVID-19 treatment: review. <i>Translational Medicine</i> , 2020, 7, 30-37.	0.1	7
1446	COVID-19 in cancer patients: risk, clinical features, and management. <i>Cancer Biology and Medicine</i> , 2020, 17, 519-527.	1.4	135
1449	Anesthesia and intensive care for patients with COVID-19. Russian Federation of anesthesiologists and reanimatologists guidelines. <i>Alexander Saltanov Intensive Care Herald</i> , 2020, , 9-120.	0.2	11
1450	Environmental Concern Regarding the Effect of Humidity and Temperature on SARS-COV-2 (COVID-19) Survival: Fact or Fiction. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
1451	The Landscape of Emerging Randomized Clinical Trial Evidence for COVID-19 Disease Stages: A Systematic Review of Global Trial Registries. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4577-4587.	1.1	9
1452	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 4673-4695.	1.1	43
1453	A Favipiravir-induced Fever in a Patient with COVID-19. <i>Internal Medicine</i> , 2020, 59, 2951-2953.	0.3	7
1454	Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors. <i>Internal Medicine</i> , 2020, 59, 2921-2925.	0.3	19
1455	Targeting COVID-19 in Parkinson's Patients: Drugs Repurposed. <i>Current Medicinal Chemistry</i> , 2021, 28, 2392-2408.	1.2	13
1456	Novel Drugs Targeting the SARS-CoV-2/COVID-19 Machinery. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1423-1433.	1.0	36
1457	Repurposing of RdRp Inhibitors against SARS-CoV-2 through Molecular Docking Tools. <i>Coronaviruses</i> , 2020, 1, 108-116.	0.2	8
1458	Toward Preparing a Knowledge Base to Explore Potential Drugs and Biomedical Entities Related to COVID-19: Automated Computational Approach. <i>JMIR Medical Informatics</i> , 2020, 8, e21648.	1.3	9
1460	A REVIEW ON THE ANTIPARASITIC DRUG IVERMECTIN FOR VARIOUS VIRAL INFECTIONS AND POSSIBILITIES OF USING IT FOR NOVEL SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2: NEW HOPE TO TREAT CORONAVIRUS DISEASE-2019. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 21-27.	0.3	5

#	ARTICLE	IF	CITATIONS
1461	COVID-19 Evolution and Alternative Medicine- A Review. Journal of Pure and Applied Microbiology, 2020, 14, 841-848.	0.3	4
1462	Drug repurposing clinical trials in the search for life-saving COVID-19 therapies; research targets and methodological and ethical issues. Vigilancia Sanitaria Em Debate: Sociedade, Ciéncia & Tecnologia, 2020, 8, 39-53.	0.3	5
1463	Pandemia de COVID-19 y enfermedad renal ¿qu¿ sabemos actualmente?. Revista Colombiana De Nefrología, 2020, 7, 23-24.	0.1	4
1464	Repurposing of drugs for COVID-19: a systematic review and meta-analysis. Panminerva Medica, 2022, 64, .	0.2	8
1465	Assessment and treatment of older individuals with COVID 19 multi-system disease: Clinical and ethical implications. Acta Biomedica, 2020, 91, 150-168.	0.2	18
1466	COVID-19 and literature evidence: should we publish anything and everything?. Acta Biomedica, 2020, 91, e2020020.	0.2	9
1467	COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. Zoological Research, 2020, 41, 517-526.	0.9	49
1468	Drug Repositioning for COVID-19. Colombia Medica, 2020, 51, e4279.	0.7	5
1470	Pharmacological treatment of COVID-19: an update. Journal of Global Health Reports, 0, , .	1.0	2
1471	Pride and Prejudice during the COVID-19 Pandemic: The Misfortune of Inappropriate Clinical Trial Design. Journal of Epidemiology and Global Health, 2021, 11, 15.	1.1	4
1472	Helmet Continuous Positive Airway Pressure in the Treatment of COVID-19 Patients with Acute Respiratory Failure could be an Effective Strategy: A Feasibility Study. Journal of Epidemiology and Global Health, 2020, 10, 201.	1.1	15
1473	Idiosyncrasies of COVID-19; A Review. Iranian Journal of Medical Microbiology, 2020, 14, 290-296.	0.1	2
1474	Koronavirüs Hastalığı (COVID-19) Tedavisinde Kullanılan İlaçlar. Kocaeli Üniversitesi Saėlık Bilimleri Dergisi, 2020, 6, 167-173.	0.3	6
1475	Overview of management of children with COVID-19. Clinical and Experimental Pediatrics, 2020, 63, 345-354.	0.9	3
1476	Management of liver diseases during the pandemic of coronavirus disease-19. Clinical and Molecular Hepatology, 2020, 26, 243-250.	4.5	8
1477	Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review. Frontiers in Pharmacology, 2020, 11, 590598.	1.6	21
1478	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. Frontiers in Physiology, 2020, 11, 596057.	1.3	15
1479	Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System. Biomedicines, 2021, 9, 11.	1.4	8

#	ARTICLE	IF	CITATIONS
1480	Targeting the SphK-S1P-SIPR Pathway as a Potential Therapeutic Approach for COVID-19. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7189.	1.8	35
1481	Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review. <i>Viruses</i> , 2020, 12, 1092.	1.5	34
1482	Plant-Based Drugs and Vaccines for COVID-19. <i>Vaccines</i> , 2021, 9, 15.	2.1	34
1484	Public Risk-Taking and Rewards During the COVID-19 Pandemic - A Case Study of Remdesivir in the Context of Global Health Equity. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.5	6
1485	Severe Acute Respiratory Distress Syndrome Secondary to Coronavirus 2 (SARS-CoV-2). <i>International Journal of Occupational and Environmental Medicine</i> , 2020, 11, 157-178.	4.1	16
1487	Encountering COVID-19 as Endocrinologists. <i>Endocrinology and Metabolism</i> , 2020, 35, 197-205.	1.3	17
1488	[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 147-150.	0.8	4
1489	Repurposing current therapeutic regimens against SARS-CoV-2 (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1845-1855.	0.8	8
1490	COVID-19 in China: From epidemiology to treatment (Review). <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	4
1491	An integrative look at SARS-CoV-2 (Review). <i>International Journal of Molecular Medicine</i> , 2020, 47, 415-434.	1.8	17
1492	Interim Guidelines on Antiviral Therapy for COVID-19. <i>Infection and Chemotherapy</i> , 2020, 52, 281.	1.0	29
1493	Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series. <i>Infection and Chemotherapy</i> , 2020, 52, 369.	1.0	12
1494	COVID-19 and the kidney. <i>Cleveland Clinic Journal of Medicine</i> , 2020, 87, 619-631.	0.6	52
1495	Antivirals for COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	26
1496	COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	21
1497	Gastrointestinal manifestations of COVID-19. <i>Cleveland Clinic Journal of Medicine</i> , 2021, , .	0.6	26
1498	Interferon therapy for COVID-19 and emerging infections: Prospects and concerns. <i>Cleveland Clinic Journal of Medicine</i> , 2020, , .	0.6	22
1499	Repurposing Screens of FDA-Approved Drugs Identify 29 Inhibitors of SARS-CoV-2. <i>Journal of Microbiology and Biotechnology</i> , 2020, 30, 1843-1853.	0.9	17

#	ARTICLE	IF	CITATIONS
1500	Updates of Cardiovascular Manifestations in COVID-19: Korean Experience to Broaden Worldwide Perspectives. <i>Korean Circulation Journal</i> , 2020, 50, 543.	0.7	13
1501	Hospital preparedness and management of pediatric population during COVID-19 outbreak. <i>Annals of Thoracic Medicine</i> , 2020, 15, 107.	0.7	12
1502	Publishing in the time of pandemic: Editorial policy of a dermatology journal during COVID-19. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2020, 86, 337.	0.2	7
1503	Clinical management of COVID-19. <i>Indian Journal of Medical Research</i> , 2020, 151, 401.	0.4	68
1504	COVID-19 pandemic: A review based on current evidence. <i>Indian Journal of Pharmacology</i> , 2020, 52, 117.	0.4	44
1505	Convalescent plasma therapy in severe coronavirus disease-2019: A narrative review. <i>Indian Journal of Rheumatology</i> , 2020, 15, 217.	0.2	1
1506	Preventive and treatment strategies of COVID-19: From community to clinical trials. <i>Journal of Family Medicine and Primary Care</i> , 2020, 9, 2149.	0.3	45
1507	Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic. <i>Endocrine Practice</i> , 2020, 26, 915-922.	1.1	8
1508	Responding to the Challenge of the Dual COVID-19 and Ebola Epidemics in the Democratic Republic of Congo—Priorities for Achieving Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 597-602.	0.6	39
1509	SARS-CoV-2 pandemic in the western world: the lessons learned. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2020, 50, 110-111.	0.2	1
1510	Current Approaches to COVID-19: Therapy and Prevention. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 838-846.	0.3	19
1511	Pathophysiological Mechanisms and Neurological Manifestations in COVID-19. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 975-980.	0.3	22
1512	Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials. <i>Indian Journal of Critical Care Medicine</i> , 2020, 24, 1106-1113.	0.3	1
1513	Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation. <i>Annals of Saudi Medicine</i> , 2020, 40, 273-280.	0.5	10
1514	A perspective on modern advances for COVID-19 (SARS-CoV-2) therapeutics. <i>European Journal of Rheumatology</i> , 2020, 7, S102-S106.	1.3	1
1515	The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists. <i>Turkish Journal of Gastroenterology</i> , 2020, 31, 348-355.	0.4	6
1516	Current status of COVID-19 treatment: An opinion review. <i>World Journal of Virology</i> , 2020, 9, 27-37.	1.3	12
1517	Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic. <i>Drug Discoveries and Therapeutics</i> , 2020, 14, 273-281.	0.6	10

#	ARTICLE	IF	CITATIONS
1518	Update on the diagnosis and management of COVID-19 in pediatric patients. <i>Clinics</i> , 2020, 75, e2353.	0.6	11
1519	COVID-19 research risks ignoring important host genes due to pre-established research patterns. <i>ELife</i> , 2020, 9, .	2.8	14
1520	The journey of remdesivir: from Ebola to COVID-19. <i>Drugs in Context</i> , 2020, 9, 1-9.	1.0	106
1521	Coronavirus disease 2019 (COVID-19): latest developments in potential treatments. <i>Drugs in Context</i> , 2020, 9, 1-14.	1.0	14
1522	Overview of the Pathogenesis and Treatment of SARS-CoV-2 for Clinicians: A Comprehensive Literature Review. <i>Cureus</i> , 2020, 12, e10357.	0.2	7
1523	Cardiac Adverse Events With Remdesivir in COVID-19 Infection. <i>Cureus</i> , 2020, 12, e11132.	0.2	58
1524	Novel COVID-19: A Comprehensive Review of Transmission, Manifestation, and Pathogenesis. <i>Cureus</i> , 2020, 12, e8184.	0.2	47
1525	Potential Treatment Options for COVID-19: A Comprehensive Review of Global Pharmacological Development Efforts. <i>Cureus</i> , 2020, 12, e8845.	0.2	15
1526	Effectiveness of early treatment of lopinavirâ€“ritonavir in patients with severe COVID-19: a case series. <i>Clinical Medicine</i> , 2021, 21, e80-e83.	0.8	1
1528	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1313, 99-134.	0.8	6
1529	COVID-19 treatment in children: A systematic review and meta-analysis. <i>Journal of Family Medicine and Primary Care</i> , 2021, 10, 3292.	0.3	14
1530	Clinical Efficacy and Adverse Event of Remdesivir Treatment in Seven COVID-19 Cases with Respiratory Failure. <i>Journal of the Japanese Association for Infectious Diseases</i> , 2021, 95, 147-152.	0.0	0
1531	Antiviral therapy and immunotherapy of COVID-19. <i>Revista Espanola De Quimioterapia</i> , 2021, 34, 53-59.	0.5	0
1532	Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry. <i>JCO Oncology Practice</i> , 2022, 18, e426-e441.	1.4	16
1533	Potential Cardiotoxic Effects of Remdesivir on Cardiovascular System: A Literature Review. <i>Cardiovascular Toxicology</i> , 2022, 22, 268-272.	1.1	39
1534	Reviewing the global economic impacts and mitigating measures of COVID-19. <i>Total Quality Management and Business Excellence</i> , 0, , 1-15.	2.4	3
1536	Overview of potential drugs for the treatment of new coronavirus Infection (COVID-19). <i>Acta Biomedica Scientifica</i> , 2021, 6, 74-86.	0.1	0
1537	Imaging and visualizing SARS-CoV-2 in a new era for structural biology. <i>Interface Focus</i> , 2021, 11, 20210019.	1.5	5

#	ARTICLE	IF	CITATIONS
1538	Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL ^{pro} from SARS-CoV-2: An integrated <i>in silico</i> approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13392-13411.	2.0	6
1539	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1759.	2.0	42
1540	Cardiopulmonary Phenotypes of Post-Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Cardiology in Review</i> , 2021, Publish Ahead of Print, .	0.6	2
1541	Assessing unproven interventions in the COVID-19 pandemic: discussion on the ethics of "compassionate therapies" in times of catastrophic pandemics. <i>Journal of Medical Ethics</i> , 2022, 48, 1000-1005.	1.0	6
1542	SARS-CoV-2 Fears Green: The Chlorophyll Catabolite Pheophorbide A Is a Potent Antiviral. <i>Pharmaceutics</i> , 2021, 14, 1048.	1.7	8
1543	Pulmonary vascular system: A vulnerable target for COVID-19. <i>MedComm</i> , 2021, 2, 531-547.	3.1	10
1544	Longer Prehospitalization and Preintubation Periods in Intubated Non-survivors and ECMO Patients With COVID-19: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2021, 8, 727101.	1.2	2
1545	Current treatment strategies for COVID-19 (Review). <i>Molecular Medicine Reports</i> , 2021, 24, .	1.1	19
1546	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. <i>Environmental Science and Pollution Research</i> , 2021, 28, 68071-68089.	2.7	15
1547	Personalized therapy: can it tame the COVID-19 monster?. <i>Personalized Medicine</i> , 2021, 18, 583-593.	0.8	4
1548	Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA in the Human Eye. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-7.	1.0	0
1549	Liposomal remdesivir inhalation solution for targeted lung delivery as a novel therapeutic approach for COVID-19. <i>Asian Journal of Pharmaceutical Sciences</i> , 2021, 16, 772-783.	4.3	26
1550	Impact of COVID-19 pandemic on liver, liver diseases, and liver transplantation programs in intensive care units. <i>World Journal of Hepatology</i> , 2021, 13, 1215-1233.	0.8	3
1552	Population-scale identification of differential adverse events before and during a pandemic. <i>Nature Computational Science</i> , 2021, 1, 666-677.	3.8	4
1553	Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report. <i>Therapeutic Apheresis and Dialysis</i> , 2022, 26, 478-479.	0.4	8
1554	Remdesivir: Quo vadis?. <i>Biochemical Pharmacology</i> , 2021, 193, 114800.	2.0	17
1555	SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies. <i>International Immunopharmacology</i> , 2021, 101, 108232.	1.7	14
1557	Induced Pluripotent Stem Cell Derived Human Lung Organoids to Map and Treat the SARS-CoV2 Infections In Vitro. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1312, 1-17.	0.8	2

#	ARTICLE	IF	CITATIONS
1558	Covid-19 "Disease Caused By Sars-Cov-2 Infection" Vaccine And New Therapies Research Development. Postepy Mikrobiologii, 2020, 59, 227-236.	0.1	4
1559	Therapeutic Approach to Coronavirus Disease. , 2020, , 67-97.		1
1560	A literature review of drugs for the treatment of COVID-19. Caribbean Medical Journal, 0, , .	0.1	0
1568	A Silent Attacker SARS-CoV-2 - A Review. European Journal of Medical and Health Sciences, 2020, 2, .	0.1	0
1572	Drug Safety Issues in Therapy COVID-19. Russian Archives of Internal Medicine, 2020, 10, 165-187.	0.0	2
1575	COVID-19: The possible medical strategies. International Journal of Clinical Virology, 2020, 4, 071-075.	0.1	0
1578	(Facts and thoughts on COVID-19 pandemic). Cor Et Vasa, 2020, 62, 11-14.	0.1	1
1580	COVID-19: A Centennial Pandemic from Origin to Clinical Trials. Acta Biologica Marisiensis, 2020, 3, 30-52.	0.1	1
1581	As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. Western Journal of Medical and Biomedical Sciences, 2020, 1, 1-18.	0.2	0
1582	Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History. Journal of Hospital Medicine, 2020, 15, 434-436.	0.7	1
1585	COVID-19 Pneumonia in a Patient in Her Seventies that Improved without Antiviral Drug Treatment: A Case Study. Journal of the Japanese Association for Infectious Diseases, 2020, 94, 568-572.	0.0	0
1587	SETTING THE PRIORITIES RIGHT IN THE COVID-19 PANDEMIC. Qeios, 0, , .	0.0	1
1588	Nutritional Considerations in COVID-19 Pandemic. Integrative Journal of Medical Sciences, 0, 7, .	0.0	0
1589	Coronaviral Infection (COVID-19) in Children (Situation on June 2020). PediatriĀskaĀ FarmakologiĀĀ, 2020, 17, 162-178.	0.1	6
1591	SETTING THE PRIORITIES RIGHT IN THE COVID-19 PANDEMIC. Qeios, 0, , .	0.0	2
1593	Treatment of Coronavirus Disease 2019: Shooting in the Dark. European Cardiology Review, 2020, 15, e59.	0.7	2
1594	Tratamiento farmacolĀgico para COVID-19 en protocolos latinoamericanos: Una revisiĀn narrativa de la eficacia y seguridad. , 2020, 8, 150-160.		4
1595	New Drug: Remdesivir for COVID-19. Australian Prescriber, 2020, 43, 176-177.	0.5	2

#	ARTICLE	IF	CITATIONS
1597	Diagn3stico da COVID-19: import4ncia dos testes laboratoriais e dos exames de imagem. Research, Society and Development, 2020, 9, e259997162.	0.0	4
1599	A public-private partnership for the express development of antiviral leads: a perspective view. Expert Opinion on Drug Discovery, 2021, 16, 23-38.	2.5	2
1600	COVID-19: risk factors for severe cases of the Delta variant. Aging, 2021, 13, 23459-23470.	1.4	24
1601	SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. International Journal of Biological Macromolecules, 2021, 193, 1249-1273.	3.6	19
1602	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clinical and Translational Science, 2022, 15, 501-513.	1.5	21
1603	Drug-Repositioning Approaches Based on Medical and Life Science Databases. Frontiers in Pharmacology, 2021, 12, 752174.	1.6	8
1604	COVID-19 Drug Repositioning: Present Status and Prospects. Studies in Systems, Decision and Control, 2022, , 645-671.	0.8	1
1605	Drug repurposing in COVID-19: A review with past, present and future. Metabolism Open, 2021, 12, 100121.	1.4	25
1607	COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. Postepy Mikrobiologii, 2020, 59, 207-225.	0.1	2
1608	Potenciales efectos proarr3tmicos de la farmacoterapia contra SARS-CoV-2. , 2020, 31, 199-204.		0
1609	Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?. International Journal of Angiology, 2021, 30, 155-159.	0.2	1
1610	Brave new world an update on COVID-19 pandemic 4A review. Developments in Health Sciences, 2020, 3, 44-51.	0.1	0
1611	Severity of Coronavirus Disease 2019 in Patients with Cancer. UKH Journal of Science and Engineering, 2020, 4, 119-126.	0.0	0
1612	Increasing Use of Compassionate Use/Managed Access Channels to Obtain Medicines for Use in COVID419. Clinical Pharmacology and Therapeutics, 2021, 110, 26-28.	2.3	6
1613	Drug-Nutrition Interactions in Infectious Diseases. , 2021, , 367-410.		2
1614	COVID-19 Treatment at a Glance. Turkish Thoracic Journal, 2020, 21, 438-445.	0.2	2
1615	Ð·Ð†ÐšÐ£Ð´ÐÐÐÐ´ ÐŸÐ’ÐžÐÐÐ´ÐŸ Ð— COVID-19 ÐÐ·Ð†Ð£ÐšÐÐ†ÐÐžÐœÐ£ Ð·ÐœÐÐŸÐ†. , 2020, , 5-17.	0.0	3
1617	COVID-19: A Critical Review on Viral Biochemistry, Environmental Transmission, Therapeutics and Safety Measures. European Journal of Biology and Biotechnology, 2020, 1, .	0.2	0

#	ARTICLE	IF	CITATIONS
1618	A Review on Drug Repurposing: A Strategy to Treat Human Coronavirus Disease (COVID-19). International Journal of Tropical Disease & Health, 0, , 42-54.	0.1	0
1619	DESAFIOS TÉCNICOS DE LA INVESTIGACIÓN BIOMÉDICA EN TIEMPOS DE COVID-19: PANORAMA EN ARGENTINA. Revista Binacional Brasil-Argentina Diálogo Entre As Ciências, 2020, 9, 251-272.	0.0	0
1620	A model to rate strategies for managing disease due to COVID-19 infection. Scientific Reports, 2020, 10, 22435.	1.6	2
1622	Covid-19: The Biggest Threat of the 21st Century: In Respectful Memory of the Warriors All Over the World. Turkish Thoracic Journal, 2020, 21, 409-418.	0.2	10
1623	Characteristics and Outcomes Based on Perceived Illness Severity in SARS-CoV-2. Southern Medical Journal, 2020, 113, 618-622.	0.3	4
1625	Study protocol for a multicentre, prospective cohort study of the association of angiotensin II type 1 receptor blockers on outcomes of coronavirus infection. BMJ Open, 2020, 10, e040768.	0.8	7
1626	Evolution Toward Severe Covid-19 From Biological Monitoring to Therapeutic Considerations. Frontiers in Immunology, 2020, 11, 562038.	2.2	0
1627	Machine Learning to Predict ICU Admission, ICU Mortality and Survivors' Length of Stay among COVID-19 Patients: Toward Optimal Allocation of ICU Resources. , 2020, , .		15
1628	Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. World Journal of Clinical Cases, 2020, 8, 6173-6181.	0.3	1
1629	Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. Coronaviruses, 2020, 01, .	0.2	1
1630	Maintaining Access to Orthopaedic Surgery During Periods of Operating Room Resource Constraint: Expanded Use of Wide-Awake Surgery During the COVID-19 Pandemic. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 2020, 4, e20.00100.	0.4	9
1631	Comparative therapeutic efficiency of remdesivir in COVID in a tertiary care center. APIK Journal of Internal Medicine, 2021, 9, 244.	0.1	0
1632	COVID-19 grave: entenda o papel da imunidade, do endotélio e da coagulação na prática clínica. Jornal Vascular Brasileiro, 2020, 19, e20200131.	0.1	10
1633	Inflammation and thrombosis in patients with COVID-19: a prothrombotic and inflammatory disease caused by SARS Coronavirus-2. Anatolian Journal of Cardiology, 2020, 24, 224-234.	0.5	22
1634	Coronavirus disease 2019: The story so far. Libyan Journal of Medical Sciences, 2020, 4, 52.	0.1	4
1635	Past, Present, and Future of Remdesivir: An Overview of the Antiviral in Recent Times. Indian Journal of Critical Care Medicine, 2020, 24, 570-574.	0.3	3
1636	Density Functional Theory Calculation Aided Screening of SARS-CoV-2 RNA Polymerase Inhibitors. Hans Journal of Medicinal Chemistry, 2020, 08, 29-37.	0.0	0
1637	Understanding the challenges and ethical aspects of compassionate use of drugs in emergency situations. Indian Journal of Pharmacology, 2020, 52, 163.	0.4	5

#	ARTICLE	IF	CITATIONS
1638	COVID-19 pandemic: Case studies and perspectives. Side Effects of Drugs Annual, 2020, 42, 291-297.	0.6	2
1640	Ethical Issues Related to Coronavirus Disease. , 2020, , 237-249.		0
1642	Other Viral Diseases. , 2020, , 169-178.		0
1643	Management of COVID-19: A brief overview of the various treatment strategies. Cancer Research Statistics and Treatment, 2020, 3, 233.	0.1	4
1644	Early Initiation of Extracorporeal Blood Purification Using the AN69ST (oXiris®) Hemofilter as a Treatment Modality for COVID-19 Patients: a Single-Centre Case Series. Brazilian Journal of Cardiovascular Surgery, 2020, , .	0.2	13
1645	Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients. SSRN Electronic Journal, 0, , .	0.4	0
1646	Pharmacological approaches to the treatment of COVID-19 patients. Journal of Translational Science, 2020, 6, .	0.2	0
1647	Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. Romanian Journal of Morphology and Embryology, 2020, 61, 321-334.	0.4	4
1648	Management of COVID infection. Apollo Medicine, 2020, .	0.0	0
1649	COMDORA-SBN recommendations for patients with rare kidney diseases in relation to the Covid-19 pandemic. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 36-40.	0.4	0
1650	Antiviral Treatment Strategies in COVID-19. International Journal of Current Research and Review (discontinued), 2020, , 23-28.	0.1	0
1651	A Multicenter Questionnaire-Based Study to Know the Awareness and Medical Treatment Plan of Physicians Involved in the Management of COVID-19 Patients. Indian Journal of Critical Care Medicine, 2020, 24, 919-925.	0.3	2
1652	Current Treatment Options Available for COVID-19 : A Review. Asian Journal of Pharmaceutical Research and Health Care, 2020, 12, 141-147.	0.0	0
1653	Design aspects of COVID-19 treatment trials: Improving probability and time of favorable events. Biometrical Journal, 2021, , .	0.6	6
1654	Machine learning and network medicine approaches for drug repositioning for COVID-19. Patterns, 2022, 3, 100396.	3.1	23
1655	Analysis of trends in patent development for coronavirus detection, prevention, and treatment technologies in key countries. Journal of Biosafety and Biosecurity, 2022, 4, 23-32.	1.4	4
1657	Identification and Development of Therapeutics for COVID-19. MSystems, 2021, 6, e0023321.	1.7	20
1658	An Update on Animal Models for Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Countermeasure Development. Frontiers in Microbiology, 2021, 12, 770935.	1.5	4

#	ARTICLE	IF	CITATIONS
1659	Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients. <i>Journal of Infection and Public Health</i> , 2022, 15, 116-122.	1.9	20
1660	Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event. <i>Proceedings of the Indian National Science Academy</i> , 0, , .	0.5	0
1661	The Impact of COVID-19 on Liver Injury. <i>American Journal of the Medical Sciences</i> , 2022, 363, 94-103.	0.4	28
1662	Remdesivir; molecular and functional measures of mitochondrial safety. <i>Toxicology and Applied Pharmacology</i> , 2021, 433, 115783.	1.3	17
1665	Äçocuklarda COVID-19 Tedavisi. <i>Turkish Journal of Pediatric Disease</i> , 0, , 9-14.	0.0	0
1668	COVID-19 Management: What We Need to Know?. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 441-445.	0.1	0
1669	Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19538.	1.2	3
1670	COVID-19: An Update Regarding the Quest for Finding an Effective Cure. <i>Cureus</i> , 2020, 12, e9010.	0.2	0
1672	Acute COVID-19 Infection in a Pediatric Patient with ROHHAD. <i>Journal of Pediatric Genetics</i> , 2022, 11, 309-312.	0.3	2
1677	Coronavirus and Homo Sapiens. <i>Journal of Cardiac Critical Care TSS</i> , 0, , .	0.0	0
1678	Venous Thromboembolism in COVID-19: Are Women Different?. <i>Indian Journal of Cardiovascular Disease in Women WINCARS</i> , 2020, 5, 200-208.	0.1	2
1683	Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings. <i>F1000Research</i> , 0, 9, 1109.	0.8	7
1684	Development of research on COVID-19 by the World Scientific Community in the first half of 2020. <i>Revista Bionatura</i> , 2020, 5, 1410-1417.	0.1	1
1685	Investigational Drugs for the COVID 19 Pandemic â€“ A Concise Review. <i>Pharmaceutical Sciences</i> , 2020, 26, S36-S48.	0.1	0
1686	A Summary of Coronavirus Disease 2019: What We Should Know?. <i>Pharmaceutical Sciences</i> , 2020, 26, S24-S35.	0.1	0
1687	EFFICACY AND SAFETY OF REMDESIVIR IN THE TREATMENT OF COVID 19: A RETROSPECTIVE STUDY. , 2020, , 1-4.		0
1688	In Silico Study of Pacific oyster Antiviral Polypeptides as Potential Inhibitory Compounds for SARS-CoV-2 Main Protease. <i>Jentashapir Journal of Cellular and Molecular Biology</i> , 2020, 11, , .	0.1	3
1689	Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2020, 2, 100224.	1.3	1

#	ARTICLE	IF	CITATIONS
1690	The COVID-19 war and the battles of rheumatologists. <i>Beyond Rheumatology</i> , 2020, 2, 41-42.	0.3	0
1693	Treatments for COVID-19: emerging drugs against the coronavirus. <i>Acta Biomedica</i> , 2020, 91, 118-136.	0.2	18
1694	BET 1: The role of remdesivir in COVID-19 infection. <i>Emergency Medicine Journal</i> , 2020, 37, 522-523.	0.4	0
1695	Effective Anti-SARS-CoV-2 RNA Dependent RNA Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin, and Baloxavir Marboxil. <i>Avicenna Journal of Medical Biotechnology</i> , 2020, 12, 246-250.	0.2	7
1696	Pharmacological approaches to the treatment of COVID-19 patients. <i>Journal of Translational Science</i> , 2020, 6, .	0.2	0
1697	Serum triglyceride level and hypertension are highly associated with the recovery of COVID-19 patients. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 6646-6654.	0.0	3
1698	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. <i>Tanaffos</i> , 2020, 19, 91-99.	0.5	10
1699	How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice. <i>Acta Biomedica</i> , 2020, 91, e2020021.	0.2	0
1700	Therapeutic strategies against COVID-19. <i>Acta Biomedica</i> , 2020, 91, e2020038.	0.2	3
1701	Diagnostic and Therapeutic Approaches to Novel COVID-19 in Intensive Care Unit: A Narrative Review. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , 2020, 48, 443-453.	0.2	0
1702	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. <i>Aging</i> , 2020, 12, 18866-18877.	1.4	0
1703	Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. <i>Iranian Journal of Pharmaceutical Research</i> , 2020, 19, 258-281.	0.3	1
1704	Knowledge of COVID-19 among Health Care Workers at a Tertiary Care Hospital of Nepal: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2020, 58, 905-910.	0.1	1
1705	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. <i>Acta Cardiologica Sinica</i> , 2021, 37, 9-17.	0.1	5
1707	The Pathogenesis and Treatment of COVID-19: A System Review. <i>Biomedical and Environmental Sciences</i> , 2021, 34, 50-60.	0.2	4
1708	Medication use during COVID-19: Review of recent evidence. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	1
1710	Knowledge, risk perception and adherence to COVID-19 prevention advisory among police officers in Makurdi Metropolis Benue State, 2020. <i>Pan African Medical Journal</i> , 2021, 38, 199.	0.3	1
1711	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 163-171.	0.2	1

#	ARTICLE	IF	CITATIONS
1712	Case fatality rate of COVID-19: a systematic review and meta-analysis. <i>Journal of Preventive Medicine and Hygiene</i> , 2021, 62, E311-E320.	0.9	6
1713	Tackling COVID-19 Using Small-Molecule Drugs. , 2022, , 73-84.		0
1714	Treatment and therapeutic agents. , 2022, , 121-176.		0
1715	Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. <i>Chemico-Biological Interactions</i> , 2022, 351, 109744.	1.7	10
1716	A Guide to Writing a Case Report According to CARE Guideline. , 2021, 5, 41-45.		0
1717	Teaching Evidence-Based Medicine Through Facilitated Journal Clubs. <i>PRIMER (Leawood, Kan)</i> , 2021, 5, 47.	0.6	1
1718	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. <i>World Journal of Pharmacology</i> , 2021, 10, 1-32.	1.3	1
1719	Role of lipid Nanoparticles in COVID-19 inrepurposing drugs and vaccines. <i>Current Nanoscience</i> , 2021, 17, .	0.7	0
1720	Retrospective Analysis of Clinical Laboratory Parameters, Therapeutics and Outcome in Patients Infected with SARS-CoV2. <i>Indian Journal of Clinical Biochemistry</i> , 2022, 37, 480-486.	0.9	2
1721	Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. <i>Scientific Reports</i> , 2021, 11, 23179.	1.6	28
1722	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. <i>Drug Development Research</i> , 2022, 83, 16-54.	1.4	13
1723	Coronavirus Disease (COVID-19) Control between Drug Repurposing and Vaccination: A Comprehensive Overview. <i>Vaccines</i> , 2021, 9, 1317.	2.1	35
1724	Clozapine and COVID-19: A Case Report and Clinical Considerations. <i>Current Drug Safety</i> , 2021, 16, .	0.3	1
1725	SARS-CoV-2 may affect the immune response via direct inhibition of T cell receptor: Mechanistic hypothesis and rationale. <i>Biochimie</i> , 2022, 195, 86-89.	1.3	4
1726	A Narrative Review of Existing Options for COVID-19-Specific Treatments. <i>Advances in Virology</i> , 2021, 2021, 1-13.	0.5	0
1728	Aeromedical Implications of Long-Term COVID-19 Sequelae. <i>Aerospace Medicine and Human Performance</i> , 2021, 92, 898-907.	0.2	3
1729	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. <i>Future Microbiology</i> , 2021, 16, 1415-1451.	1.0	12
1730	A Clinical Update on Employing Tocilizumab to Fight COVID-19. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1731	The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. <i>European Journal of Pharmacology</i> , 2022, 914, 174615.	1.7	61
1732	Anti-SARS-CoV-2 Inhibitory Profile of New Quinoline Compounds in Cell Culture-Based Infection Models. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	6
1733	Case Report: Severe SARS-CoV-2 Infection with Remdesivir in a Patient with ESRD. <i>Infectious Disorders - Drug Targets</i> , 2021, 21, .	0.4	1
1734	Favipiravir (6-Fluoro-3-hydroxy-2-pyrazinecarboxamide) a Broad Spectrum Inhibitor of Viral RNA Polymerase in COVID-19 Treatment. <i>ChemistrySelect</i> , 2021, 6, 12652-12662.	0.7	3
1735	Time Optimal Control Studies on COVID-19 Incorporating Adverse Events of the Antiviral Drugs. <i>Computational and Mathematical Biophysics</i> , 2021, 9, 214-241.	0.6	2
1736	Vaccines and Antiviral Developments for SARS-CoV-2 in the Emergence of the COVID-19 Pandemic. <i>RSC Drug Discovery Series</i> , 2021, , 45-60.	0.2	0
1737	Facile synthesis and nematicidal activity evaluation of thiophosphinyl amide [(Pz)2P(S)NHR] and thiophosphonyl diamide [(Pz)P(S)(NHR)2] (Pz = 1,3,5-trimethylpyrazole, R = biphenyl derivatives). <i>RSC Advances</i> , 2021, 11, 36250-36256.	1.7	0
1738	The Impact of COVID-19 on Health Sector Stock Returns. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1739	Recent Advances on Drugs and Vaccines for COVID-19. <i>Inquiry (United States)</i> , 2021, 58, 004695802110556.	0.5	3
1740	Nascent perspectives on COVID-19 treatments. <i>Side Effects of Drugs Annual</i> , 2021, 43, 329-335.	0.6	0
1742	COVID-19 in hemodialysis patients: Experience from a Western Indian center. <i>Indian Journal of Nephrology</i> , 2022, 32, 216.	0.2	3
1743	Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. <i>Cadernos De Saude Publica</i> , 2021, 37, e00077721.	0.4	13
1744	Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019. <i>IDCases</i> , 2021, 26, e01343.	0.4	3
1747	ADENet: a novel network-based inference method for prediction of drug adverse events. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	4
1748	Impact of Liver Functions by Repurposed Drugs for COVID-19 Treatment. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 748-756.	0.7	7
1749	Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study. <i>Computers in Biology and Medicine</i> , 2022, 141, 105155.	3.9	17
1750	Therapeutic Management of Coronavirus Disease 2019 (COVID-19): A Systematic Review and Treatment Algorithm. <i>Journal of Pharmaceutical Research International</i> , 0, , 119-134.	1.0	0
1751	Compassionate Drug Use – Time Arising for a New Law in Bulgaria in the Era of COVID-19. <i>Folia Medica</i> , 2020, 62, 592-596.	0.2	2

#	ARTICLE	IF	CITATIONS
1753	COVID-19: a risk factor for fatal outcomes in patients with comorbid cardiovascular disease. <i>Aging</i> , 2020, 12, 18866-18877.	1.4	1
1754	Pensamiento complejo en la educaci3n m3dica: un reto ineludible ante la pandemia de COVID-19. <i>Investigaci3n En Educaci3n M3dica</i> , 2020, 9, 87-95.	0.0	1
1755	Alvos Moleculares dos F3rmacos no Tratamento da COVID-19. <i>Cadernos De Prospec3o</i> , 2020, 13, 1251.	0.0	0
1756	A REVIEW ON THE USE OF REMDESIVIR IN THE CURRENT VIROSIS COVID-19.. <i>Interfaces Cient3ficas - Sa3de E Ambiente</i> , 2020, 8, 272-280.	0.1	0
1757	Knowledge of COVID-19 among Health Care Workers at a Tertiary Care Hospital of Nepal: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2020, 58, 905-910.	0.1	4
1758	Diagnostic and Therapeutic Approaches to Novel COVID-19 in Intensive Care Unit: A Narrative Review. <i>Turkish Journal of Anaesthesiology and Reanimation</i> , 2020, 48, 443-453.	0.2	0
1759	Molecular docking analysis of HER-2 inhibitor from the ZINC database as anticancer agent. <i>Bioinformation</i> , 2020, 16, 878-881.	0.2	1
1760	Evidencia disponible sobre el abordaje terap3utico de pacientes con COVID-19: una revisi3n narrativa. <i>Ciencia, Tecnolog3a Y Salud</i> , 2020, 7, 363-380.	0.0	1
1761	Early Identification of COVID-19 Infected Patients Who Need ICU Care and its Implications. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1762	Characterisation of current pharmacotherapeutic COVID-19 clinical trials in India: A registry-based descriptive analysis. <i>Indian Journal of Physiology and Pharmacology</i> , 0, 65, 141-145.	0.4	0
1763	Potential therapeutic options for COVID-19: an update on current evidence. <i>European Journal of Medical Research</i> , 2022, 27, 6.	0.9	85
1764	Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir. <i>Environmental and Molecular Mutagenesis</i> , 2022, 63, 37-63.	0.9	39
1765	Autopsy findings of a patient with severe COVID-19 treated with long-term extracorporeal membrane oxygenation. <i>Respiratory Medicine Case Reports</i> , 2022, 36, 101595.	0.2	0
1766	Cross-species virus transmission and its pandemic potential. <i>Bulletin of the National Research Centre</i> , 2022, 46, 18.	0.7	5
1768	LONG-TERM IMMUNOLOGICAL CONSEQUENCES OF COVID-19 ON HEALTH. <i>International Journal of Applied Pharmaceutics</i> , 0, , 42-49.	0.3	1
1769	Adverse Effects of COVID-19 Treatments: A Special Focus on Susceptible Populations. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2022, , .	0.6	0
1770	Antiviral Drugs and Their Roles in the Treatment of Coronavirus Infection. , 0, , .		2
1771	Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 3021-3033.	2.8	65

#	ARTICLE	IF	CITATIONS
1772	Remdesivir for pregnancy: A systematic review of antiviral therapy for COVID-19. <i>Heliyon</i> , 2022, 8, e08835.	1.4	14
1773	Strategies for drug repurposing against coronavirus targets. <i>Current Research in Pharmacology and Drug Discovery</i> , 2022, 3, 100072.	1.7	11
1774	Equitable Allocation of Remdesivir for the COVID-19 Pandemic in Los Angeles County. <i>Prehospital Emergency Care</i> , 2021, , 1-6.	1.0	0
1775	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
1776	Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. <i>BMC Infectious Diseases</i> , 2022, 22, 1.	1.3	66
1778	The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 65.	2.4	29
1779	Target-Based Virtual Screening and LC/MS-Guided Isolation Procedure for Identifying Phloroglucinol-Terpenoid Inhibitors of SARS-CoV-2. <i>Journal of Natural Products</i> , 2022, 85, 327-336.	1.5	13
1780	The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report. <i>Einstein (Sao Paulo, Brazil)</i> , 2022, 20, eRC6550.	0.3	0
1781	A Time-Series Feature-Based Recursive Classification Model to Optimize Treatment Strategies for Improving Outcomes and Resource Allocations of COVID-19 Patients. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2022, 26, 3323-3329.	3.9	8
1782	Virucidal Activity of Essential Oils From <i>Citrus x aurantium</i> L. Against Influenza A Virus H1N1: Limonene as a Potential Household Disinfectant Against Virus. <i>Natural Product Communications</i> , 2022, 17, 1934578X2110727.	0.2	6
1783	COVID-19: Gastrointestinal manifestations, liver injury and recommendations. <i>World Journal of Clinical Cases</i> , 2022, 10, 1140-1163.	0.3	27
1784	Inpatient Management and OBICU Care for Pregnant Patients With Severe COVID-19 Disease. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 189-194.	0.6	1
1785	Recombinant human interferon- λ 1b inhibits SARS-CoV-2 better than interferon- λ 2b in vitro. <i>Virologica Sinica</i> , 2022, , .	1.2	1
1786	Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies. <i>Cells</i> , 2022, 11, 253.	1.8	24
1787	Hospital outcomes of community-acquired COVID-19 versus influenza: Insights from the Swiss hospital-based surveillance of influenza and COVID-19. <i>Eurosurveillance</i> , 2022, 27, .	3.9	7
1788	The clinical course of a 79-year-old stroke survivor in the setting of a late-onset COVID-19 infection. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2110666.	0.2	0
1789	Repurposing of <i>Mycobacterium indicus pranii</i> for the severe form of COVID-19 patients in India: A cohort study. <i>Journal of Medical Virology</i> , 2021, , .	2.5	5
1790	Association of Complement C3 with Clinical Deterioration Among Hospitalized Patients with COVID-19. <i>International Journal of General Medicine</i> , 2022, Volume 15, 849-857.	0.8	7

#	ARTICLE	IF	CITATIONS
1791	Computational Approach to Combat COVID-19 Infection: Emerging Tools for Accelerating Drug Research. <i>Current Drug Discovery Technologies</i> , 2022, 19, .	0.6	4
1792	Total synthesis of remdesivir. <i>Tetrahedron Letters</i> , 2022, 88, 153590.	0.7	6
1793	A case series of myocardial infarction in SARS-CoV-2 infected patients: Same complication, different outcomes. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05304.	0.2	2
1794	Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 799-811.	1.9	10
1795	Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. <i>Journal of Biological Chemistry</i> , 2022, 298, 101529.	1.6	25
1796	Benefits from Shortening Viral Shedding by Traditional Chinese Medicine Treatment for Moderate COVID-19: An Observational Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-10.	0.5	0
1797	Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition. <i>European Journal of Medicinal Chemistry</i> , 2022, 231, 114121.	2.6	30
1799	The utility of remdesivir in SARS-CoV-2: A single tertiary care center experience from a developing country. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2022, 5, 100107.	0.6	1
1800	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment. <i>Medicina (Lithuania)</i> , 2022, 58, 261.	0.8	3
1801	Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2022, 11, 11.	1.2	5
1802	Neurological complications of COVID-19 in children and the associated immunological responses. <i>Journal of King Saud University - Science</i> , 2022, 34, 101884.	1.6	5
1803	Association of Treatment with Remdesivir and 30-day Hospital Readmissions in Patients Hospitalized with COVID-19. <i>American Journal of the Medical Sciences</i> , 2022, 363, 403-410.	0.4	9
1804	Socio-demographic Heterogeneity in Prevalence of SARS-COV-2 Infection and Death Rate: Relevance to Black College Student Knowledge of COVID-19 and SARS-COV-2. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, , 1.	1.8	2
1805	Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population. <i>PLoS ONE</i> , 2022, 17, e0255495.	1.1	5
1806	Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112700.	2.5	18
1807	COVID-19 and arrhythmia: An overview. <i>Journal of Cardiology</i> , 2022, 79, 468-475.	0.8	21
1808	AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India. <i>Complementary Therapies in Medicine</i> , 2022, 66, 102814.	1.3	21
1809	Azvodine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 414.	7.1	91

#	ARTICLE	IF	CITATIONS
1812	Clinical Features, Diagnostic Evaluation, and Management of COVID-19 Patients. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1353, 1-22.	0.8	0
1813	Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1352, 87-109.	0.8	11
1814	Current Challenges for the Effective Management of the COVID-19 Pandemic. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1353, 131-149.	0.8	1
1815	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN) Tj ETQq1 1 0,784314 rgBT /Ov	0.1	0
1819	Health crisis: What opportunities for clinical drug research?. <i>Therapie</i> , 2022, 77, 59-67.	0.6	2
1821	Optimizing peptide inhibitors of SARS-Cov-2 nsp10/nsp16 methyltransferase predicted through molecular simulation and machine learning. <i>Informatics in Medicine Unlocked</i> , 2022, 29, 100886.	1.9	5
1822	Poor prognosis of patients with severe COVID-19 admitted to an infectious disease intensive care unit during the pandemic caused by the Delta variant in Japan. <i>Global Health & Medicine</i> , 2022, 4, 122-128.	0.6	3
1823	Mitoxantrone dihydrochloride, an FDA approved drug, binds with SARS-CoV-2 NSP1 C-terminal. <i>RSC Advances</i> , 2022, 12, 5648-5655.	1.7	11
1824	Clinical features of 162 fatal cases of COVID-19: a multi-center retrospective study. <i>Emergency and Critical Care Medicine</i> , 2022, 2, 109-115.	0.1	1
1825	A comprehensive review of adverse events to drugs used in COVID-19 patients: Recent clinical evidence. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13763.	1.7	5
1826	In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity. <i>Viruses</i> , 2022, 14, 389.	1.5	2
1828	Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. <i>Antiviral Therapy</i> , 2022, 27, 135965352210827.	0.6	10
1829	Efficacy of repurposed antiviral drugs: Lessons from COVID-19. <i>Drug Discovery Today</i> , 2022, 27, 1954-1960.	3.2	24
1830	Analytical Methods for the Determination of Major Drugs Used for the Treatment of COVID-19. A Review. <i>Critical Reviews in Analytical Chemistry</i> , 2023, 53, 1698-1732.	1.8	5
1831	SARS-CoV-2 Associated Respiratory Failure in a Preterm Infant and the Outcome after Remdesivir Treatment. <i>Pediatric Infectious Disease Journal</i> , 2022, 41, e233-e234.	1.1	4
1832	COVID-19 and liver disease: Are we missing something?. <i>World Journal of Hepatology</i> , 2022, 14, 479-481.	0.8	2
1833	Rapid Response in an Uncertain Environment: Study of COVID-19 Scientific Research Under the Parallel Model. <i>Risk Management and Healthcare Policy</i> , 2022, Volume 15, 339-349.	1.2	1
1834	Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay. <i>Communications Biology</i> , 2022, 5, 169.	2.0	118

#	ARTICLE	IF	CITATIONS
1835	Survival of COVID-19 Patients Who Received Antiviral and Antiviral Therapy Combined with Anti-inflammation Therapy in a National Referral Hospital, Indonesia. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 240-244.	0.1	0
1836	An Overview on Treatment Strategies by Allopathic and Alternative Forms of Medicines in Management of COVID -19. Research Journal of Pharmacy and Technology, 2022, , 935-940.	0.2	1
1838	Ofelecin i mi Vlapinâ€™Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina (Lithuania), 2022, 58, 309.	0.8	4
1839	Uso do Remdesivir no tratamento da Covid-19: uma revisÃ£o integrativa. Research, Society and Development, 2022, 11, e11111326420.	0.0	0
1840	Evolution of prescribing practices and outcomes in the COVID-19 pandemic in metropolitan areas. Infezioni in Medicina, 2022, 30, 86-95.	0.7	1
1841	In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs. Scientific Reports, 2022, 12, 5320.	1.6	15
1842	Antibiotic Use in Suspected and Confirmed COVID-19 Patients Admitted to Health Facilities in Sierra Leone in 2020â€™2021: Practice Does Not Follow Policy. International Journal of Environmental Research and Public Health, 2022, 19, 4005.	1.2	18
1843	In vitro and in vivo efficacy of a novel nucleoside analog H44 against Crimeanâ€™Congo hemorrhagic fever virus. Antiviral Research, 2022, 199, 105273.	1.9	9
1844	Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS. Frontiers in Pharmacology, 2022, 13, 692828.	1.6	29
1845	SARSâ€™CoVâ€™2 3CL ^{pro} displays faster selfâ€™maturation <i>in vitro</i> than SARSâ€™CoV 3CL ^{pro} due to faster Câ€™terminal cleavage. FEBS Letters, 2022, 596, 1214-1224.	1.3	3
1846	Functional food: complementary to fight against COVID-19. Beni-Suef University Journal of Basic and Applied Sciences, 2022, 11, 33.	0.8	24
1847	Recovery of serum testosterone levels is an accurate predictor of survival from COVID-19 in male patients. BMC Medicine, 2022, 20, 129.	2.3	11
1848	Targeting Viral Ion Channels: A Promising Strategy to Curb SARS-CoV-2. Pharmaceuticals, 2022, 15, 396.	1.7	4
1849	Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study. ReumatologÃa ClÃnica (English Edition), 2022, 18, 150-156.	0.2	12
1850	Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry. Internal and Emergency Medicine, 2022, 17, 1115-1127.	1.0	4
1851	Transient asymptomatic bradycardia and Remdesivir in COVID-19 patients. Minerva Medica, 2022, , .	0.3	1
1852	Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice. Science Translational Medicine, 2022, 14, eabm3410.	5.8	49
1853	Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series. F1000Research, 0, 10, 512.	0.8	3

#	ARTICLE	IF	CITATIONS
1854	Nurse's Psychological Experiences of Caring for Severe COVID-19 Patients in Intensive Care Units: A Qualitative Meta-Synthesis. <i>Frontiers in Public Health</i> , 2022, 10, 841770.	1.3	13
1855	Prescribing errors in post - COVID-19 patients: prevalence, severity, and risk factors in patients visiting a post - COVID-19 outpatient clinic. <i>BMC Emergency Medicine</i> , 2022, 22, 35.	0.7	4
1857	Pharmacological consideration of COVID-19 infection and vaccines in pregnancy. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 537-542.	0.6	6
1858	Use of Antivirals in SARS-CoV-2 Infection. <i>Critical Review of the Role of Remdesivir. Drug Design, Development and Therapy</i> , 2022, Volume 16, 827-841.	2.0	12
1859	The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infections. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010220.	1.3	11
1860	Therapeutic Strategies for COVID-19 Lung Disease in Children. <i>Frontiers in Pediatrics</i> , 2022, 10, 829521.	0.9	6
1861	Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 3130-3138.	2.8	37
1862	REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	1
1863	Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. <i>Viruses</i> , 2022, 14, 763.	1.5	8
1864	Efficacy and Outcome of Remdesivir and Tocilizumab Combination Against Dexamethasone for the Treatment of Severe COVID-19: A Randomized Controlled Trial. <i>Frontiers in Pharmacology</i> , 2022, 13, 690726.	1.6	10
1865	High-cited favorable studies for COVID-19 treatments ineffective in large trials. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 1-9.	2.4	4
1866	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 834942.	2.2	10
1867	Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. <i>Lancet, The</i> , 2022, 399, 1313-1321.	6.3	124
1868	Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2. <i>Microbial Pathogenesis</i> , 2022, , 105512.	1.3	6
1869	Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis. <i>Antiviral Research</i> , 2022, 200, 105270.	1.9	14
1870	Newly developed artificial intelligence algorithm for COVID-19 pneumonia: utility of quantitative CT texture analysis for prediction of favipiravir treatment effect. <i>Japanese Journal of Radiology</i> , 2022, 40, 800-813.	1.0	11
1871	Neuropsychiatric manifestation of the drugs used in the treatment of SARS-2-CoV-2019 (COVID-19) infection and their management: An overview and practice implications. <i>Asian Journal of Psychiatry</i> , 2022, 73, 103101.	0.9	4
1872	COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?. <i>Pharmacological Research</i> , 2022, 179, 106201.	3.1	23

#	ARTICLE	IF	CITATIONS
1873	Antiviral potential of nanoparticles for the treatment of Coronavirus infections. <i>Journal of Trace Elements in Medicine and Biology</i> , 2022, 72, 126977.	1.5	25
1874	Diverse Local Epidemics Reveal the Distinct Effects of Population Density, Demographics, Climate, Depletion of Susceptibles, and Intervention in the First Wave of COVID-19 in the United States. <i>Fields Institute Communications</i> , 2022, , 1-23.	0.6	2
1875	The immunologic response to severe acute respiratory syndrome coronavirus 2. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 495-505.	1.0	5
1876	Association of the patterns of use of medications with mortality of COVID-19 infection: a hospital-based observational study. <i>BMJ Open</i> , 2021, 11, e050051.	0.8	6
1877	The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. <i>The Open Covid Journal</i> , 2021, 1, 216-234.	0.4	1
1878	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. <i>World Journal of Hepatology</i> , 2021, 13, 1850-1874.	0.8	10
1879	mTOR kinase is a therapeutic target for respiratory syncytial virus and coronaviruses. <i>Scientific Reports</i> , 2021, 11, 24442.	1.6	3
1880	A sequential test to compare the real-time fatality rates of a disease among multiple groups with an application to COVID-19 data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 348-360.	0.7	2
1881	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
1882	Editorial: A Compendium of Recent Research on Stem Cell-Based Therapy for Covid-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 813384.	1.8	0
1883	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 0, 10, 1313.	0.8	1
1884	Administration of HeberFERON in Patients with Persistent Oropharyngeal SARS-CoV-2 Wuhan/D614G Strain Viral Shedding. <i>Journal of Biomedical Research & Environmental Sciences</i> , 2021, 2, 1253-1266.	0.1	0
1885	Treatment of patients with Covid-19 with a high dose of ulinastatin. <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 121.	0.8	6
1887	Stem cell-derived biofactors fight against coronavirus infection. <i>World Journal of Stem Cells</i> , 2021, 13, 1813-1825.	1.3	4
1888	Severe Type of COVID-19: Pathogenesis, Warning Indicators and Treatment. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 3-11.	0.7	5
1889	In Silico Study of Pubchem Compounds for Solanum torvum as Antiviral Agent against SARS-CoV-2. <i>The Open Covid Journal</i> , 2021, 1, 235-242.	0.4	0
1891	Drug repurposing strategies and key challenges for COVID-19 management. <i>Journal of Drug Targeting</i> , 2022, 30, 413-429.	2.1	13
1894	Overview of clinical trials of drugs for the treatment of patients with new coronavirus infection (COVID-19). <i>Aspirantskiy Vestnik Povolzhiya</i> , 2021, 21, 177-190.	0.0	0

#	ARTICLE	IF	CITATIONS
1895	Novel coronavirus infection (COVID-19) and kidney disease. <i>Profilakticheskaya Meditsina</i> , 2022, 25, 92.	0.2	0
1896	An <i>in vitro</i> study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. <i>Human and Experimental Toxicology</i> , 2022, 41, 096032712210892.	1.1	5
1898	Epigenetic regulation of autophagy in coronavirus disease 2019 (COVID-19). <i>Biochemistry and Biophysics Reports</i> , 2022, 30, 101264.	0.7	2
1899	International Country-Level Trends, Factors, and Disparities in Compassionate Use Access to Unlicensed Products for Patients With Serious Medical Conditions. <i>JAMA Health Forum</i> , 2022, 3, e220475.	1.0	7
1901	Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2456-2465.	2.5	7
1902	Highly coordinated nationwide massive travel restrictions are central to effective mitigation and control of COVID-19 outbreaks in China. <i>Proceedings of the Royal Society A: Mathematical, Physical and Engineering Sciences</i> , 2022, 478, 20220040.	1.0	10
1903	Targeted Therapy for Inflammatory Diseases with Mesenchymal Stem Cells and Their Derived Exosomes: From Basic to Clinics. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 1757-1781.	3.3	37
1904	Clinical progress of therapeutics and vaccines: Rising hope against COVID-19 treatment. <i>Process Biochemistry</i> , 2022, 118, 154-170.	1.8	4
1905	Do Mechanically Ventilated COVID-19 Patients Present a Higher Case-Fatality Rate Compared With Other Infectious Respiratory Pandemics? A Systematic Review and Meta-Analysis. <i>Infectious Diseases in Clinical Practice</i> , 2022, 30, .	0.1	1
1932	Amphiphilic anti-SARS-CoV-2 drug remdesivir incorporates into the lipid bilayer and nerve terminal membranes influencing excitatory and inhibitory neurotransmission. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2022, 1864, 183945.	1.4	5
1933	BET 1: The role of remdesivir in COVID-19 infection. <i>Emergency Medicine Journal</i> , 2020, 37, 522.2-523.	0.4	0
1940	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2021, 13, 163.	0.2	3
1941	Medication use during COVID-19. <i>Canadian Family Physician</i> , 2021, 67, 171-179.	0.1	6
1942	Médicaments utilisés durant la COVID-19. <i>Canadian Family Physician</i> , 2021, 67, e69-e78.	0.1	0
1944	Simulating and Preventing COVID-19 Using Epidemiological Models. <i>Advances in Data Mining and Database Management Book Series</i> , 2022, , 28-57.	0.4	0
1945	Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. <i>Frontiers in Microbiology</i> , 2022, 13, 884034.	1.5	8
1946	A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses. <i>Viruses</i> , 2022, 14, 928.	1.5	20
1947	Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4828.	1.8	28

#	ARTICLE	IF	CITATIONS
1948	Synthesis and Applications of Nitrogen-Containing Heterocycles as Antiviral Agents. <i>Molecules</i> , 2022, 27, 2700.	1.7	21
1949	The mechanism and effects of remdesivir-induced developmental toxicity in zebrafish: Blood flow dysfunction and behavioral alterations. <i>Journal of Applied Toxicology</i> , 2022, 42, 1688-1700.	1.4	2
1950	A Unique Robust Dual-Promoter-Driven and Dual-Reporter-Expressing SARS-CoV-2 Replicon: Construction and Characterization. <i>Viruses</i> , 2022, 14, 974.	1.5	1
1951	Dual targeting of RdRps of SARS-CoV-2 and the mucormycosis-causing fungus: an <i>in silico</i> perspective. <i>Future Microbiology</i> , 2022, 17, 755-762.	1.0	9
1952	Remdesivir and Its Combination With Repurposed Drugs as COVID-19 Therapeutics. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
1953	SARS-CoV-2 induces barrier damage and inflammatory responses in the human iPSC-derived intestinal epithelium. <i>Journal of Pharmacological Sciences</i> , 2022, 149, 139-146.	1.1	14
1954	Global effect of COVID-19 pandemic on cancer patients and its treatment: A systematic review. <i>Clinical Complementary Medicine and Pharmacology</i> , 2022, 2, 100041.	0.9	6
1955	Characteristics of the Compassionate Use Program in Japan: An Analysis of Expanded Access Clinical Trials from 2016 to 2021. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 817-823.	2.3	3
1956	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. <i>Anti-Infective Agents</i> , 2022, 20, .	0.1	0
1957	Optimal Drug Regimen and Combined Drug Therapy and Its Efficacy in the Treatment of COVID-19: A Within-Host Modeling Study. <i>Acta Biotheoretica</i> , 2022, 70, 16.	0.7	0
1958	Post-COVID-19 hematologic complications: a systematic review. <i>Expert Review of Hematology</i> , 2022, 15, 539-546.	1.0	6
1959	“Fighting for life and losing”: Intensive Care Unit Nursing Staff’s Experience With COVID-19 Patient Deaths During the First Two Waves: A Qualitative Study. <i>Inquiry (United States)</i> , 2022, 59, 004695802210943.	0.5	1
1960	Successful Desensitization to Remdesivir Hypersensitivity in a Patient Undergoing Treatment for COVID-19. <i>Annals of Pharmacotherapy</i> , 2023, 57, 110-112.	0.9	1
1961	An overview of possible solutions putting an end to the COVID-19 pandemic.. <i>Acta Biomedica</i> , 2022, 93, e2022202.	0.2	0
1963	Pyroptosis and Its Role in SARS-CoV-2 Infection. <i>Cells</i> , 2022, 11, 1717.	1.8	17
1964	Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
1965	Carbohydrate-based drugs launched during 2000~2021. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 3783-3821.	5.7	68
1966	Anti-SARS-CoV-2 Titers Predict the Severity of COVID-19. <i>Viruses</i> , 2022, 14, 1089.	1.5	9

#	ARTICLE	IF	CITATIONS
1967	Efficacy of COVID-19 treatments among geriatric patients: a systematic review. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612210956.	1.1	3
1968	Insight into the nucleoside transport and inhibition of human ENT1. <i>Current Research in Structural Biology</i> , 2022, 4, 192-205.	1.1	1
1969	Nanomedicine to deliver biological macromolecules for treating COVID-19. <i>Vaccine</i> , 2022, 40, 3931-3941.	1.7	9
1970	Comparison of efficacy of remdesivir with supportive care alone in the treatment of critically sick adult and child COVID-19 patients: A randomized clinical trial. <i>Anti-Infective Agents</i> , 2022, 20, .	0.1	0
1971	Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
1972	Global scientific outputs of extracorporeal membrane oxygenation in COVID-19: A bibliometric overview. <i>Perfusion (United Kingdom)</i> , 0, , 026765912211054.	0.5	1
1973	Application of exosomes for the alleviation of COVID-19-related pathologies. <i>Cell Biochemistry and Function</i> , 2022, 40, 430-438.	1.4	7
1974	A Unified Decision-Making Technique for Analysing Treatments inç†@andemicç†™ontext. <i>Computers, Materials and Continua</i> , 2022, 73, 2591-2618.	1.5	1
1975	Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. , 2022, , 181-203.		0
1976	Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management. <i>Environmental Health Insights</i> , 2022, 16, 117863022211043.	0.6	2
1977	Antibody- and T Cell-Dependent Responses Elicited by a SARS-CoV-2 Adenoviral-Based Vaccine in a Socially Vulnerable Cohort of Elderly Individuals. <i>Vaccines</i> , 2022, 10, 937.	2.1	1
1978	Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab. <i>Medicina Clínica (English Edition)</i> , 2022, 158, 509-518.	0.1	0
1979	The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. <i>Inflammopharmacology</i> , 2022, 30, 1143-1151.	1.9	4
1980	Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 2652-2661.	1.6	15
1981	Venetoclax Decreases the Expression of the Spike Protein through Amino Acids Q493 and S494 in SARS-CoV-2. <i>Cells</i> , 2022, 11, 1924.	1.8	2
1982	Overview of SARS-CoV-2 and possible targets for the management of COVID-19 infections. <i>Coronaviruses</i> , 2022, 03, .	0.2	0
1983	Forecasting COVID-19 and Analyzing the Effect of Government Interventions. <i>Operations Research</i> , 2023, 71, 184-201.	1.2	16
1985	The efficacy and safety of combined chinese herbal medicine and western medicine therapy for COVID-19: a systematic review and meta-analysis. <i>Chinese Medicine</i> , 2022, 17, .	1.6	9

#	ARTICLE	IF	CITATIONS
1986	Remdesivir-induced bradycardia in a 26-year-old patient with COVID-19: a case report. <i>Infection</i> , 0, , .	2.3	1
1987	Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. <i>Clinical and Translational Science</i> , 2022, 15, 1880-1886.	1.5	8
1988	Nudix hydrolase 18 catalyzes the hydrolysis of active triphosphate metabolites of the antivirals remdesivir, ribavirin, and molnupiravir. <i>Journal of Biological Chemistry</i> , 2022, 298, 102169.	1.6	3
1989	Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6735.	1.8	7
1990	A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. <i>F1000Research</i> , 0, 10, 1313.	0.8	2
1991	A study to assess the outcome in COVID-19 confirmed cases receiving Remdesivir as compared to conventional therapy: Medical records-based audit. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 3133.	0.3	2
1992	Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. <i>Cyprus Journal of Medical Sciences</i> , 2022, 7, 287-302.	0.0	0
1993	Remdesivir (VEKLURY) for Treating COVID-19: Guinea Pig Ex Vivo and In Vivo Cardiac Electrophysiological Effects. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 80, 616-622.	0.8	1
1994	An outlook on potential protein targets of COVID-19 as a druggable site. <i>Molecular Biology Reports</i> , 2022, 49, 10729-10748.	1.0	3
1995	Challenging treatment for refractory acquired haemophilia A complicated with severe severe acute respiratory coronavirus 2 infection. <i>Blood Coagulation and Fibrinolysis</i> , 0, Publish Ahead of Print, .	0.5	1
1996	Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
1997	The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. <i>Virulence</i> , 2022, 13, 1101-1110.	1.8	7
1998	Remdesivir powders manufactured by jet milling for potential pulmonary treatment of COVID-19. <i>Pharmaceutical Development and Technology</i> , 2022, 27, 635-645.	1.1	2
1999	Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	6
2000	Remdesivir for patients with Coronavirus disease 2019 pneumonia requiring high oxygen support. <i>Qatar Medical Journal</i> , 2022, 2022, .	0.2	2
2001	Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma. <i>Journal of Mass Spectrometry and Advances in the Clinical Lab</i> , 2022, 25, 27-35.	1.3	4
2002	Potential Cell-Based and Cell-Free Therapy for Patients with COVID-19. <i>Cells</i> , 2022, 11, 2319.	1.8	9
2003	Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8845.	1.2	9

#	ARTICLE	IF	CITATIONS
2004	Remdesivir-Induced Marked Sinus Bradycardia in COVID-19. <i>Cureus</i> , 2022, , .	0.2	0
2005	Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study. <i>Medicina (Lithuania)</i> , 2022, 58, 1007.	0.8	2
2006	Potent and Broad Neutralization of SARS-CoV-2 Variants of Concern (VOCs) including Omicron Sub-lineages BA.1 and BA.2 by Biparatopic Human VH Domains. <i>IScience</i> , 2022, , 104798.	1.9	1
2007	Astaxanthin Ameliorates Diabetic Retinopathy in Swiss Albino Mice via Inhibitory Processes of Neuron-Specific Enolase Activity. <i>Processes</i> , 2022, 10, 1318.	1.3	1
2008	Methods of occupational therapy for trainers who specialize in Martial Arts after treatment of coronavirus disease. <i>Scientific Journal of National Pedagogical Dragomanov University Series 15 Scientific and Pedagogical Problems of Physical Culture (physical Culture and Sports)</i> , 2022, , 119-128.	0.1	3
2010	Combination therapy with remdesivir and immunomodulators improves respiratory status in COVID-19: A retrospective study. <i>Journal of Medical Virology</i> , 2022, 94, 5702-5712.	2.5	7
2011	DRPADC: A novel drug repositioning algorithm predicting adaptive drugs for COVID-19. <i>Computers and Chemical Engineering</i> , 2022, 166, 107947.	2.0	3
2012	Application of network pharmacology in the study of the mechanism of action of traditional chinese medicine in the treatment of COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	9
2013	Molecular Docking Study for Prediction of Chiral HPLC Separation of Hydroxychloroquine as an Alternative Antiviral of SARS-CoV-2. <i>Advances in Science and Technology</i> , 0, , .	0.2	0
2014	A Comprehensive Review on COVID-19: Emphasis on Current Vaccination and Nanotechnology Aspects. <i>Recent Patents on Nanotechnology</i> , 2022, 16, .	0.7	0
2015	Characterization of pathogen-inactivated COVID-19 convalescent plasma and responses in transfused patients. <i>Transfusion</i> , 2022, 62, 1997-2011.	0.8	7
2016	Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. <i>Infection and Drug Resistance</i> , 0, Volume 15, 4457-4466.	1.1	10
2017	Severe SARS-CoV-2 infection in a 32-week pregnant woman treated with Remdesivir-Dexamethasone combination therapy: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, .	0.2	3
2018	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2211-2233.	0.9	1
2019	Bacteriophage-Derived Double-Stranded RNA Exerts Anti-SARS-CoV-2 Activity In Vitro and in Golden Syrian Hamsters In Vivo. <i>Pharmaceuticals</i> , 2022, 15, 1053.	1.7	2
2020	Endurance of COVID 19 in Wastewater, Natural Prescription and Antiviral Medication for the Analysis of COVID 19 and its Effects on the Development of New Antiseptic Strategies. , 2022, , 100010.		0
2021	Role of Siglecs in viral infections: A double-edged sword interaction. <i>Molecular Aspects of Medicine</i> , 2022, , 101113.	2.7	5
2022	AN EVALUATION OF ADVERSE DRUG REACTIONS WITH REMDESIVIR IN PATIENTS OF COVID-19. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 88-91.	0.3	1

#	ARTICLE	IF	CITATIONS
2023	Potential of targeting host cell calcium dynamics to curtail SARS-CoV-2 infection and COVID-19 pathogenesis. <i>Cell Calcium</i> , 2022, 106, 102637.	1.1	6
2024	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. <i>International Immunopharmacology</i> , 2022, 111, 109161.	1.7	9
2025	Consequences of COVID-19 on the cardiovascular and renal systems. <i>Sleep Medicine</i> , 2022, 100, 31-38.	0.8	2
2026	Epigenetic perspectives of COVID-19: Virus infection to disease progression and therapeutic control. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166527.	1.8	4
2027	State-of-art high-performance Nano-systems for mutated coronavirus infection management: From Lab to Clinic. <i>OpenNano</i> , 2022, 8, 100078.	1.8	11
2028	Potential role of biochemical markers in the prognosis of COVID-19 patients. <i>SAGE Open Medicine</i> , 2022, 10, 205031212211086.	0.7	3
2029	Relationship between acute kidney injury requiring renal replacement treatment and mortality in patients with COVID-19. <i>Nigerian Journal of Clinical Practice</i> , 2022, 25, 1348.	0.2	0
2030	Comparison of safety and efficacy of convalescent plasma with fresh frozen plasma in severe covid-19 patients. <i>Anais Da Academia Brasileira De Ciencias</i> , 2022, , .	0.3	6
2031	CoRe study: COVID-19 and remdesivir: An insight into the current health planning and policy. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 4671.	0.3	0
2032	Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. <i>Biomedical and Biotechnology Research Journal</i> , 2022, 6, 1.	0.3	0
2033	Adverse events following remdesivir administration in moderately ill COVID-19 patients - A retrospective analysis. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 3693.	0.3	4
2034	Efficacy and Safety of Direct Hemoperfusion Using Polymyxin B-Immobilized Polystyrene Column for Patients With COVID-19: Protocol for an Exploratory Study. <i>JMIR Research Protocols</i> , 2022, 11, e37426.	0.5	1
2035	Investigating New Patterns in Symptoms of COVID-19 Patients by Association Rule Mining (ARM). <i>Journal of Mobile Multimedia</i> , 0, , .	0.9	1
2036	A propósito de un caso: uso de la silimarina/silibinina como análogo molecular del remdesivir para el tratamiento de pacientes diagnosticados de COVID-19 con síndrome de dificultad respiratoria aguda leve o moderado. Reporte de caso. <i>Revista Científica De La Facultad De Ciencias Químicas Y Farmacia</i> , 2022, 30, .	0.1	0
2037	Structural Insights into Binding of Remdesivir Triphosphate within the Replication-Transcription Complex of SARS-CoV-2. <i>Biochemistry</i> , 2022, 61, 1966-1973.	1.2	12
2038	COVID-19 And Chronic Kidney Diseases. , 2022, , 181-229.		0
2039	COVID-19 and Cardiovascular Manifestations. , 2022, , 102-136.		0
2040	COVID-19 and Pregnancy. , 2022, , 263-290.		1

#	ARTICLE	IF	CITATIONS
2041	Cationic Perylene Antivirals with Aqueous Solubility for Studies In Vivo. <i>Pharmaceuticals</i> , 2022, 15, 1178.	1.7	3
2042	Remdesivir in treating hospitalized patients with COVID-19: A renewed review of clinical trials. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
2043	Political Prescriptions: Three Pandemic Stories. <i>Science Technology and Human Values</i> , 2024, 49, 371-402.	1.7	0
2044	Evolution of Care and Outcomes Across Surges in Hospitalized Patients with Coronavirus Disease 2019. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
2045	Virus-Like Particles of SARS-CoV-2 as Virus Surrogates: Morphology, Immunogenicity, and Internalization in Neuronal Cells. <i>ACS Infectious Diseases</i> , 2022, 8, 2119-2132.	1.8	1
2046	High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors. <i>Protein and Cell</i> , 0, , .	4.8	2
2047	Using In Silico Bioinformatics Algorithms for the Accurate Prediction of the Impact of Spike Protein Mutations on the Pathogenicity, Stability, and Functionality of the SARS-CoV-2 Virus and Analysis of Potential Therapeutic Targets. <i>Biochemical Genetics</i> , 2023, 61, 778-808.	0.8	3
2048	Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10171.	1.8	6
2049	Privacy-aware multi-institutional time-to-event studies. , 2022, 1, e0000101.		4
2050	Recent Drug Development and Medicinal Chemistry Approaches for the Treatment of SARS-CoV-2 Infection and COVID-19. <i>ChemMedChem</i> , 2022, 17, .	1.6	33
2051	Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. <i>Trials</i> , 2022, 23, .	0.7	1
2052	Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Regimens in Hospitalized Patients in Shiraz. <i>Iranian Journal of Science and Technology, Transaction A: Science</i> , 0, , .	0.7	0
2053	The Mechanisms of Zinc Action as a Potent Anti-Viral Agent: The Clinical Therapeutic Implication in COVID-19. <i>Antioxidants</i> , 2022, 11, 1862.	2.2	4
2054	Factors Affecting Artificial Intelligence and Management of Institutional Response to the Event of Coronavirus in Pakistan. <i>Pertanika Journal of Social Science and Humanities</i> , 2022, 30, 1451-1472.	0.1	1
2055	Managing Covid-19 in patients with heart failure: current status and future prospects. <i>Expert Review of Cardiovascular Therapy</i> , 2022, 20, 807-828.	0.6	0
2056	Liver and Biliary Tract Disease in Patients with Coronavirus disease-2019 Infection. <i>Gastroenterology Clinics of North America</i> , 2023, 52, 13-36.	1.0	2
2057	Evaluation of the efficacy and safety of remdesivir in hospitalized patients with a new coronavirus infection COVID-19: data from a Russian university clinic. <i>Meditsinskiy Sovet</i> , 2022, , 152-160.	0.1	0
2058	Candidate Drugs for the Potential Treatment of Coronavirus Diseases. <i>Methods in Pharmacology and Toxicology</i> , 2021, , 85-114.	0.1	0

#	ARTICLE	IF	CITATIONS
2059	Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review. <i>Indian Journal of Dermatopathology and Diagnostic Dermatology</i> , 2022, 9, 47.	0.0	0
2060	COVID-19 Treatmentâ€™Current Status, Advances, and Gap. <i>Pathogens</i> , 2022, 11, 1201.	1.2	7
2061	Ultra-Large-Scale Screening of Natural Compounds and Free Energy Calculations Revealed Potential Inhibitors for the Receptor-Binding Domain (RBD) of SARS-CoV-2. <i>Molecules</i> , 2022, 27, 7317.	1.7	3
2062	Evaluation of Remdesivir in Liver Functions Covid-19 Patients At Bhayangkara H.S Samsoreri Mertojoso Hospital Surabaya. <i>Jurnal Sains Dan Kesehatan</i> , 2022, 4, 459-463.	0.0	0
2063	Outcomes of critically ill coronavirus disease 2019 patients requiring kidney replacement therapy: A retrospective cohort study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
2064	Aptamer-Gated Mesoporous Silica Nanoparticles for N Protein Triggered Release of Remdesivir and Treatment of Novel Coronavirus (2019-nCoV). <i>Biosensors</i> , 2022, 12, 950.	2.3	2
2065	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 1-12.	0.3	0
2066	A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19. <i>Life</i> , 2022, 12, 1758.	1.1	9
2067	Peptides, lipopeptides, and severe acute respiratory syndrome coronavirus-2. , 2023, , 381-422.		0
2068	Mesenchymal Stromal Cells for COVID-19 Critical Care Patients. , 2022, , 163-191.		0
2069	V. Current Treatment Approach for COVID-19. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2374-2382.	0.0	0
2070	Antiviral use in liver function abnormalities and Covid-19 patients: Serial cases. <i>Annals of Medicine and Surgery</i> , 2022, 84, .	0.5	1
2071	Molecular Docking and Dynamics Simulation Studies of Ginsenosides with SARS-CoV-2 Host and Viral Entry Protein Targets. <i>Natural Product Communications</i> , 2022, 17, 1934578X2211343.	0.2	3
2072	Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review. <i>Research in Social and Administrative Pharmacy</i> , 2023, 19, 343-355.	1.5	0
2073	Remdesivir for Patients Hospitalized with COVID-19 Severe Pneumonia: A National Cohort Study (Remdeco-19). <i>Journal of Clinical Medicine</i> , 2022, 11, 6545.	1.0	4
2074	WLLP: A weighted reconstruction-based linear label propagation algorithm for predicting potential therapeutic agents for COVID-19. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	0
2075	Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2. <i>Molecules</i> , 2022, 27, 7732.	1.7	11
2076	A country-based review in COVID-19 related research developments. <i>RAIRO - Operations Research</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
2077	C-L Case Conference: Torsades de Pointes in a Patient With Lifelong Medical Trauma, COVID-19, Remdesivir, Citalopram, Quetiapine, and Hemodialysis. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2023, 64, 147-157.	0.2	3
2078	Distribution of age, sex, race, and ethnicity in COVID-19 clinical drug trials in the United States: A review. <i>Contemporary Clinical Trials</i> , 2022, 123, 106997.	0.8	0
2079	Remdesivir inhibits the progression of glioblastoma by enhancing endoplasmic reticulum stress. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114037.	2.5	2
2080	Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus. , 2022, 10, 251513552211448.	1.4	4
2081	Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. <i>Journal of Research in Medical Sciences</i> , 2022, 27, 92.	0.4	0
2082	COVID 19: Airway Management and Pharmacological Strategies. <i>Journal of Cardiac Critical Care TSS</i> , 2022, 06, 210-215.	0.0	0
2083	SARS-CoV-2: Recent Past and Present: An Unusual Review. , 2022, 2, 1-33.		0
2084	Learning with insufficient data: a multi-armed bandit perspective on covid-19 interventions. <i>Mind and Society</i> , 2022, 21, 183-193.	0.9	0
2085	An Overview of Repurposed Drugs for Potential COVID-19 Treatment. <i>Antibiotics</i> , 2022, 11, 1678.	1.5	3
2086	Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14462.	1.8	1
2087	Clinical outcomes of and risk factors for secondary infection in patients with severe COVID-19: a multicenter cohort study in South Korea. <i>Korean Journal of Internal Medicine</i> , 2023, 38, 68-79.	0.7	3
2088	Drug-induced liver injury in COVID-19 treatment: Incidence, mechanisms and clinical management. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	4
2089	Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	37
2090	Acute liver injury in COVID-19 patients hospitalized in the intensive care unit: Narrative review. <i>World Journal of Gastroenterology</i> , 0, 28, 6662-6688.	1.4	5
2091	An In-Silico Multi-Targeted Approach in Search of Potential Drug Candidate(s) Against SARS-CoV-2 Lung Infection. <i>Coronaviruses</i> , 2022, 04, .	0.2	0
2092	Drug-Induced Liver Injury in Hospitalized Patients during SARS-CoV-2 Infection. <i>Medicina (Lithuania)</i> , 2022, 58, 1848.	0.8	6
2093	Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model. <i>Antiviral Research</i> , 2023, 209, 105492.	1.9	6
2094	Hepatic Disorders and COVID-19: From Pathophysiology to Treatment Strategy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-15.	0.8	7

#	ARTICLE	IF	CITATIONS
2095	Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19. <i>Pathology Research and Practice</i> , 2023, 241, 154280.	1.0	6
2096	Liver disease during the pandemic of COVID-19 infection: prediction of the course and tactics of management: A review. <i>Terapevticheskii Arkhiv</i> , 2022, 94, 1326-1332.	0.2	0
2097	Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. <i>Health Research Policy and Systems</i> , 2022, 20, .	1.1	3
2098	Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	20
2099	Effectivity of repurposed drugs against SARS-CoV-2 infections, A hope for COVID 19: inhibitor modelling studies by docking and molecular dynamics. <i>Heliyon</i> , 2022, 8, e12327.	1.4	2
2100	Ethics of Expanded Access During the COVID-19 Pandemic. <i>Philosophy and Medicine</i> , 2023, , 367-384.	0.3	0
2101	COVID-19 and hepatic injury: Diversity and risk assessment. <i>World Journal of Gastroenterology</i> , 0, 29, 425-449.	1.4	5
2102	Liver dysfunction-related COVID-19: A narrative review. <i>World Journal of Meta-analysis</i> , 0, 11, 5-17.	0.1	0
2103	COVID-19-related liver injury: Focus on genetic and drug-induced perspectives. <i>World Journal of Virology</i> , 0, 12, 53-67.	1.3	0
2104	Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2107	2-Deoxy-d-Glucose: A Repurposed Drug for COVID-19 Treatment. , 2023, , 479-500.		0
2108	The Potential of Nanobodies for COVID-19 Diagnostics and Therapeutics. <i>Molecular Diagnosis and Therapy</i> , 2023, 27, 193-226.	1.6	6
2109	COVID-19 and atrial fibrillation: Intercepting lines. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	11
2110	Data-Driven COVID-19 Vaccine Development for Janssen. <i>INFORMS Journal on Applied Analytics</i> , 2023, 53, 70-84.	0.7	0
2111	Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	7
2112	Severity of COVID-19 in Patients with Diarrhoea: A Systematic Review and Meta-Analysis. <i>Tropical Medicine and Infectious Disease</i> , 2023, 8, 84.	0.9	1
2114	Remdesivir for the treatment of COVID-19. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	17
2115	Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 517-525.	1.2	1

#	ARTICLE	IF	CITATIONS
2116	In silico study of novel niclosamide derivatives, SARS-CoV-2 nonstructural proteins catalytic residue-targeting small molecules drug candidates. <i>Arabian Journal of Chemistry</i> , 2023, 16, 104654.	2.3	2
2117	Insight into the mechanisms of coronaviruses evading host innate immunity. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2023, 1869, 166671.	1.8	3
2118	COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease. <i>Drug Discovery Today</i> , 2023, 28, 103579.	3.2	22
2119	Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir. <i>Fundamental and Clinical Pharmacology</i> , 2023, 37, 726-738.	1.0	5
2121	Liver involvement in patients with COVID-19 infection: A comprehensive overview of diagnostic imaging features. <i>World Journal of Gastroenterology</i> , 0, 29, 834-850.	1.4	0
2122	A Clinical Insight on New Discovered Molecules and Repurposed Drugs for the Treatment of COVID-19. <i>Vaccines</i> , 2023, 11, 332.	2.1	4
2123	Discovery of Isojacareubin as a covalent inhibitor of SARS-CoV-2 main protease using structural and experimental approaches. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
2124	Real-World Safety and Effectiveness of Remdesivir and Corticosteroids in Hospitalized Patients with COVID-19. <i>Covid</i> , 2023, 3, 198-217.	0.7	2
2125	An overview on the treatments and prevention against COVID-19. <i>Virology Journal</i> , 2023, 20, .	1.4	19
2126	How to use COVID-19 antiviral drugs in patients with chronic kidney disease. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	7
2127	Relation of COVID-19 with liver diseases and their impact on healthcare systems: The Portuguese case. <i>World Journal of Gastroenterology</i> , 0, 29, 1109-1122.	1.4	2
2128	Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study. <i>Infection</i> , 2023, 51, 1033-1049.	2.3	8
2129	Identification of Bradycardia Following Remdesivir Administration Through the US Food and Drug Administration American College of Medical Toxicology COVID-19 Toxic Pharmacovigilance Project. <i>JAMA Network Open</i> , 2023, 6, e2255815.	2.8	2
2130	Factors Influencing the Length of Hospital Stay Among Pediatric COVID-19 Patients at Queen Rania Al Abdullah Hospital for Children: A Cross-Sectional Study. <i>Cureus</i> , 2023, , .	0.2	0
2131	Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 513-521.	1.3	2
2132	Need and Possibilities of Phytocompounds against SARS-CoV-2: Recent Advances in COVID-19 Therapy. <i>Current Traditional Medicine</i> , 2023, 09, .	0.1	0
2133	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
2134	Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update. <i>Archives of Medical Sciences Atherosclerotic Diseases</i> , 2023, 8, 1-10.	0.5	8

#	ARTICLE	IF	CITATIONS
2135	Association of COVID-19 with Comorbidities: An Update. ACS Pharmacology and Translational Science, 2023, 6, 334-354.	2.5	13
2137	Oral Pathology in the Context of COVID-19: Perspectives Based on a Compilation of Literature Data. Journal of the California Dental Association, 2020, 48, 517-531.	0.0	0
2138	Clinical efficacy of probiotics in the treatment of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. Expert Review of Anti-Infective Therapy, 2023, 21, 667-674.	2.0	3
2139	Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies. Viruses, 2023, 15, 741.	1.5	8
2140	Role of TGF- β 2 Signaling in Coronavirus Disease 2019. , 2022, 9, 9.		1
2141	Evaluation of Remdesivir Utilization Pattern in Critically Ill Patients With COVID-19 in Jazan Province. Cureus, 2023, , .	0.2	0
2142	Co-administration of AYUSH 64 as an adjunct to standard of care in mild and moderate COVID-19: A randomized, controlled, multicentric clinical trial. PLoS ONE, 2023, 18, e0282688.	1.1	4
2143	Modulation of gut microbiota as a potential therapy to manipulate drug-induced hepatic damage in COVID-19 patients. World Journal of Gastroenterology, 0, 29, 1708-1720.	1.4	3
2144	Retrospective Analysis of the Effectiveness of Remdesivir in COVID-19 Treatment during Periods Dominated by Delta and Omicron SARS-CoV-2 Variants in Clinical Settings. Journal of Clinical Medicine, 2023, 12, 2371.	1.0	2
2145	Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting. Viruses, 2023, 15, 811.	1.5	9
2146	Impact of Drug Repurposing on SARS-Cov-2 Main Protease. Russian Journal of Physical Chemistry A, 2022, 96, 3311-3330.	0.1	1
2147	Influence of COVID-19 and employees' response to deviations on employee enactment. Corporate Governance and Organizational Behavior Review, 2023, 7, 118-127.	0.5	1
2148	Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?. Clinical Infectious Diseases, 2023, 77, 32-37.	2.9	2
2149	Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). Applied Sciences (Switzerland), 2023, 13, 4471.	1.3	1
2150	The role of the endothelium in severe acute respiratory syndrome coronavirus 2 infection and pathogenesis. Current Opinion in Physiology, 2023, 34, 100670.	0.9	3
2151	Updated landscape of inhaled medications to combat COVID-19. Therapeutic Delivery, 2023, 14, 5-9.	1.2	0
2152	COVID-19 in Adult Patients with Hematological Malignancies"Lessons Learned after Three Years of Pandemic. Biology, 2023, 12, 545.	1.3	2
2153	Advances in the synthesis of antiviral agents from carbohydrate-derived chiral pools. Journal of Carbohydrate Chemistry, 0, , 1-87.	0.4	0

#	ARTICLE	IF	CITATIONS
2154	Revisiting the COVID-19 Pandemic: An Insight into Long-Term Post-COVID Complications and Repurposing of Drugs. Covid, 2023, 3, 494-519.	0.7	1
2155	Current Strategies to Combat COVID-19. , 2023, , 361-374.		0
2157	Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. Microorganisms, 2023, 11, 1000.	1.6	2
2158	Efficacy of convective-diffusion models to study the transient behaviour of a sewage-sludge-filled packed column for aqueous phase adsorption of fluoroquinolones: Consideration of pseudo-kinetics driven depletion of species. Journal of Environmental Chemical Engineering, 2023, 11, 109896.	3.3	3
2159	RECOVERY and SURVIVAL of patients with moderate to severe acute RESPIRATORY distress syndrome (ARDS) due to COVID-19: a multicenter, single-arm, Phase IV itolizumab Trial: RESURRECT. Expert Opinion on Biological Therapy, 2023, 23, 443-454.	1.4	0
2160	Effect of remdesivir post-exposure prophylaxis and treatment on pathogenesis of measles in rhesus macaques. Scientific Reports, 2023, 13, .	1.6	2
2161	Drug target of natural products and COVID-19: how far has science progressed?. Annals of Medicine and Surgery, 2023, 85, 2731-2742.	0.5	0
2178	Drug Repurposing and Computational Drug Discovery for Viral Infections and COVID-19. , 2023, , 355-366.		0
2188	VEKLURY [®] (REMDESIVIR), A NUCLEOTIDE PRODRUG APPROVED FOR THE TREATMENT OF COVID-19. Medicinal Chemistry Reviews, 0, , 545-569.	0.1	1
2230	Potential therapeutic landscape of COVID-19: molecular targets, repurposed drugs, and nano- and cell-based intervention. , 2024, , 139-157.		0
2231	COVID-19 therapy directed against pathogenic mechanisms of severe acute respiratory syndrome coronavirus 2. , 2024, , 2697-2726.		0
2234	Computational analysis on herbal medicine potential of irradiated piperine as SARS-CoV-2 main protease inhibitors. AIP Conference Proceedings, 2024, , .	0.3	0
2236	Update to Years 2020, 2021, and 2022, with Information on COVID-19. , 2023, , 333-356.		0